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Almost one third of all annual deaths in the Netherlands is caused by cancer1. Carcinogen-
esis is a process in which several subsequential alterations in a cell drive the progression 
of normal human cells into cancer cells. Cancer cells break the most basic rules of cell 
behavior. Whereas normal cells carefully control cell growth to maintain normal tissue 
architecture and function, cancer cells become masters of their own destiny and prolifer-
ate continuously2. This abnormal growth will give rise to a neoplasm; the tumor. Tumors 
usually acquire (epi)genetic alterations, which can increase the ability of cancer cells to 
invade and colonize distant environments that are normally reserved for other cells3-5. 
Once cancer cells show these characteristics, they are considered to be malignant. Second-
ary tumors at other sites in the body, called metastases, are hard to eradicate and generally 
kill the patient.
Uveal melanoma
Uveal melanoma (UM) is a malignant neoplasm arising from melanocytes in the eye. Dur-
ing embryogenesis, neural crest cells migrate not only to the skin to develop into pigment-
producing melanocytes, but also to the uveal tract of the eye. The uveal tract is a pig-
mented tissue located between the outer layer of the eye (cornea and sclera) and the inner 
layer (retina). It has several functions, such as improving the contrast of the retinal image 
by absorbing excessive light and allowing nutrition and gas exchange via the blood ves-
sel6. Since the sclera and lens lack any intrinsic blood supply, the uveal tract also indirectly 
supplies diffusible nutrients to these structures. UM can arise in every part of the uveal 
tract, but the choroid is the most common location (72%), followed by the ciliary body 
(23%) and iris (5%) (Figure 1). The iris is a thin circular structure that controls the amount 
of light entering the eye by controlling the size of the pupil. Whereas the ciliary body 
holds and controls the shape of the lens, in order to focus light on the retina. 
Figure 1. Cross section of an eye containing an UM (left) and a schematic representation of the different ocular 
structures (right).
Approximately 80% of the primary ocular tumors in adults are UM. The incidence of UM 
has remained stable over the last years and ranges from 4.3 to 10.9 per million in the West-
ern World, with the highest incidence in Scandinavia7, 8. The diagnosis of UM is based on 
the clinical appearance of the tumor. Techniques such as fundoscopy, optical coherence 
tomography and ultrasonography can detect the unusual mass inside the eye. Whenever 
tumor tissue is available, the diagnosis can be confirmed by histopathological examina-
tion as well. 
 
Primary UM can be successfully treated by surgery or radiotherapy. The type of treatment 
depends on multiple factors, such as tumor size and tumor location. In case of a large tu-
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mor or a tumor located closely to the optic nerve, total removal of the eye - enucleation- is 
preferred. Smaller tumors can be successfully treated by irradiation, which induces lethal 
chromosomal injury and damage to blood vessels in the tumor. Despite successful treat-
ment of the primary tumor, approximately 50% of the UM patients will die due to meta-
static disease, often within 2 years after enucleation8. Interestingly, the metastatic risk is 
the same for all treatment options9, 10. Since metastasis can still occur years after complete 
removal of the eye, it is hypothesized that micrometastases are already present at time of 
diagnosis, but can remain dormant for many years11, 12. Several clinical features have been 
shown to associate with increased metastatic risk, such as large tumor size and high age. 
Additionally, histopathological features can predict metastatic risk. Hematoxylin and eo-
sin (H&E) staining can be used to differentiate between spindle and epithelioid cell type, 
with the latter being more frequent in high metastatic risk UM (Figure 2)13, 14. Other histo-
pathological features, such as mitotic activity, presence of necrosis, extraocular extension 













Figure 2. HE staining of UM cells shows A) epitheloid cells with larger nuclei and B) spindle cells with elongated 
nuclei (200x).
At this moment there are no standardized treatments for metastatic UM. In case of a local, 
single metastatic lesion, partial liver resection can extend the lifespan of a metastatic UM 
patient18. Whereas multiple local metastatic lesions can be treated by isolated hepatic per-
fusion (IHP). With IHP the liver is isolated from the systemic circulation, thereby allowing 
a much higher concentration of chemotherapeutic agent to be used. In case of multiple, 
diffuse metastatic lesions experimental therapies are offered to the patient. Unfortunately, 
all of these treatments can only postpone death by several months; no curative treatment 
options are present at this time for metastatic UM19, 20.
Genetics 
The human body consists of approximately 100 trillion cells that, even though they are 
very different from each other, contain exactly the same genetic information. This genetic 
information is stored as deoxyribonucleic acid (DNA) and packaged into 23 chromosome-
pairs in the nucleus of the cell. DNA consists of a double-stranded structure formed by 
bases attached to a deoxyribose sugar-phosphate backbone21, 22. The genetic information 
is stored as a code made up of four bases; adenine, thymine, guanine and cytosine. Hu-
man genes consist of a unique sequence of bases and can code for a specific protein. Each 
gene has two copies in each cell, positioned on paired chromosomes (except for the genes 
located on the X and Y-chromosome). Once activated, a gene is first transcribed into mes-
sengerRNA (mRNA)23. This mRNA can then be translated into a string of amino acids 








 1The expression of genes is controlled at many levels. A gene can be turned on or off via binding of activating or inhibitory proteins. Gene expression can also be influenced by 
permanent alterations in the DNA sequence, called mutations. In cancer cells, the pres-
ence of specific mutations alter the expression of genes2. These mutations can be silent, 
missense or nonsense mutations. Silent mutations do not encode for a different amino acid 
and therefore do not change the protein. Missense mutations cause a change in amino acid, 
that produces a changed protein and non-sense mutations cause a premature stop-codon 
and thereby results in a truncated protein (Figure 3). Furthermore, larger regions of a gene 
can be altered by deletion of several nucleotides. Hence, DNA mutations can impact the 
cells’ functioning by changing the amount of protein or the proteins’ structure, which can 
enhance or impair the specific function carried out by the protein. In cancer cells, inacti-
vating mutations are generally found in tumor suppressor genes; genes that protect a cell 
from becoming carcinogenic by regulating processes such as apoptosis, DNA repair or 
cell cycle. DNA mutations that activate the proteins function are frequently found in on-









Figure 3. The effect of silent, missense and nonsense mutations on the DNA sequence. Every three-letter word rep-
resents an amino acid. Silent mutations do not result in a different sentence/protein, missense mutations result in a 
different but correct sentence, whereas nonsense mutations result in a completely wrong sentence.
 
Genetics of UM
Of all cancer types UM has one of the lowest mutational burdens26, 27. Only few genes are 
known to be frequently mutated in UM. The first gene that was found to be mutated in 
UM, was the guanine nucleotide-binding protein α Q (GNAQ). It is hypothesized that 
melanocytes become pre-malignant by mutations in GNAQ or its paralogue guanine nu-
cleotide-binding protein α 11 (GNA11)28,29. Mutations in these genes result in an overacti-
vation of the Gα11/Q pathway, that stimulates cell growth and proliferation by initiating 
several downstream pathways in the cell. More than 95% of the UM harbor a mutually 
exclusive mutation in amino acid residues Q209 and R183 of GNAQ or GNA11, which 
suggests that these mutations are initiating mutations in the tumorigenesis of UM. UM 
that do not show mutated GNAQ or GNA11, usually have a mutation in the cysteinyl 
leukotriene receptor 2 (CYSTLR2) or phospholipase C beta 4 (PCLB4); two proteins that 
act respectively upstream and downstream of GNAQ and GNA1130, 31. Hence, mutations 
in these two genes cause activation of the same signaling pathways as mutations in GNAQ 
and GNA11. Mutations in these genes do not correlate with metastatic risk32, 33. The ag-
gressiveness of UM is determined by secondary driver mutations in the BAP1, SF3B1 and 

























 The majority of the metastatic UM show loss of the BAP1 protein. Mutations in the BAP1 
gene, located on chromosome 3, can be found through the entire gene and can range from 
a single basepair mutation to large deletions involving several exons. Since loss of function 
mutations require the loss of both wildtype alleles, most BAP1-mutated UM also show 
loss of one chromosome 3 (monosomy 3). Loss of BAP1 protein can be detected by im-
munohistochemical staining (IHC) and is a strong indicator for risk of metastatic disease 
(Figure 5) 34-36. BAP1 is a deubiquitinating enzyme (DUB), which are critical regulators of 
ubiquitin signaling. It has been shown that BAP1 interacts with many different proteins, 
such as the DNA repair protein BRCA1 and transcription-factors such as YY137, 38. Unfor-
tunately, it is not clear yet how exactly loss of BAP1 protein contributes to UM metastasis. 
Figure 5. BAP1 IHC in UM shows A) positive nuclear BAP1 staining and B) negative BAP1 staining. 
In a quarter of the UM a mutation in the gene SF3B1 is observed39-41. SF3B1 encodes for 
subunit 1 of the splicing factor 3b, a protein that is involved in pre-mRNA splicing. Genes 
are transcribed into pre-mRNA which still contains introns and subsequently the spliceo-
some-complex removes these introns in order to produce mature mRNA. Correct splicing 
of pre-mRNA is crucial for cell survival42. Dysregulated splicing can produce aberrantly 
spliced mRNA, resulting in a loss of protein-expression or they can be translated into 
unique, aberrant proteins43. Mutations in spliceosome genes have also been observed in 
other cancers, such as breast and hematologic cancers, suggesting that dysregulated splic-
ing could be advantageous for cancer cells44-46. SF3B1 is the most frequently mutated spli-
ceosome gene in UM, but mutations in U2AF1 and SRSF2 have been described as well47. 
Most UM patients harboring an SF3B1-mutated UM will develop metastases eventually, 
however they do show a longer disease-free survival than patients with a monosomy 3, 
BAP1-mutated UM48. The disease-free survival can vary greatly between patients with an 
SF3B1-mutated UM, as some develop metastases within 5 years while others after 15 years. 
Another frequently mutated gene in disomy 3 tumors is EIF1AX (eukaryotic translation 
initiation factor 1A, X-linked)41. EIF1AX is involved in translation, a process where the 
ribosome converts the mRNA into a protein49. When the ribosome is scanning the mRNA 
for the startcodon EIF1AX stabilizes the ribosome and thereby facilitates proper transla-
tion of the mRNA50, 51. EIF1AX mutations occur in ~20% of the UM and do not result in loss 
of the protein but rather a change of function. EIF1AX-mutated UM hardly metastasize. 
Indicating that mutations in the EIF1AX gene might make melanocytes more malignant, 
but it is not enough to initiate metastasis.
 
Chromosomal anomalies in UM
Besides mutations in the DNA, other alterations can also occur in cancer, such as varia-







 1random chromosomal aberrations can occur on either the short (p) or long (q) arm of chromosomes 1, 3, 6 and 8 (Figure 6)52. As described previously, monosomy 3 is most 
significantly associated with metastatic disease53. It is observed in approximately 50% of 
the UM. Since monosomy 3 is often observed with other chromosomal aberrations, it is 
thought to be an early event in UM tumorigenesis54. Some tumors duplicate the remaining 
chromosome 3, thereby causing isodisomy of chromosome 3 which results in loss of het-
erozygosity (LOH)55. It is thought that the monosomy 3 not only reduces the expression of 
BAP1, but also that of other chromosome 3 genes. By duplicating chromosome 3, a cell can 
compensate for this reduced expression and thereby stimulate UM progression.
 
 
Figure 6. Karyotype of an UM showing several chromosomal anomalies, such as loss of chromosome 3, loss of 
chromosome 6q and gain of chromosome 8 (courtesy of the Department of Clinical Genetics, Erasmus MC).
Another chromosomal anomaly often found in metastatic UM is gain of chromosome 8 
56. This gain can occur by either entire chromosome 8 gain, formation of isochromosome 
8q of by partial amplification of 8q. The latter is mainly observed in disomy 3 UM, while 
isochromosome 8q is frequently found in monosomy 3 UM57, 58. Given the high prevalence 
of increased copies of 8q in metastatic UM, the chromosome 8q region probably contains 
genes that contribute to UM metastasis. Several oncogenes have been identified on chro-
mosome 8q, such as MYC, PVT1 and DDEF27, 59. However, the exact underlying genetic 
mechanism of 8q gain is yet to be elucidated. 
UM can show rearrangements on both arms of chromosome 6. Gain of chromosome 6p 
have been observed, as well as deletion of chromosome 6q57, 60. However, both CNVs do 
not show an association with survival. Thirty percent of UM patients also show deletion 
of chromosome 1p, which is associated with high metastatic risk. Chromosome 1p loss is 
often observed together with monosomy 3, in which monosomy with loss of chromosome 
1p has a worse prognosis than monosomy without chromosome 1p loss61. Abnormalities 
on other chromosomes in UM have been described, such as chromosome 9p and 16q, but 
do not occur frequently and show no correlation to metastatic risk. Around 17% of the UM 
show polyploidy, meaning that their genome contains more than the normal two copies of 
each chromosome. It is in general associated with worse prognosis; however in UM it has 
been shown that polyploidy does not significantly affect survival62. 
Epigenetics in UM
Gene expression can also be affected by alterations that do not affect the DNA sequence 
itself, these are called epigenetic modifications. Numerous epigenetic modifications exist, 
however the most studied one is DNA methylation. DNA methylation involves the trans-
fer of a methyl-group (CH3-group) to the C-5 position of the cytosine ring of DNA by the 
enzyme DNA-methyltransferase. Methylation of the DNA is dynamic and can occur at 
18
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any cytosine in the genome, however more than 98% of the DNA methylation occurs at cy-
tosines in the CG-sequence. The human genome contains around 28 million of these CpG-
dinucleotides and they often cluster in very CG-rich regions, which are called CpG islands 
63. Most, if not all, CpG islands are situated in regions that are involved in transcription 
initiation. How exactly DNA methylation helps to control gene expression is not fully 
understood. It is suggested that DNA methylation interferes directly with the binding of 
proteins necessary for transcription initiation. Additionally, several proteins are known 
to specifically bind methylated DNA and could thereby prevent transcription-proteins 
from binding the DNA. DNA methylation aids in the process of repressing unneeded 
eukaryotic genes to very high degree. The importance of DNA methylation is shown by 
the widespread involvement of errors in this mechanism in carcinogenesis64-66. Several 
studies indicate a large amount of changes in DNA methylation during tumor progres-
sion. Regarding UM, several studies show increased methylation in the promoters of p16, 
PRAME, TIMP3 and RASSF167-70. A change in methylation can contribute to UM develop-
ment, progression and metastasis by downregulating genes that suppress these processes.
 
Another way to control the expression of a gene is by microRNA (miRNAs) expression. 
These small non-protein-coding RNA molecules are incorporated into a protein com-
plex termed RNA-induced silencing complex (RISC). A miRNA-loaded RISC can control 
gene expression by binding to complementary mRNA71, 72. Depending on the degree of 
complementarity, miRNAs can silence genes by cleavage and degradation of the mRNA 
or by translational repression. Currently 1872 annotated precursor-miRNA genes have 
been identified that can produce ~2578 mature miRNAs. Over the past decade it has been 
shown that miRNA expression is heavily dysregulated in cancer cells73. A few pilot stud-
ies have investigated miRNA expression in UM and identified upregulation of several 
miRNAs in metastatic UM, such as miRNA-32, miRNA-146b, miRNA143, miRNA-34b/c 
and miRNA-13774-78. Which (oncogenic) pathways could be influenced by differential miR-
NA expression is often difficult to determine, since one miRNA can bind many different 
mRNAs. Interestingly, miRNAs are very stable in tissues and body fluids, indicating that 
they could serve as non-invasive metastatic-biomarkers.
 
A plethora of mechanisms contributes to altered gene function and malignant transfor-
mation of a cell (Figure 7). The majority of UM research has focused on identifying UM-
specific copy number variations and mutations, since these alterations can result in an up 
or downregulation of a specific protein in a cell. But epigenetic alterations may be just as 
important in the development and metastasis of UM, or even more important. It has been 
shown that loss of gene expression occurs about 10 times more frequently by transcription 
silencing, than by mutations in the DNA79. Therefore, it could be beneficial to shift our 
focus more towards the epigenetic alterations that drive UM development and metastasis. 
 








Figure 7. The central dogma describes the flow of genetic information within a cell. DNA is transcribed into 
RNA, which is then translated into the bioactive molecule: the protein. The protein level can be affected by many 
mechanisms, such as copy number variations, mutations, methylation of the DNA, aberrant splicing, initiation of 









As previously described in this chapter, UM patients at risk for metastases can be identi-
fied by different methods with the mutation profile being the most reliable method. Most 
UM patients are treated by eye conserving therapies, such as radiotherapy or proton ther-
apy, meaning that there is no tumor tissue available for prognostication unless an invasive 
biopsy is taken. Therefore many UM patients would profit from the development of a 
non-invasive biomarker that can predict metastatic risk. As mentioned before, detecting 
oncogenic miRNAs in the circulation of patients could be a promising non- invasive bio-
marker. Another non-invasive biomarker that is often used in cancer screening is cell-free 
DNA (cfDNA); small fragments of DNA that are released into the bloodstream by apop-
totic and necrotic cells. Detecting mutated cfDNA or an increase in oncogenic miRNAs 
has been shown to be useful for diagnostic applications in several cancer types80. How-
ever, the studies investigating the presence of cfDNA and oncogenic miRs in the circula-
tion of UM patients show variable results and are not conclusive. Since genetic material is 
released into the blood by all cells, it could be that UM are too small to secrete a detectable 
level of oncogenic miRs or mutant cfDNA into the blood.
 
A potentially more promising non-invasive biomarker for UM are extracellular vesicles 
(EVs). It has been shown that cancer patients show an increased level of EVs in their blood. 
EVs function in cell-to-cell communication by transporting bioactive molecules such as 
miRNA, mRNA, DNA and proteins. They allow cells to communicate with each other 
even if they are located far apart from each other81. Many cell types release EVs, which can 
be found in most body fluids, including blood, saliva, urine breast milk and plasma82-84. 
Vesicles derived from various tissues differ in their molecular composition. Depending on 
their cellular origin, EVs can be classified as apoptotic bodies (ABs), microvesicles (MVs) 
and exosomes. ABs are the biggest vesicles (1000-5000 nm) and are released by apoptotic 
cells. MVs have a size of 100-1000 nm and are shed from the plasma membrane. Exosomes 
are derived from multivesicular endosome and are the smallest vesicles (30-100 nm)85. 
They are the product of a process called endocytosis, in which invagination of the cells’ 
plasma membrane and membrane fission results in the formation of vesicles into an early 
endosome. As the early endosome matures into a multivesicular endosome, intraluminal 
vesicles are formed inside the endosome. Multivesicular endosomes can fuse with lyso-
somes, thereby degrading the contents of the vesicles, or they can fuse with the plasma 
membrane which releases the vesicles into the extracellular environment (Figure 8)86.
 
 
Figure 8. Biogenesis of exosomes starts with invagination of the plasma membrane, resulting in the formation of 
an early endosome. The early endosome matures into a multivesicular endosome containing vesicles. The multive-
sicular endosome can fuse with the lysosome, which results in degradation of the vescicles or it can fuse with the 
plasma membrane leading to the release of vesicles, called exosomes.
20
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The last years exosome research has received substantial interest with the discovery that 
they contain mRNA and miRNAs87. Additionally, tumor cells secrete an increased amount 
of exosomes and these vesicles often exhibit unique cargo making them a promising prog-
nostic marker 88. The exact mechanism of how exosomes interact with recipient cells is 
unknown. However, it has been shown in numerous studies that exosomes are involved 
in many processes that contribute to tumorigenesis, including angiogenesis89, drug resis-
tance mechanisms 90, immune-suppression91, epithelial to mesenchymal transition92, 93 and 
educating the pre-metastatic niche94-96. This shows the importance of secreted exosomes 




























 1Scope of this thesis
This thesis aims to elucidate the (epi)genetic and transcriptional mechanisms contributing 
to metastatic spread of UM. The research performed is outlined in the following parts;
Chapter 2 describes the development of two methods that facilitate metastatic risk predic-
tion in UM patients. As previously described in chapter 1, there are several factors that 
can predict metastatic risk in UM. If tissue is available, CNVs, expression profiles and 
mutations in DNA can be identified. The choice for these methods depends largely on 
the available material. In chapter 2.1 we describe a method that we developed that allows 
simultaneous detection of UM-specific mutations and CNVs in small amounts of DNA. 
In chapter 2.2 we discuss CNV patterns that are associated with specific secondary driver 
mutations in EIF1AX, SF3B1 and BAP1.
 
With the development of next generation sequencing techniques, the genetic aberran-
cies driving UM progression have been described extensively. However, the changes on 
the epigenetic level have been discussed to lesser extent. Recent studies have shown that 
abnormal epigenetic silencing of genes is no less important than mutations in DNA se-
quences for the development of most cancers. The aim of chapter 3 is to elucidate how epi-
genetic mechanisms contribute to UM metastasis. In chapter 3.1 we compare the miRNA 
expression between low, intermediate and high metastatic risk UM by performing RNA 
sequencing. We investigate up and downregulation of several miRNAs in high metastatic 
risk UM and integrate the miRNA data with mRNA data in order to identify the down-
stream effects of aberrant miRNA expression. In chapter 3.2 we describe methylation-pat-
terns that show association with metastatic disease by making use of a new genome-wide 
methylation analysis technique. 
 
Even though extensive research regarding UM metastasis has been done, up until now 
no effective treatment is available for metastatic UM. In chapter 4 we describe how UM 
surveillance and therapy could be improved in the future. Chapter 4.1 describes our first 
steps towards a possible new non-invasive biomarker; exosomes. We characterize exo-
somes secreted by cultured UM cells, analyze the genetic content and make suggestions 
about how these exosomes could be used in the future as liquid biomarker to predict 
metastatic risk. In chapter 4.2 we review what is already known about the aberrant mecha-
nisms behind UM development. In this review we discuss which mechanisms could be 
targeted in metastatic UM treatment and hypothesize about promising future treatment 
options.
  
Finally, in chapter 5 the main findings are summarized and, where possible, overall con-
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Uveal melanoma is a highly aggressive cancer of the eye, in which nearly 50% of the pa-
tients die from metastasis. It is the most common type of primary eye cancer in adults. 
Chromosome and mutation status have been shown to correlate with the disease free 
survival. Loss of chromosome 3 and inactivating mutations in BAP1, which is located 
on chromosome 3, are strongly associated with ‘high risk’ tumors that metastasize early. 
Other genes often involved in uveal melanoma are SF3B1 and EIF1AX, which are found to 
be mutated in intermediate- and low risk tumors, respectively. To obtain genetic informa-
tion of all genes in one test we developed a targeted sequencing method that can detect 
mutations in uveal melanoma genes and chromosomal anomalies in chromosome 1,3 and 
8. With as little as 10ng DNA we obtained enough coverage on all genes to detect muta-
tions, such as substitutions, deletions and insertions. These results were validated with 
Sanger sequencing in 28 samples. In more than 90% of the cases, the BAP1 mutation status 
corresponded to the BAP1 immunohistochemistry. The results obtained in the Ion Tor-
rent single nucleotide polymorphism assay were confirmed with several other techniques, 
such as fluorescence in situ hybridisation, multiplex ligation-dependent probe amplifica-
tion and Illumina SNP-array. By validating our assay in 27 formalin-fixed paraffin-em-
bedded and 43 fresh uveal melanomas, we show that mutations and chromosome status 
can reliably be obtained using targeted next-generation sequencing. Implementing this 
technique as a diagnostic pathology application for uveal melanoma will allow prediction 
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Introduction
Uveal melanoma is the most common primary intraocular malignancy in adults with a 
worldwide annual incidence in Caucasians of 5-7 per million per year1. Despite success-
ful treatment of the primary tumor, nearly 50% of the patients develop liver metastasis 
within 5 years. Once metastatic disease is diagnosed, survival is between 2 and 9 months2. 
Approximately 40% of uveal melanoma patients developed metastases within 4 years, but 
dissemination can occur even up to 4 decades after diagnosis3. This demonstrates that the 
prognosis for uveal melanoma patients can strongly vary between patients, and is depen-
dent on a number of factors, including clinical and histological parameters, as well as the 
underlying genetic ‘make up’ of the tumor cells4.
 
Chromosomal anomalies are often found in solid tumors, but previous work has shown 
that most of the chromosomal anomalies in uveal melanoma are limited to chromosome 
1, 3, 6 and 8. Some of these chromosomal variations correlated with metastasis, such as 
loss of chromosome 35. Monosomy 3 is observed in half of the patients and is strongly as-
sociated with poor survival. Loss of chromosome 3 is thought to be an early event, since it 
is present in the majority of the cells and often accompanies other chromosomal anoma-
lies, such as gain of chromosome 8q6,7,8. Another common anomaly in metastasizing uveal 
melanoma with monosomy 3 is loss of chromosome 1p9. Chromosome 6 shows frequent 
rearrangements in both p- and q-arm in uveal melanoma; yet, deletion of 6q or gain of 6p 
are not associated with metastatic disease10. 
Uveal melanoma are genetically well-characterized tumors. Recent research using ge-
nome-wide sequencing led to the discovery of several genetic alterations, which correlate 
to a distinct survival pattern. Activating mutations in guanine-nucleotide binding protein- 
Q (GNAQ) and -alpha 11 (GNA11) were found in the majority of uveal melanoma patients 
(83-93%), and are therefore thought to be initiating mutations11,12,13. Inactivating mutations 
in the BRCA-associated protein 1 (BAP1), located on chromosome 3p, were found in the 
early metastasizing patients14. Recently two other genes have been reported that play a 
role in uveal melanoma biogenesis. Mutations in the eukaryotic translation initiation fac-
tor 1A (EIF1AX) were observed in non-metastasizing tumors15 and a hotspot mutation in 
the splicing factor 3 subunit 1 (SF3B1)-gene was detected in late metastasizing tumors16,17. 
Both of these genes are known to be mutually exclusive.
Current clinical diagnostics for uveal melanoma include several techniques, such as ex-
pression profiling18, copy number analysis by Illumina single nucleotide polymorphism 
(SNP)-array19, multiplex ligation-dependent probe amplification20 or fluorescence in situ 
hybridisation21, immunohistochemistry of the BAP1 protein22,23 and Sanger sequencing of 
EIF1AX, SF3B1 and BAP1. In some cases, whole-genome sequencing or whole-exome se-
quencing is used to identify the somatic mutations present in the tumor15,24. In this study 
we performed Ion Torrent next-generation sequencing with a custom made panel on 70 
uveal melanomas to determine if targeted sequencing can be implemented in the routine 
uveal melanoma-diagnostics. This panel has been designed specifically for uveal mela-
noma, covering all major hotspot mutations in the five relevant genes and several single 
nucleotide polymorphisms on chromosome 1, 3 and 8 to allow analysis of clinically rel-










Sixty-five uveal melanoma samples were selected from our Rotterdam Ocular Melanoma 
Study Group-database and 5 were external samples from patients who underwent enucle-
ation, received for diagnostics from the Liverpool Ocular Oncology Research Group. Sam-
ples included in this study were diagnosed as uveal melanoma, collected between 1988 
and 2016, and include formalin-fixed paraffin-embedded and fresh specimens. A written 
informed consent was obtained before treatment, the study was performed according to 
the guidelines of the Declaration of Helsinki and was approved by the local ethics com-
mittee.
DNA extraction
Targeted next-generation sequencing was performed on DNA extracted from fresh- and 
formalin-fixed paraffin-embedded samples. For all tumor samples, an ophthalmic pathol-
ogist reviewed and selected tumor areas with an estimated minimal tumor cell percentage 
of 85%. DNA isolation from fresh tissue was carried out using the QIAmp DNA mini kit 
(Qiagen, Hilden, Germany), according to the manufacturer’s instructions. For formalin-
fixed paraffin-embedded samples, depending on the size of the tumor, 2-6 5µm sections 
were de-paraffinized and hematoxylin stained prior to isolation of the DNA. Formalin-
fixed paraffin-embedded tumor tissue was micro-dissected by scraping the cells manually 
from hematoxylin-stained sections. DNA was then extracted by incubation of the tissues 
overnight at 56°C in lysis buffer (Promega, Madison, WI, USA), containing 5% Chelex 
(Bio-Rad, Berkley, CA, USA) and Proteinase K (Qiagen). Proteinase K was inactivated by 
incubating the sample for 10 minutes at 95°C and cell debris was pelleted down together 
with the Chelex by centrifugation in a micro-centrifuge at maximum speed. DNA concen-
trations were measured with the Quant-iT Picogreen assay kit (Thermofisher Scientific, 
Grand Island, NY, USA), as described by the manufacturer. All DNA samples were stored 
at -20°C. The DNAs provided by the Liverpool Ocular Oncology Research Group had 
been extracted as previously described using the Qiagen DNeasy Blood and Tissue kit25.
Targeted Next-Generation Sequencing
A custom primer panel covering the five uveal melanoma genes and several single nucleo-
tide polymorphisms located on chromosomes 1, 3 and 8, was designed using Ion Am-
pliseq Designer 2.0 (ThermoFisher Scientific). This resulted in an 11.5 kb amplicon panel, 
containing 98 amplicons. Amplicons designed for GNAQ, GNA11, EIF1AX and SF3B1 
covered only the exons containing the known mutation hotspots. All exons of the BAP1 
gene were covered by amplicons. On chromosome 1 and 8, seventeen amplicons were 
designed to cover highly polymorphic regions in the entire chromosome (Supplementary 
table 1). These highly polymorphic regions with a global minor allele frequency of at least 
45% were selected based on data found in the NCBI SNP database26. For chromosome 3 
twenty-one amplicons were designed, due to the clinical relevance. The DNA input varied 
between 3 and 10 ng, depending on the amount of DNA available per sample. Library 
construction was performed using the AmpliSeq Library Kit 2.0. Next-Generation ampli-
con sequencing of the libraries was performed by semiconductor sequencing with the Ion 
Torrent Personal Genome Machine (Thermofisher Scientific) on an Ion Chip, according to 
the manufacturer’s protocol. 
Mutation Analysis
Adapter trimming and filtering of poor quality reads was performed on raw Ion Torrent 
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er Scientific). The generated sequence reads were analysed with Coverage Analysis and 
Variant Caller v3.6 plugins to perform sequence coverage analysis and identify variants, 
respectively. Variants identified as a common polymorphism in the 1000 Genomes-da-
tabase and variants that were present in >90% of the samples were excluded. If variants 
were present in a frequency higher than 15% and if they had a minimum read depth of 
100 reads, they were called as mutations. Analysis of the detected mutations was done 
by visualizing the reads in Integrative Genomics Viewer software (Broad Institute, Cam-
bridge, MA, USA) and comparing them to the Ensemble genome database (NM_002072; 
NM_002067; NM_004656; NM_012433; NM_001412). 
Sanger sequencing
DNA from 28 tumor samples was sequenced using the Sanger method to confirm results 
found by next-generation sequencing. Selected regions of the genes of interest were am-
plified by polymerase chain reaction (PCR). Subsequently, sequencing of the PCR prod-
ucts and mutation analysis of GNAQ, GNA11, BAP1 and SF3B1 and EIF1AX was done 
as reported previously13,16,22. Alignment of the sequence reads was done with reference 
sequence Hg19 from the Ensemble genome database.
Immunohistochemical staining
To detect loss of the BAP1 protein in tumors, immunohistochemical staining of BAP1 was 
performed on 4µm formalin-fixed paraffin-embedded sections of tumors. Staining was 
done by an automated immunohistochemistry staining system (Ventana Medical Systems 
Inc, Tucson, AZ, USA) as described before22. BAP1 protein expression data were also avail-
able for the cases received from Liverpool Ocular Oncology Research Group, which were 
stained as previously described27. Sections were evaluated by the ophthalmic pathologists 
in Rotterdam and Liverpool (RV and SEC, respectively).
Copy number variation analysis
Validation of the copy number status of the chromosomes was performed by SNP-array, 
multiplex ligation-dependent probe amplification and fluorescence in situ hybridisation 
analysis. Two hundred nanograms of fresh tumor DNA was used for the Illuminia 610Q 
SNP-array (Illumina, San Diego, CA, USA). Results were analyzed with Nexus Software 
(BioDiscovery, El Segundo, CA, USA). One hundred nanograms of DNA from each forma-
lin-fixed paraffin-embedded uveal melanoma was used for multiplex ligation-dependent 
probe amplification analysis of chromosomes 1p, 3, 6 and 8 as previously described20. 
Fluorescence in situ hybridisation analysis was performed on directly fixed tumor mate-
rial, with probes for chromosome 1, 3 and 8 as reported previously21
Results 
 
Coverage of uveal melanoma genes
To detect mutations in the GNAQ-, GNA11-, EIF1AX-, SF3B1- and BAP1 gene, 43 ampli-
cons were used to sequence these genes reliably. Samples with a minimum total read 
count of 40.000 were analyzed for mutations in the five uveal melanoma genes. The total 
amount of read counts for fresh samples was on average slightly higher than those of 
formalin-fixed paraffin-embedded samples (Figure 1A). Most of the amplicons covering 
the five uveal melanoma genes consisted of 1 – 2% of the total read count, which corre-
sponds to a minimum of 400 reads (Figure 1B). The median read count of all amplicons 
was 1.1%. Several amplicons obtained a coverage of less than 1% of the total read count, 
such as EIF1AX exon 1 and BAP1 exon 1 and 3. By adding extra amplicons in the primer 
mix for these areas, we compensated for these lower read counts. 
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Figure 1. Sequencing efficiency of formalin-fixed, paraffin-embedded and fresh uveal melanoma specimens
A) Boxplots showing the total read count for all fresh- (top plot) and formalin-fixed, paraffin-embedded (FFPE) 
samples (bottom plot) B) Percentage of total reads visualized for all amplicons covering the five uveal melanoma
genes. Solid line indicates median for all amplicons and light grey area shows second- and third quartile.
Mutation analysis
Seventy uveal melanoma samples were sequenced with our targeted panel. DNA was 
isolated from fresh specimens (n=43) and from formalin-fixed paraffin-embedded mate-
rial (n=27). From all 70 samples sufficient DNA was extracted for sequencing. Forty-one 
percent of the samples harbored a GNAQ exon 5 c.626A>C or c.626A>T mutation, 3% a 
GNAQ exon 4 c.548G>A mutation, 41% a GNA11 exon 5 c.626A>T mutation, 1% a GNA11 
exon 4 c.547C>T mutation and in the remaining samples no mutations in either of these 
two genes were detected (Table 1). Mutations in the BAP1 gene were found in 41% of the 
cases, mutations in SF3B1 in 16% and EIF1AX in 20% of the samples (Supplementary Table 
2). From 28 samples we extracted enough DNA from fresh tissue to perform Sanger se-
quencing as well. All the mutations found by next-generation sequencing in these samples 









Figure 2. The overlap between the chromosome 3 status, BAP1 mutation status and BAP1 expression
A doughnut chart visualizing the chromosome 3 status (outer ring), BAP1 mutation status (middle ring) and BAP1 
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Detection of loss of BAP1 protein expression
Absence of the BAP1 protein is often associated with monosomy 3 uveal melanoma. The 
loss of nuclear BAP1 expression can be immunohistochemically assessed, which is rou-
tinely performed in a diagnostic setting. Uveal melanoma samples were sequenced and 
analysed for BAP1 mutations. Half of all the samples showed loss of chromosome 3. 74% 
of these monosomy 3 samples harbored a BAP1 mutation and 26% did not. BAP1 immu-
nohistochemistry was carried out for 59 samples, since we did not have tissue available for 
immunohistochemistry in all samples. In the BAP1-mutated samples of which we obtained 
BAP1 immunohistochemistry data, 80% showed a negative BAP1 immunohistochemistry 
(-), 5% showed a mixture of positive and negative BAP1 cells in the tumor (+/-) and 15% 
showed a positive BAP1 immunohistochemistry (+) (Figure 2 and Supplementary table 2). 
The results obtained from three samples are depicted in figure 3. Hematoxylin and eosin 
staining indicated a high presence of tumor cells in all three samples (Figure 3A). BAP1 
staining was positive for the upper sample and negative for both the middle and lower 
sample (Figure 3B). Ion Torrent sequencing of the BAP1 gene revealed no mutations in the 
top sample but did show a mutation in the other two samples (Figure 3C), confirming the 








Figure 3. Histopathological and genetic aspects of three uveal melanoma specimens
A) Hematoxylin and eosin-staining (HE) of three uveal melanoma samples (200x) B) Immunohistochemistry (IHC) 
staining of BAP1 protein showing strong nuclear BAP1 expression in the top sample and loss of BAP1 expression 
in middle and bottom sample (200x) C) From top to bottom: no mutation observed in the BAP1-gene,  a 5-basepair 
deletion and insertion in exon 14 resulting in a frameshift (c.175_179delinsA ) and a point mutation in exon 6 
which changes a Glutamate into a STOP-codon (c.406G>T).
Copy number analysis
SNP-array, multiplex ligation-dependent probe amplification and fluorescence in situ hy-
bridisation analyses are commonly used to identify chromosomal changes in tissues. To 
determine whether the Ion Torrent uveal melanoma custom panel allows a reliable detec-
tion of allelic imbalances caused by (partial) losses and gains of chromosome 1, 3 and 8, we 
compared results obtained by fluorescence in situ hybridisation and SNP-array with the 
copy number variation results from our custom panel. Single nucleotide polymorphism 
covering amplicons were evenly distributed over the entire chromosome (Figure 4A), 
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which allowed us to observe partial aberrations as well. Fluorescence in situ hybridisation 
results showed disomy 3 for the top sample and monosomy 3 for the lower sample (Figure 
4B). This was confirmed with the SNP-array, where the Log R Ratio and B-allele frequency 
shows no loss of heterozygosity for chromosome 3 in the upper sample and monosomy 3 
for the lower sample (Figure 4C). The same pattern of allelic distribution was seen with the 
Ion Torrent single nucleotide polymorphism-analysis of chromosome 3 (Figure 4D). The 
B-allele frequencies for chromosome 1 and 8 were confirmed as well, as shown in supple-
mentary figure 1. Across all samples we found that 50% showed monosomy 3, 30% loss of 
chromosome 1p and 57% gain of chromosome 8q. These percentages overlapped with the 
percentages found by other copy number variation-techniques. Thirty-four samples were 
validated with only an Illumina SNP-array, 15 with SNP-array and fluorescence in situ 
hybridisation, 7 with only fluorescence in situ hybridisation and 5 samples with multiplex 
ligation-dependent probe amplification (Supplementary table 3). 
 
Figure 4. Copy number analysis of chromosome 3
A) Visualization of the evenly spread amplicons covering highly polymorphic single nucleotide polymorphisms 
on chromosome 1,3 and 8.  B) Fluorescence in situ hybridisation (FISH) of chromosome 5 (red) and chromosome 
3 (green) shows no loss for chromosome 3 in the top sample and loss of chromosome 3 in the bottom sample C) 
Top SNP-array visualizes chromosome status for chromosome 1 to 8. Both Log R Ratio and B-allele frequency 
indicate disomy 3, whereas the SNP-array for the bottom panel shows loss of chromosome 3 D) Single nucleotide 
polymorphism (SNP) analysis performed by the targeted uveal melanoma panel visualizes the B-allele frequency 
for chromosome 3. Top single nucleotide polymorphism analysis shows heterozygosity for the single nucleotide 
polymorphisms, indicating disomy 3, while bottom sample shows no heterozygous variants indicating loss of 
heterozygosity of chromosome 3.
Discussion
Uveal melanoma is characterized by recurrent mutated genes and chromosomal anoma-
lies. In this study we present a novel custom-designed next-generation sequencing assay 
for uveal melanoma, which can be used to predict uveal melanoma patients’ prognoses 
based on mutation status and chromosome status of chromosome 1,3 and 8. The assay can 
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fixed paraffin-embedded material. This is the first study that establishes a method that 
can be used for uveal melanoma diagnostics on both formalin-fixed paraffin-embedded 
and fresh material. Our assay is cost-effective, since one method can replace techniques, 
such as fluorescence in situ hybridisation, SNP-array and Sanger sequencing and it can 
be considered as a good alternative for BAP1 immunohistochemistry. Other important 
advantages are the low amount of DNA (10 ng) necessary for sequencing, which makes 
the technique suitable for transvitreal fine needle aspirations biopsies and the small am-
plicon-size, allows sequencing of partially degraded DNA from formalin-fixed paraffin-
embedded tissue. Our assay could be performed on other next-generation sequencing 
platforms than Ion Torrent sequencing as well, if these two characteristics are taken into 
account. Furthermore, compared to other techniques that only identify the high risk pa-
tients that metastasize early, this technique also allows us to identify the potentially late 
metastasizing patients that often harbor a SF3B1 mutation.
Prognostication of uveal melanoma patients can be achieved by analyzing mutation sta-
tus. Currently, this is usually performed by Sanger sequencing. Mutations in GNAQ, 
GNA11 and SF3B1, all gain of function mutations, occur almost exclusively in hotspot 
locations, therefore only these locations have to be sequenced. Since mutations can occur 
throughout the entire BAP1 gene, large amounts of DNA are needed for the sequencing 
of multiple exons. Whole-exome sequencing is a reliable and easy method to obtain muta-
tion status as well. However, since only a few genes are involved in the oncogenesis of 
uveal melanoma, many irrelevant reads will be produced. Whole-exome sequencing is 
less cost-effective for the diagnostic setting, compared to targeted Ion Torrent sequencing.
Several regions of the human genome are difficult to cover with next-generation sequenc-
ing. As shown in figure 1B, a few exons, such as BAP1 exon 1 and the first two exons of 
EIF1AX, show a relatively low read count. Due to this low read count, it is more difficult 
to detect mutations in this particular exon. These findings are not only observed in our 
targeted uveal melanoma panel, but also in whole-genome sequencing data of uveal mela-
noma17,28. Since exon 1 of the BAP1 gene is located in the non-translated region, the effect 
of a mutation in this UTR region is not always clear. Another region, which is sensitive 
for sequencing errors is exon 1 of EIF1AX, caused by a pseudogene on chromosome 1. 
Amplicons covering only exon 1 may also produce reads derived from chromosome 1. By 
adding a second set of reads generated by a different amplicon for EIF1AX, we now cover 
not only exon 1 but also a part of the 3’UTR, which will obtain longer reads that can only 
be derived from EIF1AX exon 1. 
In our cohort we observed mutations in all of the major uveal melanoma genes. Eighty-
six percent of the samples showed a mutation in GNAQ or GNA11. Mutations in EIF1AX 
were found in 20%, mutations in SF3B1 in 16% and mutations in BAP1 were detected in 
41% of the cases. The obtained results do not exactly overlap with the mutation rates for 
uveal melanoma that we previously reported16, but those differences can be explained 
by the bias in our sample population. Samples selected for this study were not randomly 
chosen, but rather selected based on follow-up length and tissue availability. Figure 2 
shows that only 74% of the monosomy samples harbor a BAP1 mutation, which can be ex-
plained by studies showing that BAP1 mutations arise after loss of chromosome 329. Most 
of the BAP1-mutated samples showed a negative BAP1 immunohistochemistry, but some 
had positive and negative BAP1 immunohistochemistry cells, which possibly indicates 
that not all of the cells in the tumor have acquired the mutation yet. However, we also 
observed BAP1-mutated samples that showed a positive BAP1 immunohistochemistry. 
For the disomy 3 samples, this can be explained by the presence of a BAP1 wildtype gene, 
but this is not the case for the monosomy 3 samples. In these samples we hypothesize that 
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the mutated mRNA is not degraded by nonsense mediated decay and could thereby still 
be translated into a partially functional or non-functional protein. If the antibody binds 
at a different location as where the mutation is found, it will show a positive immunohis-
tochemistry. However, for the majority (91.6%) of the samples the uveal melanoma panel 
can correctly detect mutations corresponding to the observed loss of BAP1-expression.
Besides mutation status-analysis, our panel also provides information about the copy 
number status. Techniques such as fluorescence in situ hybridisation, multiplex ligation-
dependent probe amplification and SNP-array can provide information about the chro-
mosomal change of one or several chromosomes in the tumor in most cases, but these 
techniques also have their disadvantages. The probes used for fluorescence in situ hy-
bridisation are specific for a certain region, i.e. fluorescence in situ hybridisation testing 
does not screen the entire chromosome. It is also a relatively laborious technique, which 
can take up to several days. Performing a SNP-array requires less time, but the amount 
of DNA necessary (200 ng) is significantly higher than other techniques. Furthermore, 
standard SNP-array is less successful on DNA extracted from formalin-fixed paraffin-
embedded tissue compared to freshly obtained DNA. With our uveal melanoma panel, 
we reliably detect copy number variations by sequencing of highly polymorphic single 
nucleotide polymorphisms. Since this assay requires less DNA than conventional SNP-
arrays and less time than fluorescence in situ hybridisation, it is a promising method for 
routine uveal melanoma diagnostics. Copy number analysis by next-generation sequenc-
ing can be challenging in case of low tumor percentages, but since uveal melanoma typi-
cally tend to have a high tumor cell content and little heterogeneity for chromosome 3 
we do not expect this will pose a problem in our assay30. Chromosome 1 and 8 might 
have more heterogeneity, thus in case of low tumor cell content and non-conclusive Ion 
Torrent single nucleotide polymorphisms array results, additional experiments might be 
necessary. The single nucleotide polymorphism analysis performed with this uveal mela-
noma panel does not allow detection of polyploidy in samples. However, recently it has 
been shown that polyploidy in uveal melanoma does not change the mutation prevalence, 
which means that detecting polyploidy in uveal melanoma patients has little impact in 
this method since it does not affect the prognosis31.
Our Ion Torrent uveal melanoma panel is in the current state already suitable for imple-
mentation in uveal melanoma prognostication, with the advantage that it can easily be 
expanded by adding the more recently discovered genes into our panel. Recently, it has 
been reported that a small percentage of the uveal melanoma samples contain mutations 
in other spliceosome components, SR2F2 and U2AF1. It is thought that these tumors act 
in the same way as SF3B1-mutated tumors32. Other rare alterations in uveal melanoma are 
mutations in PCLB4 and CYSTLR2, which are downstream targets of GNA11 and GNAQ 
and are thereby thought to be less suitable for prognostication33. 
In summary, we present a next-generation sequencing based assay that can readily be 
implemented as a diagnostic pathology application for uveal melanoma. Mutation and 
copy number variation data can be obtained by one technique, which can reliably predict 
the patients’ outcome and potentially assess eligibility for new therapies. At present there 
is no successful treatment for metastasized uveal melanoma; however, with the develop-
ment of new therapies, identification of high-risk patients will be very important, particu-
larly in adjuvant therapy trials. Our custom-designed uveal melanoma panel will make a 
valuable contribution to the rapid stratification of uveal melanoma patients. 
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Supplementary Table 1. List of the highly polymorphic single nucleotide polymorphisms 
(SNP) covered by the uveal melanoma panel
 
 
   SNP-number  Position (bp)
 Chromosome 1 rs7418256   4,084,304
   rs7412149   9,579,964
   rs12048851   16,382,718
   rs10907287   18,497,478
   rs6425861   34,372,503
   rs639298   42,001,530
  rs11209106   68,001,206
   rs480304   82,123,485
   rs10493903   98,900,818
   rs17258467   120,323,058
   rs1752380   151,347,746
   rs3856201   163,736,341
   rs10753786   169,288,770
   rs2072040   175,096,333
  rs138685314  188,228,295
   rs6681013   215,154,797
   rs592197   234,817,283
 Chromosome 3 rs1601368   10,829,535
   rs1549356   21,528,837
   rs7612272   28,816,226
   rs7648156   34,497,918
   rs1274960   39,192,542
  rs267218   45,633,834
   rs9311387   46,115,590
   rs295449   47,375,955
   rs3821659   54,987,923
   rs2702143   55,738,509
   rs9868630   56,012,096
   rs62259027   57,747,389
   rs9310190   70,420,837
   rs12497448   86,741,603
   rs1151334   102,257,506
  rs3749299   111,673,147
   rs4045771   121,962,478
   rs975149   134,666,475
   rs1004009   152,754,481
   rs9866779   175,021,665
   rs11717776   197,569,559
 Chromosome 8 rs2405488   2,141,263
   rs4498602   10,180,242
  rs17577614   15,470,729
   rs13275706   19,327,151
   rs6557699   23,602,610
   rs1882928   31,023,822
   rs10095600   36,911,156
   rs4147426   47,909,945
   rs10107875   60,526,565
   rs6995640   68,904,187
  rs2120410   79,844,006
   rs13261311   87,705,504
   rs4735258   94,935,937
   rs4734993   108,686,209
   rs2142250   117,093,062
   rs6415522   131,905,690
   rs7008457   145,536,593
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Supplementary Table 2. Mutation status, BAP1 immunohistochemistry and chromosome 
3 status of all 70 samples
Mutation status:
●: mutation observed      ●ѕ: mutation validated by sanger sequencing      
BAP1 immunohistochemistry:
+: positive BAP1 staining             +/-: mixed positive and negative BAP1 staining in tumor        -: negative BAP1 staining               NE: not evaluated 
Copy number status: 


















UM-1 FFPE ●ѕ ●ѕ  +
UM-2 FFPE ● ● - ●
UM-3 FFPE ● ● +/-
UM-4 FFPE ● ● ne ●
UM-5 FFPE ● ● ne ●
UM-6 FFPE ● ● ne ●
UM-7 FFPE ● ●  ne
UM-8 FFPE ● ●  ne
UM-9 FFPE  + ●
UM-10 FFPE ● + ●
UM-11 FFPE ● ●  +
UM-12 FFPE ● ●  +
UM-13 FFPE ● ●  +
UM-14 FFPE ●  +
UM-15 FFPE ●  +
UM-16 FFPE ●  +
UM-17 FFPE ● ● - ●
UM-18 FFPE ● ●  +
UM-19 FFPE ● ● + ●
UM-20 FFPE ● - ●
UM-21 FFPE ● ●  +
UM-22 FFPE ● ●  +
UM-23 FFPE ● ● - ●
UM-24 FFPE ● ●  +
UM-25 FFPE ●ѕ ●ѕ +/- ●
UM-26 FFPE ●ѕ  +
UM-27 FFPE ●ѕ ●ѕ - ●
UM-28 Fresh  ne
UM-29 Fresh ●ѕ ●ѕ + ●
UM-30 Fresh ●  +
UM-31 Fresh ● ●  +
UM-32 Fresh  +/-
UM-33 Fresh ● ●  + ●
UM-34 Fresh  +
UM-35 Fresh ●ѕ ●ѕ  +
UM-36 Fresh ● ● - ●
UM-37 Fresh ● ● ne ●
UM-38 Fresh ●ѕ  ne ●
UM-39 Fresh ●ѕ ●ѕ + ●
UM-40 Fresh ●ѕ ●ѕ  +
UM-41 Fresh  +
UM-42 Fresh ●ѕ ●ѕ  +
UM-43 Fresh ● ●  +
UM-44 Fresh ●ѕ ●ѕ ne ●
UM-45 Fresh ● ●  +
UM-46 Fresh ●  ne ●
UM-47 Fresh ● ● +
UM-48 Fresh ●ѕ ●ѕ - ●
UM-49 Fresh ● ● - ●
UM-50 Fresh ●ѕ  - ●
UM-51 Fresh ●ѕ ●ѕ - ●
UM-52 Fresh ●ѕ ●ѕ +
UM-53 Fresh ●ѕ ●ѕ  +
UM-54 Fresh ●ѕ ●ѕ  + ●
UM-55 Fresh + ●
UM-56 Fresh ●ѕ ●ѕ - ●
UM-57 Fresh ●ѕ ●ѕ - ●
UM-58 Fresh ● ● - ●
UM-59 Fresh ●ѕ ●ѕ - ●
UM-60 Fresh ●ѕ  - ●
UM-61 Fresh ●ѕ ●ѕ  +
UM-62 Fresh ●ѕ ●ѕ  +
UM-63 Fresh ●ѕ ●ѕ  +
UM-64 Fresh ●ѕ ●ѕ  +
UM-65 Fresh ●ѕ ●ѕ - ●
UM-66 Fresh         ● ● ne ●
UM-67 Fresh ●ѕ ●ѕ - ●
UM-68 Fresh ●ѕ ●ѕ  +
UM-69 Fresh  +































Supplementary Figure 1. Copy number analysis of chromosome 1 and 8
A) Single nucleotide polymorphism analysis indicates no loss of the entire chromosome 1 B) The 
absence of heterozygous variants in the B-allele frequency in the 1p arm of chromosome 1, indicates 
loss of 1p and normal 1q C) Single nucleotide polymorphism analysis shows two copies of  chromo-
some 8 D) Loss of the p-arm of chromosome 8 and allelic imbalance of the 8q arm. 
 
 
Supplementary Table 3. Chromosome status of chromosome 1p, 3 and 8q determined by Iontorrent 


























Loss of chromosome 1p Loss of chromosome 3 Gain of chromosome 8q
Iontorrent SNP assay 30% (19/63) 52%  (33/63) 57% (36/63)
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Correlation of gene mutation status with 
copy number profile in uveal melanoma
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Copy number variations (CNV) , gene expression profiling but also the recurrent gene 
mutations in BAP1, SF3B1, or EIF1AX, can be used to stratify uveal melanoma (UM) pa-
tients 1-4. Recently, Decatur et al described an association between specific gene mutations 
and gene expression profiles5. In this report we describe the relationship between muta-
tional status of BAP1, SF3B1 and EIF1AX and CNV patterns using conventional karyotyp-
ing data to explore the nature of these CNVs.
In total, 277 patients from the Rotterdam Ocular Melanoma Study Group (ROMS)  were 
included in this study. Details of the patient population and methods are described in 
the Supplementary Methods (available at www.aaojournals.org). For 207 samples, single 
nucleotide polymorphism array data and mutational status were available. These patients 
were divided into 4 subgroups: patients with (1) immunohistochemically BAP1-negative 
tumors (BAP1neg); (2) SF3B1-mutated tumors (SF3B1mut) and (3) EIF1AX-mutated tu-
mors (EIF1AXmut). Patients in which the tumors were immunohistochemically BAP1 
positive and contained no SF3B1 or EIF1AX mutations were classified as (4) no recurrent 
mutations (NRM) tumors. This group was further split into subgroups with and without 
the loss of heterozygosity (LOH) of the BAP1 locus (NRMLOH+ and NRMLOH-, respec-
tively). 
We visualized sample distribution of the single nucleotide polymorphism array data 
across the predefined groups to obtain chromosomal patterns (Fig 1A) and found that 
BAP1neg tumors (n = 84) were characterized by loss of chromosome 3 (95% of the cases) 
and gain of the entire long (q) arm of chromosome 8 (80%). Gain of chromosome 8q was 
often accompanied by loss of chromosome 8p (26%). Loss of chromosome 1p, 6q and 16q 
was also observed frequently (25%, 19% and 20%, respectively). SF3B1mut tumors (n = 
42) were characterized by gain of chromosome 6p (85%) and 8q (73%), and loss of chro-
mosome 6q (52%) and 11q (45%). In addition, loss of chromosome 1p (36%) and gain of 
chromosome 9q (24%) were present in SF3B1mut tumors. 
BAP1neg UMs showed gains or losses of entire chromosomes or chromosome arms , 
whereas SF3B1mut UMs were characterized by structural variants of the distal ends 
of the chromosomes (e.g. gain of chromosome 8q23qter, 8q13qter, 6p12.3pter or loss of 
6q16.1qter and 11q22qter). EIF1AXmut tumors (n = 26) showed gain of chromosome 6p 
(often 6p21.33pter) in 65% of the cases. No other recurrent CNVs were observed in EI-
F1AXmut UMs. NRMLOH- tumors (n = 28) were characterized by gains of the distal ends 
of chromosome 6p (53%) and 8q (28%). NRMLOH+ UMs (n = 19) were characterized by 
monosomy 3, because we stratified for LOH of BAP1. These samples showed a very simi-
lar CNV profile as the BAP1neg UMs because these tumors also contained the typical gain 
of the entire arm of chromosome 8q, often accompanied by loss of chromosome 8p, and 
gain of the entire arm of chromosome 6p with loss of chromosome 6q. 
To substantiate the finding that BAP1neg UMs contain mainly entire chromosome or 
chromosome arm CNVs, and SF3B1mut UMs smaller, partial chromosome CNVs, we cal-
culated the percentages of aneuploidy and the number of CN events for all groups. These 
results (Fig 1B) showed significant greater percentages of aneuploidy in BAP1neg tumors 
compared with SF3B1mut tumors (11.8% and 9.3%, respectively; P = 0.024). EIF1AXmut 
tumors and NRMLOH- UMs harbored the least percentage of aneuploidy (1.7% and 4.3%, 
respectively), which were significantly lower than in BAP1neg and SF3B1mut tumors (P 
< 0.001 for all). As for CN events, SF3B1mut UMs harbored the most CN events, although 
this was not significantly higher than BAP1neg UMs (P = 0.074) in the single nucleotide 
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bored more CN events than EIF1AXmut and NRMLOH- UMs (P ≤ 0.01 for all; Fig 1C). 
Furthermore, cytogenetic data and mutational status of 70 patients were used for analysis 
of the different types of chromosomal anomalies. Translocations or partial chromosome 
arm CNVs were categorized as chromosomal structural variants (CSVs) and were numer-
ated manually. Although cases were limited, SF3B1mut UMs strongly associated with >3 
CSVs per tumor compared to BAP1neg (P = 0.002; Fig 1D). Moreover, 70% (7 of 10) of the 
UMs with >3  harbored an SF3B1 mutation, showing that tumors with multiple CSVs are 
most likely to be SF3B1-mutated. 
 
Figure 1. A) Summary plots showing the chromosomal patterns for the different groups of uveal melanomas 
(UMs). The chromosomes are depicted on the x-axis. The Y-axis shows the cumulative percentage of copy number 
variation per group. Dark blue indicates gain of chromosome and red indicated loss of chromosome. The sex-
chromosomes are excluded. B) Statistical comparisons of the percentage of aneuploidy between the groups and C) 
the total number of copy number (CN) events. D) Comparison of the number of chromosomal structural variants 
obtained from cytogenetic data. The continuous lines between the groups are statistically significant differences (P 
< 0.05) between the groups. The dashed line depicts no significant difference between the groups.
Another type of chromosomal anomaly found in UMs were isochromosomes. These were 
observed in 74% (25/34) of all BAP1neg tumors (Supplementary Table, available at www.
aaojournals.org), whereas both SF3B1mut and EIF1AXmut UMs harbored no isochromo-
somes. Remarkably, besides isochromosomes 8q, also isochromosome 6p was recurrent 
in BAP1neg UMs. Other chromosomal changes in BAPneg UMs were almost exclusively 
translocations with breakpoints in the centromeric regions (and thus entire chromosome 
arms) whereas SF3B1mut tumors contained more structural aberrations with recurrent 
distal breakpoints on chromosome 6 and 8, suggesting that different mechanisms play a 
role in causing these anomalies.
These novel insights in the chromosomal patterns and different types of chro-
mosomal anomalies show that UMs with different mutated genes represent dis-
tinct molecular classes. We and others have shown that stratification based on 
BAP1, SF3B1 and EIF1AX mutations reveal that patients with these mutated genes 
have a high, intermediate or low risk of developing metastases, respectively4, 5. 
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A limitation in this study was the use of BAP1 immunohistochemistry to replace –in part 
- BAP1 sequencing. For example, we expect BAP1 mutations in the NRMLOH+ group, 
because these tumors revealed similar CNVs as the BAP1neg UMs. We are currently in-
vestigating this using deep sequencing and Western blotting. Furthermore, in this study 
all except 2 tumors were obtained from enucleated eyes; therefore, the tumor popula-
tion is skewed towards larger tumors. These tumors tend to have a worse prognosis than 
eyes that undergo eye-conserving therapy. Nevertheless, this limitation does not affect the 
clinical significance of our observations that UMs have different molecular classes. 
In conclusion, in this report we show that patients with UMs harbor mutation-spe-
cific chromosomal patterns in the tumor. These chromosomal patterns are character-
ized by different types of chromosomal anomalies, thus illustrating that distinct bio-
logical mechanisms underlie uveal melanoma pathogenesis. These pathways could 
possibly be specifically targeted with future diagnostics and types of treatment. 
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Uveal melanoma (UM) is the most frequently found primary intra-ocular tumor in adults. 
It is a highly aggressive cancer that causes metastasis-related mortality in up to half of 
the patients. Many independent studies have reported somatic genetic changes associ-
ated with high metastatic risk, such as monosomy of chromosome 3 and mutations in 
BAP1. Still, the mechanisms that drive metastatic spread are largely unknown. This study 
aimed to elucidate the potential role of microRNAs in the metastasis of UM. Using a next-
generation sequencing approach in 26 UM samples we identified thirteen differentially 
expressed microRNAs between high-risk UM and low/intermediate-risk UM, including 
the known oncomirs microRNA-17-5p, microRNA-21-5p, and miR-151a-3p. Integration 
of the differentially expressed microRNAs with expression data of predicted target genes 
revealed 106 genes likely to be affected by aberrant microRNA expression. These genes 
were involved in pathways such as cell cycle regulation, EGF signaling and EIF2 signal-
ing. Our findings demonstrate that aberrant microRNA expression in UM may affect the 
expression of genes in a variety of cancer-related pathways. This implies that some mi-
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Introduction
Uveal melanoma (UM) is an aggressive cancer that arises from melanocytes located in the 
uveal tract of the eye. Although treatment of primary tumors has a high success rate, up to 
half of the patients develop metastasis which often results in death within several months1. 
UM display chromosomal aberrations and genetic abnormalities that underlie both the 
development and metastasis of UM tumors. Most tumors carry a GNAQ or GNA11 mu-
tation. These mutations are considered to be tumor-initiating mutations and do not in-
crease the risk of metastasis2–4. UM patients can be stratified into three different metastatic 
risk groups; those who have a low-, intermediate-, or high-risk of developing metastasis5. 
High-risk UM harbor a mutation in the tumor suppressor gene BRCA-associated protein 
(BAP1), located on chromosome 36. Mutations in this gene often coincide with monosomy 
3, resulting in loss of expression of the BAP1 protein. BAP1 is a deubiquitinating enzyme 
known to be active in several cellular processes such as DNA damage response, apoptosis, 
and chromatin remodeling7–9. Intermediate-risk tumors carry a mutation in the gene-en-
coding splicing factor 3 subunit 1 (SF3B1), which is part of a protein complex involved in 
pre-mRNA splicing5,10,11. SF3B1 mutations in UM are known to result in aberrantly spliced 
transcripts that can either be degraded by nonsense-mediated decay or translated into 
unique, aberrant proteins. Low-risk UM often harbor a mutation in the eukaryotic trans-
lation initiation factor 1A (EIF1AX) gene, which is involved in the transfer of methionyl 
initiator tRNA to the small ribosomal subunit during translation10.
Besides the classification of UM into different metastatic risk groups based on gene muta-
tions, the disease can also be separated into two subclasses based on mRNA expression 
analysis. Each subclass has a distinct gene expression profile. Class 2 tumors, which include 
high-risk UM, have a stem cell-like expression pattern; whereas class 1 tumors, which include 
low- and intermediate-risk UM, have the transcriptome of a differentiated melanocyte12. 
Another mechanism that is thought to be essential in the development and metastatic 
progression of a tumor is aberrant expression of microRNAs. MicroRNAs (miRNAs) are 
small, single-stranded, non-coding RNAs that can regulate gene expression by binding 
to mRNA13,14. Although limited studies of miRNA expression in UM have been done 15–24, 
the miRNA profiles of the three risk groups and the downstream effects of any aberrant 
miRNA expression remains unclear. In this study we; therefore, performed small RNA 
sequencing in UM tissue. Additionally, mRNA sequencing of all UM samples allowed 
us to determine associations between miRNAs that were differentially expressed and the 
expression of their putative downstream mRNA-targets. Our aim was to identify miRNAs 
that might contribute to the invasive and metastatic potential of UM.
 
Materials and Methods  
Tissue Samples
26 patients diagnosed with UM were selected from our Rotterdam Ocular Melanoma Study-
group (ROMS) database. The specimens were collected from enucleated eyes between 
1995 and 2010 at the Erasmus University Medical Centre and the Rotterdam Eye Hospital 
(Rotterdam, The Netherlands). Shortly after surgery, half of the tumor was snap-frozen in 
liquid nitrogen to allow for DNA and RNA extraction. The other half of the eye was for-
malin-fixed paraffin-embedded and stained with hematoxylin and eosin for routine histo-
logical examination by an ophthalmic pathologist to verify neoplastic nature. This study 
was performed according to the guidelines of the Declaration of Helsinki (MEC-2009-





DNA was extracted from fresh tumor tissue using the QIAmp DNA-mini kit (Qiagen, Hilden, 
Germany) according to the manufacturer’s instructions. Mutation analysis of EIF1AX, SF3B1 
and BAP1 was carried out using Sanger sequencing as reported in previous publications4,25. 
Isolation and Sequencing of Small RNA and mRNA
Total RNA was isolated from sections of snap-frozen tumor samples, using the Qiagen 
miRNeasy isolation kit (Qiagen) according to the manufacturer’s manual. The quantity 
and purity of the RNA was determined using Bioanalyzer (Agilent Genomics, Santa Clara, 
CA, USA). A total amount of 4 µg RNA (RIN > 7.0) was used for the preparation of the 
small RNA and larger RNA libraries using the Ion Total RNA-seq kit (Thermofisher Sci-
entific, Waltham, MA, USA) following the manufacturer’s protocol. Both RNA libraries 
were subsequently sequenced with the Ion Proton sequencer (Thermofisher Scientific). 
Analysis of the Sequencing Data
Adapter sequences, low quality reads, and reads containing poly-N were removed from 
the generated RNA sequenced data using the Torrent Suite Software V 4.4.3 (Thermo-
fisher Scientific, Waltham, MA, USA). Reads shorter than 15 nucleotides were removed 
from downstream analysis in the small RNA dataset. The remaining reads were aligned 
against a miRBase reference genome using an in-house developed script26. Read per 
million mapped reads (RPM) was applied to quantify the expression of each miRNAs. 
Differential expression and fold changes of miRNAs between each of the patients sets 
was determined using the statistical package DEseq, with the cut-off fold discovery 
rate (FDR) < 0.05 (v.1.32.0)27. The miRNAs at low expression levels were removed by 
requiring an average of at least 250 RPM. Short Time-Series Expression Miner28, under 
the K-mean clustering method, was used to perform the miRNA expression cluster-
ing analysis. The long sequencing reads (>25 bp) were aligned to the human reference 
genome (hg19) with TopHat229. Genes at low expression level were removed by the 
requiring an average of at least 10 RPM. Differentially expressed genes were identi-
fied using DEseq30 with the cut-off FDR < 0.05. Genes were considered to be differen-
tially expressed if they had at least a log2FC of 1.5. The selected resulting genes were 
used as input for Ingenuity Pathway Analysis (IPA) (Qiagen) for the canonical pathway 
analysis. All analyses were performed using R statistical environment version 3.5.1. 
miRNA Target Gene Prediction and Validation
To obtain functional information from the differentially expressed miRNAs we integrated 
mRNA expression data with the miRNA expression data by cluster analysis. A list of pu-
tative target genes from the differentially expressed miRNAs was composed using miR-
walk 3.031, Targetscan 7.232, Diana micro-T 5.033, and miRDB 6.034. Genes were considered 
to be target genes if they were reported by at least two different prediction algorithms. 
Acquisition of TCGA Data
miRNA expression data of 80 UM samples35 were retrieved from the publicly accessible 
data repository at the Genomic Data Commons Data Portal (https://portal.gdc.cancer.gov/) 
Results 
Sample Collection and Analysis
Twenty-six UM patients were enrolled in this study and grouped into three subtypes 
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tus). Clinical, molecular, and histopathological characteristics of all patients are listed in 
Figure 1A. All patients had a choroidal or ciliary body UM, iris UM were excluded. Seven 
patients showed a mean DFS of 145 months and had an UM harboring an EIF1AX muta-
tion. These patients were included in the low-risk group and did not show disease pro-
gression. Twelve patients with a mean DFS of 103 months and an SF3B1 mutated UM were 
included in the intermediate-risk group. The high-risk group consisted of seven patients 
with a mean DFS of 28 months, a BAP1-mutated tumor, and a negative BAP1 immunohis-
tochemistry (IHC). Within the high-risk UM, all patients died due to metastasis, whereas 
in the intermediate group three patient were still metastasis-free and died because of other 
causes. From all 26 samples, mRNA and miRNA sequencing was performed and differen-
tially expressed (DE) miRNA and mRNA were identified (Figure 1B ). DE-miRNAs were 
verified in The Cancer Genome Atlas (TCGA) dataset. The target genes identified by the 
prediction algorithm analysis that also showed a significant negative correlation with the 
corresponding miRNA were considered to be a potential miRNA target gene and were 





Figure 1. A) The clinical, histological and molecular characteristics of all 26 UM patients B) Flowchart indicating 
the downstream analysis of the miRNA and mRNA sequencing data. Differentially expressed (DE) miRNAs be-
tween the high-risk samples and low/intermediate-risk samples were integrated with the DE genes extracted from 
the mRNA data. Subsequently, pathway analysis was performed in order to identify which canonical pathways 
were affected by differential miRNA expression. 
 
Identification of Differentially Expressed miRNAs
To investigate which miRNAs might be involved in the metastatic progression of UM, 
differential count analyses were performed among the three risk groups. We found 423 
mature miRNAs to be expressed in UM. To identify samples with a similar miRNA ex-
pression, we generated a principal component analysis (PCA) plot based on total miRNA 
expression. Unsupervised clustering revealed different clusters; one containing the high-
risk UM and the other cluster containing low-risk UM (Figure 2A). The intermediate-risk 
UM were found in a larger cluster that partially overlapped with the other two clusters. 
Seventeen miRNAs were differentially expressed between high- vs. low-risk UM, 20 DE-
miRNAs were identified between high- vs. intermediate-risk UM, and two DE-miRNAs 
were found between low- vs. intermediate-risk UM (Figure 2B,C and Figure S1). Since 
we aimed to identify miRNAs involved in the early metastasis of UM, we continued with 
thirteen miRNAs that were differentially expressed in the high-risk group, compared to 
the other two groups (Figure 2D). Of these thirteen, five miRNAs were upregulated sig-
nificantly in high-risk UM and eight miRNAs were downregulated significantly in high-
risk UM. Specifically, miRNA 132-5p, 151a-3p, 17-5p, 16-5p, and 21-5p all had a higher 
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expression in high-risk tumors, whereas miRNA 181b-5p, 101-3p, 378d, 181a-2-3p, 99a-5p, 
let-7c-5p, 1537-3p, and 99a-3p showed downregulation in the high-risk UM (Figure 2E). 





Figure 2. Differential miRNA expression within UM subtypes. (A) Principal Component Analysis (PCA) plot 
showing the unsupervised clustering based on total miRNA expression of all samples. (B) Volcano plot indicating 
which miRNAs are differentially expressed between high- vs. low-risk UM. (C) High- vs. intermediate-risk UM. 
Blue dots indicate downregulation and red dots indicate upregulation of the miRNA (D) The correlation between 
high- vs. low-risk and high- vs. intermediate-risk UM (E) Heatmap showing the set of 13 miRNAs identified to be 
potentially involved in the high-metastatic-risk UM.
Integration of miRNA and mRNA Expression Data Identifies Target Genes
To explore the biological relevance of the differentially expressed miRNAs involved in the 
metastatic progression of UM, such as their interaction with cancer-related genes, miRNA 
expression data were integrated with mRNA expression data. We performed mRNA se-
quencing on all 26 tumors and unsupervised clustering based on total mRNA expression 
showed a similar clustering as seen with the miRNA data (Figure 3A). The high-risk UM 
clustered in a separate group, whereas the low and intermediate-risk UM showed a partial 
overlap. All DE genes (log2FC > 1.5) with a p-value of less than 0.05 were separated into 
two clusters; one cluster contained all genes that showed downregulation in the high-risk 
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subsequently generated a target gene list for each miRNA by using four different predic-
tion algorithms (Figure S3). If a gene was predicted to be a target gene by at least two 
prediction algorithms and showed anti-correlation with its predicted miRNA, the gene 
was included into our analysis (n = 106) (Figure 3C).
 
 
Figure 3. Integration of miRNA and mRNA data. (A) PCA plot showing the unsupervised clustering of all 
samples based on total mRNA expression. (B) DE genes were clustered according to gene expression pattern. One 
group contained all genes that showed downregulation in the high-risk group, compared to the low-risk group. 
The other group contained genes that were upregulated in the high-risk group. (C) The predicted target genes that 
show anti-correlation with a specific DE miRNA. An asterisk indicates that more than one miRNA regulates the 
gene.
miRNA Target Genes From Several Cancer-Related Pathways
The 106 identified target genes were analyzed by Ingenuity Pathway Analysis (IPA) 
software, to elucidate which canonical pathways were mainly affected by aberrant 
miRNA expression (Table S1). One of the most significantly enriched pathways was 
the cell cycle: G1/S-checkpoint regulation pathway. Moreover, 13 other pathways from 
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IPA also showed a highly significant enrichment, including fibroblast growth factor 
signaling, Apelin endothelial signaling, and Leukocyte extravasation signaling (Fig-
ure 4A). Four target genes were found to be involved in cell cycle regulation (Figure 4B 
and Figure S4). MiRNA-101-3p inhibits the cyclin-dependent kinase 6 (CDK6) which 
regulates the G1/S phase transition by inhibiting RB1. It also targets E2F transcrip-
tion factor 8 (E2F8), which inhibits the G1/S phase transition. The miRNA let-7c-5p 
inhibits cyclin D2 (CCND2) which binds to CDK6, in order to activate the protein ki-
nase complex. Histone deacetylase 4 (HDAC4) is being targeted by two different miR-
NAs; miRNA-1537-5p and microRNA-181a-2-3p. Whereas all other genes are involved 





Figure 4. Ingenuity Pathway Analysis. (A) Ingenuity pathways with at least three target genes and a log (p-value) 
above 2. (B) A cluster analysis visualizing the involvement of DE-miRNAs in the cell cycle. The light blue nodes 
indicate genes targeted by DE-miRNAs (darker blue nodes), whereas the grey genes are not.
 
Discussion
In this study we identified a set of miRNAs that are likely to be involved in the meta-
static progression of UM by comparing miRNA expression in high-metastatic-risk UM 
and low/intermediate-metastatic-risk UM. Hierarchical clustering of total miRNA expres-
sion showed three different clusters, which corresponded to metastatic risk. In the UM 
samples, 423 mature miRNAs were shown to be present, of which 13 miRNAs were differ-
entially expressed between low-, intermediate- or, high-risk UM. MiRNAs that are highly 
expressed in high-risk UM include several known oncomirs such as miRNA-17-5p36-38 
miRNA-151a-3p39, and miRNA-21-5p40-43. MiRNA-17-5p has been described to promote 
cell proliferation, invasion, and metastasis through several mechanisms, such as PTEN re-
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miR-151a-3p have been shown to be involved in the epithelial-mesenchymal transition 
necessary for metastasis. However, we also identified two new potential oncomirs; miR-
NA-16-5p and miRNA-132-5p. Interestingly, miRNA-16-5p has been described to be sta-
bly expressed in breast cancer and normal breast tissue44, indicating that aberrant miRNA 
expression differs per tumor type. We observed a downregulation of eight miRNAs, of 
which most are known to function as tumor suppressors. MiRNA-99a-5p has been shown 
to inhibit cell proliferation in bladder and breast cancer45,46. Whereas miRNA-101-3p is in-
volved in suppressing epithelial-to-mesenchymal transition, necessary for metastasis47-49.
 
Several studies have investigated miRNA expression in UM, of which most are done in 
cell lines or very small sample sizes. These studies already identified miRNAs that were 
shown to be differentially expressed in high-risk UM, such as miRNA-21, miRNA-146b, 
miRNA-143, miRNA-199a, and miRNA-13417,23,43. However, not all of these previously 
identified miRNAs showed differential expression in our dataset. The lack of overlap 
between these studies and our results can be explained by the employment of different 
techniques and different tissues (cell lines versus tumor tissue). The majority of the articles 
describing the miRNA expression in UM analyze the miRNA expression by microarrays, 
which is known to produce data that does not fully overlap with RNA sequencing data. 
Comparing our dataset to The Cancer Genome Atlas (TCGA) dataset, which is the only 
study that performed miRNA analysis in UM by using next-generation sequencing, we 
did observe an overlap (e.g., miRNA-21-5p, miR-101-3p, miR-181a-2-3p, miR-181b-5p, let-
7c-5p, and miRNA-17-5p)35. As shown in Figure S2, the observed fold changes of each 
miRNA have the same directionality in both studies, but the observed fold changes and 
corresponding p-values do show some differences. This could be explained by a platform 
bias, but also by the fact that we could not differentiate in our own analysis of the TCGA 
dataset between the 3p- and 5p-miRNAs.
 
In order to determine the downstream effect of the DE-miRNAs, we integrated miRNA 
data with matching mRNA data containing expression data of target genes by at least 
two different prediction algorithms. Since miRNAs are known to downregulate or de-
grade mRNA of their target genes, we only selected genes that were negatively correlated 
with miRNA expression. Four of these identified target genes (HDAC4, CDK6, E2F8, and 
CCND2) play a crucial role in the regulation of the cell cycle. The development of cancer 
is tightly linked to changes in the activity of the cell cycle50. In normal cells there is a 
checkpoint between the G1 phase and S phase, in order to regulate proliferation. This 
checkpoint is controlled by several regulators, such as CDK651. Cancer cells; however, 
require increased cell division in order to proliferate and invade other tissues and one 
way to achieve this is by aberrant miRNA expression. Previous research has shown that 
high metastatic risk UM vastly express Ki-67, a protein that is only present in actively 
dividing cells, indicating that high-metastatic-risk UM has a greater proliferative activ-
ity than low-metastatic-risk UM52. Since no UM-specific mutations have been identified 
in cell cycle-related genes, this indicates that miRNAs probably play a crucial role in cell 
cycle deregulation in UM. We also observed several target genes to be deregulated in the 
EIF2 signaling pathway. Protein synthesis is a regulated process in the cell and initiation 
of translation requires several eukaryotic initiation factors (eIFs), such as eIF2. In cancer 
cells the function of these eIFs is hampered, inhibiting translation and, thereby, promot-
ing translation of mRNA by alternative mechanisms43. Incorrect translation of oncogenes 
and tumor suppressor genes can promote abnormal proliferation in cancer cells. Restoring 
these eIFs in UM cells could reduce the oncogenic potential of UM and might; therefore, 
be an interesting therapeutic target53.
 
Another pathway that could affect the metastatic potential of UM cells is epidermal 
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growth factor (EGF) signaling. Several studies show involvement of aberrant EGF signal-
ing in the development of several cancer types54. The EGF pathway plays a crucial role in 
several cellular processes, such as proliferation, migration, and survival. In addition, the 
fibroblast growth factor (FGF) pathway contributes to the same cellular processes56. All 
of these processes could make uveal melanocytes more malignant and promote metasta-
sis. However, functional assays in which a specific miRNA is overexpressed or knocked-
down in an UM cell line are still needed to investigate to what extent these DE-miRNAs 
contribute to metastasis. Since one miRNA can target a large number of genes and most 
studies use target genes identified by online prediction algorithms, it is important to per-
form these additional experiments. For several miRNAs this has already been done in UM 
cell lines or other cancer cell lines; overexpressing miRNA-21 in UM cell lines resulted 
in increased migration and invasion43. Whereas inhibition of miRNA-17 suppresses the 
epithelial-mesenchymal transition in gastric cancer cell lines57.
 
Because of their stable nature in tissues and body fluids, it is often suggested that miR-
NAs are excellent biomarkers for clinical applications. They could serve as early prognosis 
indicators and as a marker for therapy efficiency58,59. In our study we have observed a 
large number of differentially expressed miRNAs between low/intermediate-risk UM and 
high-risk UM, indicating that these miRNAs could be used to distinguish between these 
UM subtypes. However, differentiating between low- and intermediate-risk UM based 
on miRNAs expression will be challenging, since we only identified two miRNAs to be 
differentially expressed. The miRNA signature specific for high-risk UM might also be 
detectable in the plasma of UM patients and could; therefore, be a promising non-invasive 
biomarker to identify high-risk UM patients. This has already been shown in several can-
cer types, such as germ-cell tumor60. Non-invasive biomarkers will allow us to provide all 
UM patients, including the patients treated with radiotherapy or proton therapy, with a 
prognosis and good clinical counselling.
 
This study shows that miRNAs play an important role in the deregulation of several onco-
genic pathways in UM and can, thereby, promote metastatic spreading to distant organs, 
such as the liver. Differentially expressed miRNAs could be an interesting biomarker for 
metastatic risk in diagnostics, furthermore it also offers us a promising therapeutic target. 
Until now, no successful treatment has been developed for metastatic UM. miRNA mim-
ics and molecules targeted at miRNAs (anti-miRs) have shown promising results in pre-
clinical development and could compensate for the upregulation of oncogenic pathways, 
and thereby aid in UM management and treatment61-63   .
 
Conclusion
In this study we elucidated the potential role of miRNAs in the early metastasis of UM 
by integrating miRNA and mRNA sequencing data derived from 26 UM samples. We 
showed that differentially expressed miRNAs could play an important role in several 
oncogenic pathways, such as cell cycle regulation and EGF signaling, which could con-
tribute to the early metastasis of UM. These results do not only bring us one step closer 
to unraveling the mechanisms that drive UM metastasis, but it also provides us with a 
promising potential target for future treatment. Targeting these differentially expressed 
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Supplementary Figure 2. miRNA expression analysis of TCGA cohort 
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Supplementary Figure 4. Heatmap showing the differential expression of the four cell-cycle related genes; CDK6, 
CCND2, E2F8 and HDAC4
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Chapter 4.1  
Exosome-encapsulated microRNAs as 
a potential non-invasive biomarker for 
metastatic uveal melanoma
K.N. Smit, T. Lunavat, S.C. Jang, T. Brands, C. Lässer, R.M. Verdijk, R. Willemsen, H. 







Uveal melanoma is an intra-ocular malignancy that causes metastasis-related death in 
approximately half of the patients. Histopathological and genetic analyses can prognosti-
cally categorize patients, however this can only be done in uveal melanoma patients that 
underwent enucleation or, in case of eye-preserving treatments, a biopsy. Since biopsies 
are not entirely without risk there is an urgent and unmet need for a non-invasive bio-
marker that can predict the metastatic risk in uveal melanoma patients. In this study we 
characterize extracellular vesicles secreted by three uveal melanoma cell lines harboring 
an EIF1AX, SF3B1 or BAP1-mutation. Respectively, mass spectrometry was performed to 
characterize the membrane-proteins present in uveal melanoma exosomes. Forty-two per-
cent of the membrane proteins were shared between the three exosome samples. Amongst 
these shared proteins were classical UM proteins, such as CD81, Flotillin-1 and CD63, but 
also proteins that are generally only present in melanocytes, like GP100 and TYRP1. Sub-
sequently, exosomal and cellular small-RNA was sequenced and we observed a unique 
miRNA signature in each subset of exosomes. Exosomes secreted by the BAP1-mutated 
cell line showed an increased expression of the oncomiRs miRNA-21, miRNA-365 and 
miRNA-10B.  Exosomes with a unique, metastatic uveal melanoma signature are a prom-
ising, non-invasive biomarker for metastatic UM. The presence of melanocyte-specific 
proteins on UM exosomes can be used to enrich for melanocyte exosomes and thereby 
achieve a higher diagnostic and prognostic efficiency. However, further research is need-
ed to validate whether exosome-encapsulated miRNAs can be interesting novel targets for 
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Introduction
Uveal melanoma (UM) is an aggressive type of cancer arising from the uveal melanocytes 
located in the eye. The primary tumor can be treated by enucleation or by eye-conserving 
treatments, such as proton therapy, radiotherapy or brachytherapy1. Approximately half 
of all UM patients will develop metastatic disease; some metastasize a few years after 
diagnosis, whereas others metastasize several decades after diagnosis2. Several histo-
pathologic and genetic biomarkers can discriminate between low, intermediate metastatic 
risk UM and high metastatic risk UM. However, an increasing amount of UM patients is 
treated with eye-conserving treatments and these patients cannot be classified into a prog-
nostic group, unless a biopsy is taken. Since biopsies are not entirely without risk3, 4, there 
is an urgent and unmet need for a non-invasive biomarker that can predict metastatic risk 
in UM patients without the necessity of tumor material.
While efforts have been made to develop a non-invasive biomarker for metastatic risk in 
UM, results have been limited so far which could be caused by the relatively small tumor 
size. Recently, extracellular vesicles (EVs) have been acknowledged to be advantageous 
over the circulating tumor cells and cell-free DNA, as they are increased in the blood of 
cancer patients5. EVs are lipid-bilayer particles that are released by all eukaryotic cells 
into various body fluids, such as blood. They are packed with nucleic acids, proteins and 
lipids which they can transfer from one cell to another. The ability of EVs to transfer their 
cellular cargo and effectively deliver it to recipient cells has been primarily demonstrated 
for the transfer of functional RNA and proteins6. EVs are known to be intricately involved 
in cancer progression, metastasis and angiogenesis by shuttling their cargo from cancer 
cells to other cells7-9. 
The size of EVs differs; exosomes are vesicles with a size of approximately 100 nm and are 
generated by the fusion of multivesicular endosomes with the plasma membrane, whereas 
the larger microvesicles (~500 nm) are shed by outward vesiculation of the plasma mem-
brane10, 11. It was shown that exosomes are enriched for miRNAs, suggesting a selective 
loading mechanism, while the larger microvesicles contained less RNA12, 13. In addition, 
exosomal miRNA patterns differ between cancer patients and healthy individuals, sug-
gesting that pathophysiological changes can influence this mechanism14. Exosomes from 
mesenchymal stem cells could promote tumor progression in adjacent cells by delivering 
specific miRNAs15.
In this study we explore the use of exosomes as a non-invasive biomarker for metastatic 
UM. Firstly, we perform mass spectrometry on exosomal membrane-proteins to charac-
terize the proteome of UM exosomes. The exosomes are obtained from three different UM 
cell lines; 92.1, MEL202 and MP38. The latter shows loss of BAP1, an important indicator 
for high metastatic risk, whereas 92.1 and MEL202 contain a EIF1AX and SF3B1 mutation 
indicating a low or intermediate metastatic risk, respectively. Moreover, exosomal and 
cellular small RNA was sequenced from each cell line, in order to investigate the miRNA 
pattern in UM exosomes. Taken together, the knowledge gained in this study bring us one 
step closer to the development of a highly-specific, non-invasive biomarker for UM. 
Material and methods 
Cell culture
Three established UM cell lines, 92.1, MEL202 and MP38, were used for this study (kindly 
gifted by Prof. M. Jager, Leiden University, The Netherlands). 92.1 and MEL202 cells were 
cultured in RPMI 1640 medium (Gibco, Thermo Fisher Scientific, Waltham, MA, USA), 
containing 10% FBS, 100 units/ml penicillin, 100 µg/ml streptomycin and 2 mM L-Gluta-
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mine. MP38 cells were cultured using IMDM-Glutamax medium (Gibco) containing 20% 
FBS, 100 units/ml penicillin and 100 ug/ml streptomycin. Prior to use, FBS was EV-deplet-
ed by ultracentrifugation at 120.000 x g for 18h at 4°C and subsequently filtered through a 
0.22 um filter16. For the RNA profiling experiments, commercially available depleted FCS 
(Gibco) was used. All cells were grown at 37°C in a 5% CO2 humidified incubator. Cells 
were passaged every 2-3 days at 70-80% confluency.
 
Exosome isolation
Conditioned cell culture medium (150-200 ml) was obtained from 80% confluent cells 
grown in T175 cell culture flasks. Cells were first removed from the medium by centrifu-
gation of the medium at 300 x g for 10min at 4°C and cell debris and larger vesicles were 
removed by subsequent centrifugation at 2,000 x gavg for 20min at 4°C. Microvesicles 
were purified from the conditioned medium by ultracentrifugation at 16,500 x gavg for 
20min at 4°C using polypropene Quick-seal tubes (Beckman Coulter, Brea, CA, USA) in 
a Type 45 Ti fixed-angle rotor in the Optima XE-90 Ultracentrifuge (Beckman Coulter). 
Subsequently, exosomes were pelleted by centrifugation at 118,000 x gavg for 3h at 4°C. 
EV pellets were resuspended in 200 µl PBS (Sigma-Aldrich, St Louis, MO, USA) and were 
freshly processed or stored at -80°C.
 
Western blot
Purified exosomes were treated with RIPA-buffer (Sigma-Aldrich) and subjected to sever-
al sonication steps, to extract proteins. For protein extraction from cells, cells were collect-
ed and washed twice in ice-cold PBS before lysing them in RIPA-buffer (Sigma-Aldrich) 
supplemented with cOmplete Protease Inhibitor-cocktail (Roche, Basel, Switzerland)  im-
mediately before use. The lysed samples were incubated on ice for 15min, followed by 
several vortex steps.  The protein concentration was determined using the BCA protein as-
say kit (Thermo Fisher Scientific) according to the manufacturer’s protocol. Twenty µg of 
protein was separated by SDS-page and transferred to a Trans-Blot mini PVDF membrane 
using the Trans-Blot Turbo Transfer system (Bio-Rad, Hercules, CA, USA). The mem-
branes were blocked in 5% non-fat dry milk in TBS containing 0.05% Tween-20 and sub-
sequently incubated with primary antibodies overnight at 4°C and HRP-conjugated sec-
ondary antibodies for 1h at RT. The antibodies used were as followed: anti-CD81 (1:1000 
dilution, sc-9158, Santa Cruz, Dallas, TX, USA); anti-Flotillin-1(1:1000 dilution, sc-74566); 
anti-Calnexin (1:1000 dilution, sc-11397); donkey anti-rabbit IgG HRP-linked (1:10.000 di-
lution, NA9340, GE Healthcare, Chicago, IL, USA) and sheep anti-mouse IgG HRP-linked 
(1:10.000, NA9310). The protein staining was visualized with ECL Prime Western Blotting 
Detection (GE Healthcare) according to the manufacturer’s recommendations using the 
VersaDoc 4000 MP imaging system (Bio-Rad).
 
Flow Cytometry
Exosomes were coupled to magnetic anti-CD81 and CD9 beads (Invitrogen, Carlsbad, CA, 
USA) by incubating them together in assay buffer (0.1% BSA in PBS; 0.22 µm filtered) for 
16h at 4°C under constant agitation. Bead-exosome complexes were purified by using a 
magnetic rack and subsequently incubated for 1h at RT  under constant agitation with 
the following fluorochrome-conjugated antibodies; PB anti-CD81 (clone 5A6, Biolegend, 
San Diego, CA, USA), PE anti-CD63 (clone H5C6, Biolegend) and PerCP-Cy5.5 anti-CD9 
(clone H19a, Biolegend). The samples were analyzed using the LSR Fortessa (BD Biosci-
ences, Franklin lakes, NJ, USA) and the FACSdiva software (BD Biosciences). The data was 
analyzed using FlowJo software (BD Biosciences). 
 
Particle measurement
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(Malvern Nano ZS, Malvern, UK) were used to determine the size of the EV samples. 
 
Transmission Electron Microscopy
Carbon-coated formvar 200-mesh grids (Ted Pealla Inc, Redding, CA, USA) were UV-treat-
ed for 5 minutes. 10 µg exosomes was loaded,  incubated for 15 minutes, fixed for 10 minutes 
in 2% paraformaldehyde  (Sigma-Aldrich)  and 1% glutaraldehyde (Sigma-Aldrich)  and 
contrasted using 2% uranyl acetate  (Sigma-Aldrich). Immunostaining of the exosomes was 
performed with the anti-CD63 antibody (BD Bioscience), isotype control (Sigma-Aldrich) 
and anti-GP100 (sc-393094, Santa Cruz) followed by staining with 10 nm gold-labelled sec-
ondary antibody (Sigma-Aldrich) and subsequent fixation with 2,5% glutaraldehyde (Sig-
ma-Aldrich), washed and contrasted in 2% uranyl acetate.  Samples were examined using an 
LEO 912AB Omega electron microscope operated at 120 kV (Carl Zeiss NTS, Jena, Germany). 
RNA isolation and RNA sequencing
Total RNA was extracted from exosomes and cells using the miRCURY RNA isolation kit 
(Exiqon, Vedbaek, Denmark) according to the manufacturer’s protocol. The RNA concen-
tration and size distribution was analyzed using capillary electrophoresis (Agilent 2100 
Bioanalyzer, Agilent Technologies, Santa Clara, CA, USA) with a total RNA 6000 Nano 
chip. Cellular and exosomal RNA was sequenced using an updated version of a previ-
ously published RNAome protocol17. Briefly, total RNA was rRNA depleted using the 
Illumina Ribo-Zero magnetic gold kit (Illumina, San Diego, CA, USA) and sheared using a 
Covaris instrument (Covaris, Brighton, UK).  Subsequently, the cDNA libraries were pre-
pared using the NEXTflex Small RNA-seq Kit (v3; PerkinElmer, Waltham, MA, USA) and 
sequenced on an Illumina HiSeq2500 sequencer (Illumina). After removing the adapter 
sequences, the fragments were aligned to the human GRCh38 reference genome using 
HISAT2.
 
Purification of exosomal membrane-proteins by Iodixanol density cushion
To open the exosome membrane-structure, exosome samples were incubated with 
200mM  sodium carbonate solution (Na2CO3 ; pH 12) for 1h at RT with rotation. 1 M 
potassium chloride solution (KCl) was added and further incubated for 1h to remove 
non-covalently bound to the membrane. Subsequently, the samples were subjected to 
a Iodixanol (Sigma-Aldrich) density gradient to purify the EV-membranes. In brief, a 
60% Iodixanol layer was mixed with the sample and overlaid with a 30% and 10% Io-
dixanol layer respectively forming a discontinuous gradient. The samples were centri-
fuged at 178,000 x gavg (SW41 TI Rotor, Beckman Coulter) for 2h at 4°C. The exosom-
al membranes were collected from the interphase between the 30% and 10% Iodixanol 
and analyzed using liquid chromatography-tandem mass-spectometry (LC-MS/MS). 
Proteomic analysis by LC-MS/MS
Mass spectrometry was performed at the Proteomics Core Facility at the Sahlgrenska Acad-
emy, University of Gothenburg as described before18. In short, samples contained 30 µg 
protein and were digested using the previously described filter-aided sample preparation 
(FASP) method19. The samples were reduced by incubating with 100 mM dithiotrheitol for 
30 minutes at 60°C, transferred to a 30 kDa MWCO Pall Nanosep centrifugation filter (Sig-
ma-Aldrich) and washed with 8 M urea and once with digestion buffer prior to alkylation 
with 10 mM methyl methanethiosulfanote in digestion buffer for 3 minutes. Subsequently, 
the sample was digested by adding 300 ng trypsin (Pierce MS-grade; Thermo Fisher Sci-
entific) in 50 mM triethylammonium bicarbonate (TEAB) and 1% sodium deoxycholate 
(SDC) buffer for 3 hours, followed by the addition of another 300 ng trypsin (Thermo Fish-
er Scientific) which was incubated overnight at 37°C. The digested samples were desalted 
using PepClean C18 spin columns (Thermo Fisher Scientific) according to the manufac-
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turer’s protocol. Peptide samples were resolved in 3% acetonitrile, 0.1% formic acid solu-
tion and analysed on a Q Exactive mass spectrometer (Thermo Fisher Scientific) interfaced 
with an Easy-nLC 1200 nanoflow liquid chromatography system. The peptides were sepa-
rated using a C18 analytical column (200x0.075mm I.D., 3uM) using a gradient from 5% to 
25% acetonitrile in 0.1% formic acid for 75 minutes and finally from 25% to 80% acetronile 
in 0.1% formic acid for 5 minutes at a flow rate of 200 nl/minute. The obtained results were 
analysed using the Proteome Discover software (version 1.4; Thermo Fisher Scientific) 
and the human Swissprot database 2017 (Swiss Institute of Bioinformatics, Switzerland). 
Bioinformatics
To identify the proteins enriched in the vesicle proteome the Database for Annotation, 
Visualization and Integrated Discovery (DAVID; http://david.abcc.ncifcrf.gov/) was 
used. To compare protein content between samples Venny was used (http://bioinfogp.
cnb.csic.es/tools/venny/index.html) 
Results 
Characterization of extracellular vesicles 
Extracellular vesicles were isolated from conditioned cell culture medium according to a 
serial centrifugation protocol (Supplementary Figure 1). By western blot we analyzed the 
protein content in cell lines, exosomes and microvesicles (Figure 1A). All samples showed 
presence of the cell membrane marker flottilin-1, whereas the vesicle marker CD81 was 
only present in exosomes and microvesicles. Calnexin, an endoplasmic reticulum marker 
only present in cells, was absent in exosomes and microvesicles. Flow cytometry con-
firmed the presence of CD81 and CD63 in all samples, whereas only the exosomes derived 
from MP38 were positive for CD9 (Supplementary Figure 2). We characterized the exo-
somes based on their size and morphology using electron microscopy and nanoparticle 
tracking analysis. Particle analysis showed that the isolated exosome samples contained 
particles with a size of approximately 100 nm, which corresponds with the size described 
in literature (Figure 1B). Electron microscopy revealed vesicles with a typical spherical 














Figure 1. Characterization of extracellular vesicles. A) Immunoblotting of the exosomal protein CD81, the endo-
plasmic reticulum protein calnexin and the exosomal and cellular protein flotilin-1 in isolates from cellular extract, 
exosomes and microvesicles B) Particle analysis shows that the exosome-fraction mainly contain vesicles of a 100 
nm size  C) A representative electron microscopy image of an exosomes derived from the 92.1; MEL202 and MP38 
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Proteomic analysis of exosomes reveals the presence of melanocyte-specific membrane 
proteins
To analyze the membrane-protein repertoire on exosomes isolated from all three UM cell 
lines we treated exosomes with a high pH-solution, causing the exosomal membrane to 
open. Proteins that were ionically bound to the exosomal membrane were removed and 
membrane proteins were isolated by applying the sample on a density gradient. Subse-
quently the samples were analyzed by mass spectrometry. We detected 1714 different pro-
teins, of which 727 were found in exosomes from all three cell lines (Figure 2A). In total, 
1052, 1311 and 1244 were identified from MEL202, 92.1 and MP38 exosomes, respectively. 
Among these 727 common proteins, were the classic exosome proteins CD81, CD63 and 
flotillin-1, suggesting that the exosomes are indeed exosomes rather than artefacts of the 
isolation procedure or necrotic particles. The exosomal protein CD9 was only detected in 
the MP38 exosomes, as also observed in previous flow cytometry experiments. Interest-
ingly, we also found a set of melanocyte-specific proteins to be present in the exosomal 
membrane (Figure 2B). This was confirmed by performing electron microscope using anti-
GP100 antibodies conjugated to a gold particle. Both for CD63 and GP-100, we observed 
antibody-binding at  the surface of MEL202 exosomes (Figure 2C). This implies that be-
sides the tetraspanin proteins CD81, CD63 and CD9 and the lipid raft flottilin-1, UM exo-
somes also harbor melanocyte-specific proteins in their membrane (Figure 2D). Among 
the highly abundant proteins we detected six proteins that were increased in the MP38 
exosomes, such as MYOF and EPHX1, and 10 proteins decreased in the MP38 exosomes, 
including PCDH7 (Supplementary Figure 3).
Figure 2. A) Membrane proteins present in 92.1; MEL202 and MP38 derived exosomes were compared amongst 
each other B) Several membrane proteins were plotted with their relative abundance derived from mass spectrom-
etry analysis. Blue indicate the MP38-derived exosomes, green indicates the MEL202-derived exosomes and grey 
indicate the 92.1-derived exosomes. C) Presence of CD63 and GP100 was validated by EM analysis D) Visualiza-




The RNA profile in cells, microvesicles and exosomes from all three UM cell lines was 
analyzed by capillary electrophoresis. Since microvesicles  contained far less RNA than 
exosomes, we performed RNA sequencing on exosomal RNA. RNA extracted from exo-
somes showed a typical exosomal RNA profile, lacking the 18S and 28S ribosomal sub-
unit (Supplementary Figure 4). The electrophoresis profile included RNA in the size of 
miRNA and to analyze the exosomal miRNA content we performed RNA sequencing. 
The majority of the miRNAs that were detected in the cell, were observed in the exo-
somes as well (Figure 3A). However there were slight differences between the miRNA 
patterns of the three UM cell lines. The ten most common miRNAs observed in exo-
somes were miRNA-3142HG, miRNA-146A, miRNA-92A, miRNA-17HG, miRNA-
30D, miRNA-92A , miRNA-423, miRNA-211, miRNA-let-7b and miRNA-21 (Figure 
3B). Most miRNAs correlated well between exosome samples, however we did ob-
serve miRNA expression patterns specific for the exosomes from each cell line (Figure 
3C). Reassuringly, one of the miRNAs that showed a higher read count in the BAP1-





























Figure 3 A) The amount of miRNAs detected in the three UM cell lines and exosomes B) The top 10 highest ex-
pressed miRNAs in the exosome samples. The read counts per million is shown for every miRNA C) Exosomes from 
the three different UM cell lines show differential expression of several microRNAs. Red indicated upregulation, 
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Discussion
The aim of this study was to explore the possibility of using  exosome-encapsulated miR-
NAs as a liquid biomarker. Using western blot, flow cytometry and EM we could detect 
significant amounts of extracellular vesicles secreted from UM cell lines. Since exosomes 
are known to be enriched for miRNAs, we analyzed the miRNA pattern in exosomes from 
all three UM cell lines. Most of the miRNAs that were identified in the cells, were present 
in the exosomes as well, indicating that the exosome content partially reflects the donor 
cells content, however we did observe differences in miRNA-levels. Interestingly, miR-
NA profiling suggested that exosomes from the BAP1-mutated cell line have a different 
miRNA profile compared to the two other UM cell lines. We observed an increased nor-
malized read count for miRNA-365, miRNA-21, miRNA-10B, miRNA-199a and miRNA-
29A in the BAP1-mutated UM cell line, implying that these miRNAs are more abundant 
in exosomes secreted by high risk UM. MiRNAs-21, 365 and 10B have already been de-
scribed in literature as oncomiRs. A study by Duan et al revealed that miRNA-365 binds 
PKHD1, thereby suppressing cell-cell adhesion20. Both miRNA-21 and miRNA-10B were 
found to be upregulated in hepatocellular cancer and promoted metastasis21, 22. miRNA-21 
is a well-known oncomiR that promotes carcinogenesis by inhibiting the expression of the 
tumor-suppressor gene PDCD423. Exosomes secreted by colon cancer cells and esophageal 
squamous cancer cells have been shown to contain an increased number of miRNA-21 as 
well24, 25. These significant amounts of miRNAs can induce several functional effects in 
recipient cells. Uptake of exosomal oncomiRs could stimulate the oncogenic features of 
recipient cells present in the same tissue, in addition they could be taken up by distant 
future metastatic sites given their stabile structure. 
A previous study by Eldh et al investigated the RNA content from exosomes ex-
tracted from the liver perfusate of 12 patients with metastatic UM5. They observed a 
higher concentration of exosomes in the blood of metastatic UM patients compared to 
healthy controls. However, this study could not identify exosomal miRNAs that are 
differentially expressed high metastatic risk UM and low metastatic risk UM,  since 
they only analyzed exosomal miRNA from metastatic UM and non-UM cell lines. 
Exosome-encapsulated miRNAs could be an attractive candidate for metastatic liquid 
biomarkers. In particular by using a fluorescent detection system. Quantitative detection 
of exosomal miRNAs has already been validated in a study by Lee et al26. A recently de-
veloped method using FAM-labelled hairpin-probes and gold nanoparticles could very 
sensitively quantify miRNA-21 down to 50 pM by combining fluorescent and colorimetric 
signaling27.  In addition to utilizing exosomal miRNAs as biomarkers, they could also 
provide us with interesting possibility for future therapies. Since exosomes show good 
bioavailability and little toxicity, they could be promising drug delivery vehicles28, 29. By 
modulating the cargo of exosomes, genetically engineered exosomes can mediate multiple 
biological effects in recipient cells. Additionally, it has  been shown that exosomes con-
tain a specific repertoire of integrines on their surfaces which can dictate a preference for 
specific recipient cells30. Certain integrines, such as ITβ5, on UM exosomes might dictate 
a specific preference for liver cells, the most common metastatic site in UM. Interestingly, 
our preliminary data show presence of ITβ5 on MEL202 and MP38 exosomes, while most 
other integrines were present on exosomes from all three cell lines. In future studies, UM 
exosomes could be produced in large quantities and be engineered to provide liver cells 
with therapeutic molecules. A study by Monfared et al described the use of engineered 
exosomes packed with a miRNA-21 sponge construct. In a rat model of glioblastoma these 
engineered exosomes could reduce the level miRNA-21 and consequently upregulate the 




Mass spectrometry protein analysis allowed us to study the membrane proteome of UM 
exosomes in an unbiased manner. We detected four melanocyte-specific proteins to be pres-
ent in the membrane of UM exosomes; GP100, MART1, TYRP1 and GPR143. The presence 
of these proteins might offer us to the possibility to capture exosomes with a melanocytic 
origin, by making use of antibody-coated magnetic beads. Immuno-isolation of exosomes 
by magnetic beads is a simple and rapid method that has been shown to obtain a higher re-
covery and purity, than ultracentrifugation32.  Immuno-isolation of exosomes has already 
been successfully done for a number of cancer cells, including lung and colon cancer33, 34.  As 
UM are known to be relatively small tumors, isolating non-specific biomarkers will obtain 
an incredibly low amount of tumor material. By incubating plasma of UM patients with 
magnetic beads conjugated to antibodies against GP100, MART1, TYRP1 and GPR143 only 








Figure 4 Schematic overview of the proposed protocol that allows to enrich for exosomes with a melanocyte-
origin in plasma samples.
Additionally, we identified highly abundant surface proteins that were specifically up-
regulated or downregulated in the exosomes from BAP1-mutated UM cell line.  The di-
agnostic potential of exosomal membrane proteins definitely deserves additional studies 
in which the presence of these proteins is validated and quantified in an antibody-based 
assay. Exosomal membrane proteins are of biological interest as well, since they can act as 
a ligand for certain receptors and thereby activate downstream signaling pathways. One 
of the proteins that showed strong upregulation in exosomes from BAP1-mutated UM 
cell line was myoferlin (MYOF). This membrane protein regulates tyrosine kinase recep-
tor functioning and has been shown to be overexpressed in cancers where it stimulates 
migration and invasion35. 
            
However multiple critical issues should be considered when interpreting our study. First-
ly, since our results are based on cultured UM cells, they may not entirely reflect the 
true situation in vivo. Therefore, further validation is required in exosomes secreted by 
dissected primary UM before continuing with plasma samples. Second, enrichment for 
melanocyte-exosomes will result in only a low number of exosomes, therefore it will re-
quire a highly specific and highly sensitive downstream technique to analyze the nucleic 
acid content. Third, it should be investigated whether non-malignant skin or uveal mela-
nocytes secrete exosomes with these markers as well, since this might mean our method 
will extract non tumorigenic exosomes as well. 
Taken together, given that exosomes from UM cells with different secondary driver mu-
tations show a unique miRNA signature and they are widely distributed in body fluids, 
exosomes might be a promising non-invasive biomarker for metastatic UM. The pres-
ence of melanocyte-specific membrane proteins could allow the selective extraction of 
melanocyte-exosomes from a plasma sample, thereby providing us with a highly spe-
cific non-invasive biomarker for metastatic UM. In the future, a simple, cost-effective 
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Supplementary Figure 1. Flowchart showing the serial centrifugation protocol for vesicle isolation from condi-
tioned cell culture medium
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Supplementary Figure 2. Detection of CD81, CD9 and CD63 by flow cytometry in exosome isolates from the cell 
lines 92.1, MEL202 and MP38. The orange peaks show the exosomes samples, whereas the blue curve indicates 
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Supplementary figure 3. Highly abundant proteins that were shown to be increased (left) or decreased  (right) in 
the MP38 exosomes. The line indicates the expression-trend of the membrane proteins.
Supplementary Figure 4. The Bioanalyzer RNA profiles obtained from exosomal and cellular RNA from the UM 
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Uveal melanoma:  
towards a molecular understanding
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Uveal melanoma is an aggressive malignancy that originates from melanocytes in the eye. 
Even if the primary tumor has been successfully treated with radiation or surgery, up to 
half of all UM patients will eventually develop metastatic disease. Despite the common 
origin from neural crest-derived cells, uveal and cutaneous melanoma have few over-
lapping genetic signatures and uveal melanoma has been shown to have a lower muta-
tional burden. As a consequence, many therapies that have proven effective in cutane-
ous melanoma -such as immunotherapy- have little or no success in uveal melanoma. 
Several independent studies have recently identified the underlying genetic aberrancies 
in uveal melanoma, which allow improved tumor classification and prognostication of 
metastatic disease. In most cases, activating mutations in the Gα11/Q pathway drive uveal 
melanoma oncogenesis, whereas mutations in the BAP1, SF3B1 or EIF1AX genes predict 
progression towards metastasis. Intriguingly, the composition of chromosomal anomalies 
of chromosome 3, 6 and 8, shown to correlate with an adverse outcome, are distinctive in 
the BAP1mut, SF3B1mut and EIF1AXmut uveal melanoma subtypes. Expression profiling 
and epigenetic studies underline this subdivision in high-, intermediate-, or low-meta-
static risk subgroups and suggest a different approach in the future towards prevention 
and/or treatment based on the specific mutation present in the tumor of the patients. In 
this review we discuss the current knowledge of the underlying genetic events that lead 
to uveal melanoma, their implication for the disease course and prognosis, as well as the 
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Introduction
Uveal melanoma (UM) is the second most common form of melanoma, arising from mela-
nocytes located in the uveal tract of the eye. It is a highly aggressive disease, with a strong 
tendency to metastasize from the eye to other organs, such as the liver. The primary tumor 
can be treated successfully using several options, such as enucleation, stereotactic radio-
therapy, brachytherapy and proton therapy1, 2. At the time of diagnosis of the primary 
tumor, only 4% of patients show detectable metastases; however, up to half of all UM 
patients will eventually develop metastatic disease despite earlier successful local treat-
ment of the primary tumor. This implies that UM already develops micro-metastases ear-
ly during tumorigenesis and that these micro-metastases may remain dormant for several 
months or even years3. Once these micro-metastases become overt, the prognosis is poor 
and disease-related death usually occurs within one year4. Metastases are often detected 
within a few years after diagnosis, but they can also be observed several decades after the 
initial diagnosis5-7. In general, UM can be subdivided into three metastatic risk groups: 
high, intermediate and low risk. 
Several clinical and histological features can predict high metastatic risk, such as large tu-
mor size, extraocular extension, high mitotic activity and an epithelioid cell type, whereas 
the spindle cell type is associated with low metastatic risk (Figure 1)8-10. Genetic features 
associated with metastatic disease include loss of chromosome 3 and mutations in the 
BAP1 and SF3B1 gene. BRCA-associated protein 1 (BAP1) mutations are observed in ap-
proximately half of all UM and usually result in metastasis within 5 years11. Our group has 
shown that tumors with an SF3B1 mutation also frequently metastasize, but this can take 
up to 15 years and these tumors are therefore considered to have an intermediate meta-
static risk12. UM that harbor a mutation in the EIF1AX gene seldom metastasize13. None 













Figure 1. The fundoscopic and histologic appearance of UM. A) A dome-shaped pigmented mass in the posterior pole. 
B) Hematoxylin-eosin (HE) staining shows that the tumor consists of spindle-type UM cells and several adipocytic ap-
pearing cells (100x). Reproduced with permission from Yavuzyigitoglu et al, 2016a, via Copyright Clearance Center.
 
Recurrent chromosomal alterations are frequently observed in UM and the majority occur 
in the context of a specific mutation. Most of the BAP1-mutated UM show loss of chro-
mosome 3, as well as gain of 8q. Tumors with a mutation in the EIF1AX or SF3B1 gene 
often show gain of chromosome 6p14. Since there is little heterogeneity in UM, it is likely 
that although these mutational and chromosomal events can occur sequentially, both are 
mandatory in the development of UM to result in tumor growth15. Downstream mRNA 
expression can also be determined to predict metastatic risk. As previously described by 
Onken et al, UM patients can be classified into a low or high metastatic risk group based 
on the expression profile of 15 genes16. These two groups are known as class 1 and class 
2, with class 2 having the worst prognosis; class 1 can be divided into 1a and 1b. A more 
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recent subdivision which is based on chromosomal data from The Cancer Genome Atlas17, 
separates the tumors into categories A-D18.
Despite extensive research, the survival of metastasized UM patients did not improve 
over the last three decades1. Whereas treatments such as immunotherapy and BRAF-in-
hibitors show promising results in patients with cutaneous melanoma (CM), UM seem 
to be unresponsive despite their shared origin as neural-crest derived melanocytes. This 
indicates that different mechanisms play a role in tumorigenesis. Oncogenic mutations in 
BRAF and NRAS are the main drivers in CM, but these mutations have only been found 
in iris melanoma and do not occur in posterior UM19, 20. Most CM (80%) exhibit a muta-
tional signature specific to DNA damage caused by ultraviolet radiation, characterized by 
C>T transitions at the 3’ end of pyrimidine dinucleotides. Even though population studies
suggest a geographic predisposition, there is no molecular evidence for this signature in
UM17. UM has a remarkably low mutational burden; with a rate of <1 single nucleotide
variations (SNVs) per Mb, this mutation burden is much lower than observed in most
cancer types. Only 35% of the observed SNVs in UM are C>T transitions and there is no
enrichment of these lesions at the 3’ position of pyrimidine dinucleotides, further showing 
that CM and UM have a different etiology21.
So far, UM clinical trials have focused on treatment modalities copied from CM. How-
ever, despite these therapeutic options, the prognosis of patients with metastatic UM has 
not improved, which emphasizes the need to explore and develop UM-specific therapies. 
In this review, we highlight several scientific findings and studies that provide us with 
insight into the mechanisms of oncogenesis of GNAQ, GNA11, BAP1, SF3B1 and EIF1AX 
mutations. Elucidating the development of UM and obtaining a better understanding of 
the complex interaction between genetic factors, molecular signaling and potential targets 
will aid in developing new therapies specific for UM. 
2. Genes involved in the development of UM
An updated mutational overview of our previously published ROMS cohort containing
over 900 UM patients, shows initiating hotspot mutations in GNAQ in 57% of the UM tu-
mors and in GNA11 in 41% (Figure 2A)12. Samples that do not contain a GNAQ or GNA11
mutation are usually found to harbor a mutation in another gene linked to the Gα11/Q
pathway: PLCB4 and CYSTLR2. GNAQ and GNA11 mutations are already observed in
most nevi22. In addition, in UM, one can often discern a mutation in one of the three sec-
ondary driver genes (BAP1, SF3B1, EIF1AX): forty-four percent of our 175 UM samples
showed a BAP1 mutation, 26% a mutation in SF3B1 and 21% a mutation in EIF1AX. We
and others have noticed that even with next generation sequencing (NGS) technology mu-
tations in BAP1, especially deletions encompassing whole exons, can be missed and more
sophisticated calling algorithms, in combination with RNA sequencing have to be applied
to detect these BAP1 mutations15. We are using a combined BAP1-immunohistochemistry
(IHC) and targeted NGS approach which is also suitable for small biopsies and formalin-
fixed, paraffin-embedded (FFPE) tissue samples23. The BAP1 gene acts as a classic tumor-
suppressor gene and in combination with loss of chromosome 3, no active nuclear BAP1
protein is present in the tumor cells24. Missense mutations in SF3B1 or indels in EIF1AX
mutations are in-frame and create a small change in the respective proteins, albeit with a
large effect on many cellular RNAs and proteins13. Missense mutations in SF3B1 usually
arise at amino acid R625, a UM hotspot; however, some samples also show mutations
outside this hotspot region, such as at amino acids K666 or H662 or in related spliceosome
complex genes as SRSF2 and U2AF117. Although not actually a hotspot, EIF1AX in-frame
mutations are located in the first 10-15 AA of this gene which limits the region to be ana-
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on chromosome 1. When possible, we use a SNP array to detect chromosomal aberrations 
to confirm the UM subclass. Our results and the observed percentages do not deviate 
substantially from previously observed mutation rates (Figure 2B)11-13, 25-29. The second-
ary mutations are in general mutually exclusive, although 1-2% of the tumors did harbor 
(hotspot) mutations in two of these metastasis-associated genes. In these latter cases it 
would be interesting to see whether these mutations arise in the same cells.
Figure 2. Driver mutations in UM. A) Donut chart showing the mutation status of 165 UM patients of the ROMS 
cohort. The outer ring shows initiating mutations in GNAQ, GNA11, PLCB4 and CYSTLR. The inner ring indicates 
co-mutations in BAP1, SF3B1 or EIF1AX. The black dots indicate SF3B1 Q625 hotspot mutations B) The mutation 
rate of each gene observed in our study and other studies. Adapted from (Yavuzyigitoglu et al, 2016b)
2.1 Activation of the Gα11/Q pathway drives neoplastic growth of uveal melanocytes
The first gene reported to be mutated in UM was the guanine nucleotide-binding protein 
alpha Q (GNAQ) gene26. Most of the UM samples that do not harbor a mutation in GNAQ 
carry a mutation in its paralogue GNA1125. Both proteins are involved in the Gα11/Q path-
way, which regulates several cellular processes such as proliferation and cell growth. In 
this pathway, leukotrienes activate the G protein-coupled receptor CYSTLR2 located at 
the cell surface. Guanine nucleotide-binding proteins (G-proteins) consist of three sub-
units: alpha, beta and gamma. GNAQ and GNA11 are alpha subunits (Gα) bound to a 
guanosine diphosphate (GDP). Upon binding of the ligand to CYSTLR2, G proteins are 
activated by exchanging GDP for guanosine triphosphate (GTP)30. GTP binding initiates a 
conformation change in the G-protein, which allows the G protein to be released from the 
CYSTLR2 receptor and to activate a large number of downstream effectors, such as PLCB4 
and ARF631, 32(Figure 3).      
 
Activation of ADP-ribosylation factor 6 (ARF6) by GNAQ or GNA11 initiates several pro-
cesses, such as β-catenin release from the cytoplasm to the nucleus and activation of the 
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growth-inducing gene YAP133. YAP1 is critical for growth and is therefore often found in 
the nucleus of proliferating cells. Inhibiting YAP1 strongly limits the proliferation of UM 
cells33, 34. Activated PLCB4 causes a rise in cytoplasmic Ca2+, thereby activating several cal-
cium-regulated pathways35. PLCB4 also indirectly activates the mitogen-activated protein 
kinase (MAPK) and AKT/mTOR pathway through the downstream effector RasGRP332, 36. 
MAPK and AKT/mTOR promote cell growth and proliferation and are often upregulated 
in cancer. 
 
Figure 3. Schematic overview of the Gα11/Q pathway and their downstream effectors. Activated GNAQ binds to a 
guanine nucleotide exchange factor (GEF), which in turn activates ARF6. ARF6 initiates β-catenin release, which pro-
motes gene transcription. GNAQ and GNA11 can also activate the protein TRIO and the TRIO dependent RHO-GT-
Pases; RHOA and RAC1. Once activated, RHO and RAC1 trigger the release of YAP and stimulate YAP-dependent 
transcription . ARF6 also activates PLCB4 which initiates hydrolysis of phosphatidylinositol 4,5-biphosphate (PIP2) 
and produces two second messengers; inositol 1,4,5-triphosphate (IP3) and diacylglycerol (DAG). The production of 
IP3 causes a rise in cytoplasmic Ca2+, which stimulates several calcium-regulated pathways. With the help of DAG, 
protein kinase C (PKC) is activated and subsequently stimulates several processes, such as cell proliferation. DAG 
and PKC together also activate RAS guanyl-releasing protein 3 (RASGRP3), by binding and phosphorylation. RAS-
GRPR3 is a GEF, that integrates GNAQ and GNA11 to the MAPK- and PI3K/AKT pathway by activating RAS. GEFs 
stimulate the release of GDP and the subsequent binding of GTP, thereby yielding active RAS(RAS-GTP)31, 33,34,36, 38.
Over 95% of the UM contain a mutually exclusive mutation in GNAQ or GNA11. Muta-
tions in GNAQ and GNA11 affect residues Q209 and R183, which are required for the 
GTPase activity25, 26. In non-malignant cells, this activation is intrinsically terminated by 
a guanosine triphosphate (GTPase); oncogenic GNAQ or GNA11 on the other hand are 
constitutively activated and therefore result in over-activation of the aforementioned sig-
naling pathways. UM that do not harbor a mutation in GNAQ or GNA11 usually have a so-
matic mutation in CYSTLR2 (3%) or PLCB4 (2%)37, 38. Wildtype CYSTLR receptors become 
active after binding of the ligand and transition to the inactivated state is initiated upon 
release of the ligand. However, mutated receptors stay active even after ligand dissocia-
tion and thereby constitutively activate GNAQ and GNA1138. This confirms the require-
ment of aberrant Gα11/Q signaling in the development of UM. 
 
Introducing GNAQ and GNA11 mutations (Q209L) in zebrafish results in increased prolif-
eration, signaling and migration39. However, most UM carry a GNAQ and GNA11 muta-
tion regardless of their tumor stage. This suggests that GNAQ and GNA11 mutations are 
necessary to initiate tumorigenesis, but are insufficient to induce full malignant transfor-
mation, as is also shown by our finding that these mutations are also present in nevi22. The 
aggressiveness of UM is determined by secondary driver mutations but treatments target-
ing oncogenic GNAQ and GNA11 signaling or one of their many downstream targets 
might reduce the proliferative potential of UM and can therefore be promising for future 
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2.2 Loss of BAP1 is linked to metastatic UM
The majority of the metastasizing UM harbor -in addition to a GNAQ or GNA11 muta-
tion- a mutation in the BAP1 gene located on chromosome 311. We and others observed, 
using immunohistochemical analysis, (partial) loss of the BAP1 protein in BAP1-mutated 
UM (Figure 4)40-44. Other studies show that loss of BAP1 staining is strongly correlated 
to GEP class 2 and chromosome 3 loss and that loss of BAP1 protein expression is of-
ten associated with lower BAP1 mRNA expression45. This implies that these mutations 
are loss-of-function mutations, requiring the loss of the other allelic copy harboring the 
wildtype gene (monosomy 3). Surprisingly, some BAP1-mutated/immunohistochemically 
BAP1-negative tumors still show expression of BAP1 mRNA, suggesting that negative 
nuclear staining for BAP1 protein is not solely caused by nonsense-mediated RNA decay 
but rather by an as yet unexplained different mechanism (unpublished data). Mutations 
in BAP1 are found throughout the entire gene and are not restricted to a specific domain, 
although we did observe a skewed distribution towards the N-terminal region (Figure 5)40. 
In the ROMS cohort, we observed a large variety of mutations, such as large out-of-frame 
deletions, but also missense mutations. In a preliminary analysis we did not find a signifi-
cant association between mutation-type or location with disease-free survival. 
Figure 4. BAP1-stained sections from three UM. Immunohistochemistry (IHC) staining of BAP1 protein (red) in A) 
A UM with positive BAP1 expression B) A UM with negative BAP1 expression and C) A UM showing a heteroge-
neous distribution of BAP1 throughout the tumor (400x). Reproduced with permission from: Koopmans et al, 2014.
Despite extensive research exploring the function of the BAP1 protein, it is as yet unclear 
how BAP1 loss in UM promotes the development of UM metastasis. BAP1 belongs to a 
specific group of proteases, called deubiquitinating enzymes (DUB), which function as 
a critical regulator of ubiquitin signaling by removing ubiquitin from proteins. Initially, 
BAP1 was identified because of its interaction with breast cancer 1 (BRCA1), a tumor sup-
pressor gene involved in homology directed DNA-repair. The absence of BAP1 inhibits 
homology directed DNA-repair and thereby forces cells to rely on the more error-prone 
non-homologous end joining (NHEJ)46. Surprisingly, the mutational load in UM is signifi-
cantly lower than in other cancer types, suggesting that BAP1 loss in UM does not heavily 
impair DNA-damage repair mechanisms. Other proteins that interact more frequently 
with BAP1 could therefore be a more interesting target.
Some new proteins identified in these studies as interactors with BAP1 are the forkhead 
transcription factors FOXK1 and FOXK2, the histone acetyltransferase HAT1, the histone 
lysine demethylase KDMB1B, the polycomb group proteins ASXL1 and ASXL2, host cell 
factor C1 HCF1, and the ubiquitin-conjugated enzyme UBE2047-52. Most of these proteins 
are involved in the regulation of chromatin-associated processes such as transcription. 
This large number of interacting proteins implicates that absence of BAP1 can have a 
plethora of downstream effects. One protein that predominantly interacts with BAP1 is 
HCF1, a protein involved in regulating the cellular localization of BAP1 through the for-
mation of multiprotein complexes with transcription factors such as Yin Yang1 (YY1) and 
FOXK1/248, 53. HCF1 plays an important role in stem cell maintenance by regulating genes 
involved in RNA processing and the cell cycle49. RNAi-mediated depletion of BAP1 ex-
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pression triggered a primitive, stem-like phenotype in UM cells. Genes involved in the 
maintenance of stem cells and developmental processes were upregulated and melano-
cyte-specific genes, such as MITF, were downregulated54. Thus, loss of BAP1 dysregulates 
transcriptional programs which are essential in the maintenance of the differentiated me-
lanocytic phenotype. The acquisition of a stem cell like-phenotype is a common event in 
cells undergoing the epithelial-to-mesenchymal (EMT) transition required for metastasis. 
EMT programming may contribute to the highly metastasizing potential of BAP1-mutated 
UM cells by enabling cells to physically disseminate from the primary tumor. It also pro-
vides cells with the self-renewal capability that is crucial for clonal expansion at the site 
of dissemination 55. 
The interaction of BAP1 with ASXL1 and ASXL2, important catalytic subunits of the 
polycomb repressive deubiquitinase (PR-DUB) complex, could influence the regulation 
of homeobox genes by deubiquitinating histone H2A56, 57. Histone H2A plays a role in 
several cellular processes, such as stem cell maintenance and cell proliferation58. The 
ubiquitination of histones alters the chromatin structure and thereby regulates the ac-
cessibility of the DNA for the transcriptional machinery59. Knock down of BAP1 by 
RNA interference induced an increase in H2A ubiquitination in UM cells, implying 
















Figure 5. Overview of the BAP1 protein and its functional and interacting domains. The BAP1 mutations we 
observe in our ROMS cohort are depicted below the protein and classified according to their mutation type and 
location. The N-terminal UCH domain ranges from amino acid 1-250, the HCF1-binding domain (HMB)-like motif 
from amino acid 363-366, the UCH37-like domain (ULD) from 634-396 and the two nuclear-localization signaling 
(NLS) from amino acid 656-661 and 717-722. BAP1 also shows binding domains for BARD1, HCFC1, BRCA1 and 
YY1. The binding site of the BAP1 IHC antibody is indicated with the dashed line. Reproduced with permission 
from: Koopmans et al, 2014.
Besides the aforementioned nuclear roles of BAP1, it also plays a role outside the nucleus. 
BAP1 can be localized in the endoplasmic reticulum (ER), where it stabilizes the type 3 
inositol-1,4,5-triphosphate receptor (IP3R3). IP3R3 is involved in promoting apoptosis by 
tightly regulating the release of Ca2+ from the ER into the cytosol. Loss of BAP1 reduces 
the amount of stable IP3R3, resulting in reduction of Ca2+ influx and thereby preventing 
cell apoptosis60. However, recent work from Farquhar et al questioned the role of cytoplas-
mic BAP1 in the metastasis of UM, since they did not find a correlation between disease-
free survival of UM patients and the cytoplasmic expression of BAP124, 44. 
 
This large number of potentially relevant proteins makes it difficult to determine the ex-
act function of BAP1 due to the complex interaction networks. BAP1 assembles into a 
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yet which of these many transcription factors plays the crucial role in the metastasis of 
UM, showing that additional research regarding BAP1 in UM is necessary. For this, it is 
interesting to study the outliers in the BAP1-mutated group. For example, in our cohort 
we observed seven patients with BAP1-mutated tumors who remained metastasis-free for 
over 10 years. It has also been described that patients who carry a germline BAP1 mutation 
do not have a substantially earlier age-of-onset of UM than other UM patients 61. Addition-
ally, these UM patients with germline mutations in BAP1 have a better prognosis than pa-
tients with somatic mutations in BAP1. This suggests that in these patients, mechanism(s) 
have developed that could temporarily counteract the metastasis-promoting effect of 
BAP1 loss. Elucidating which mechanisms would be capable of doing that will contribute 
significantly to the development of a therapy targeted against BAP1 loss in UM.
2.3 SF3B1 mutations result in aberrantly spliced mRNA
Metastasizing UM that do not show a BAP1 mutation often harbor a mutation in the gene 
SF3B112, 13, 21, 27. SF3B1 encodes subunit 1 of the splicing factor 3b, which is responsible for 
proper branchpoint recognition during splicing of pre-mRNA. Correct RNA splicing is 
crucial for cell survival and allows cells to produce multiple proteins from one single 
gene. Somatic mutations in components of the spliceosome have been observed in several 
malignancies, such as breast, pancreatic and hematologic cancers62-64. The prevalence of 
cancer-associated mutations in spliceosome genes suggests that dysregulation of splicing 
can efficiently lead to the development of cancer. 
 
SF3B1 mutations can result in aberrant splicing and it has been shown that these muta-
tions in UM result in alternative splicing at the 3’ end of exon borders65. These aberrantly 
spliced transcripts can be degraded by nonsense-mediated RNA decay, resulting in a loss 
of expression, but they can also be translated into unique, aberrant proteins66 (Figure 6). 
Several genes have been shown to be affected in UM, such as ubiquinol-cytochrome C 







Figure 6. Splicing of pre-mRNA into mature mRNA. Wildtype SF3B1 binds to the branchpoint (BP) of the pre-
mRNA, which is usually an adenosine located ~25 nt upstream of the 3’ splice site (3’ ss). This allows a correct 
assembly of the spliceosome on the pre-mRNA, resulting in mature mRNA and a canonical protein. Whereas 
mutant SF3B1 recognizes an alternative BP (BP’), resulting in mis-spliced mRNA. This mis-spliced mRNA can be 
translated into an aberrant protein or degraded by nonsense-mediated RNA decay, resulting in downregulation 




The SF3B1 protein consists of an N-terminal hydrophilic region and a C-terminal region 
consisting of 22 non-identical HEAT (Huntington, elongation factor 3, protein phospha-
tase 2A, targets of rapamycin) repeats. UM-associated mutations in SF3B1 are found al-
most exclusively in the fifth HEAT-repeat at codon position arginine (R) 625. In other can-
cer types, such as breast cancer and leukemia, mutations in SF3B1 are more prevalent in 
the sixth and seventh HEAT-repeat at lysine residues K666 and K700, respectively. These 
lineage-specific mutations can be explained by several factors, such as tissue-specific in-
teraction partners, the mutation rate of the gene and the activity of several pathways in a 
specific tissue that might confer survival advantage67. However, since these residues are 
predicted to be spatially close to one another, it is not surprising that these mutations have 
a similar functional impact on transcription. RNA-sequencing data from SF3B1-mutated 
UM and breast cancer samples show some unique aberrant transcripts but the majority 
of the aberrant transcripts is observed in both malignancies (unpublished data). Samples 
harboring a mutation outside the HEAT-domains do not show aberrant splicing, implying 
a different effector on splicing or no effect at all68. 
 
SF3B1 is the most frequently mutated spliceosome gene in UM, but mutations in U2AF1 
and SRSF2 have also been described17. U2AF1 and SRSF2 are both involved in the as-
sembly of the spliceosome and it has been shown that mutations in these genes produce 
alternative transcripts in hematological malignancies. Similar to the SF3B1 gene, particu-
lar SRSF2 mutations are more prevalent: we observed that 4 of the 5 in-frame deletions 
involve the same protein residues (AA 92-99), indicating that this particular activity of 
SRSF2 creates a specific effect on splicing, required in UM etiology69. Whether the down-
stream effects of these mutations are similar is unclear but these observations are intrigu-















Figure 7. Disease-free survival of UM patients. A) Kaplan-Meier curve showing the disease-free sur-
vival of the SF3B1mut UM in the overall or disomy 3 group. B) In the overall survival curve contain-
ing all UM; it can be observed that every mutation status corresponds with a distinct survival pat-
tern. Reproduced with permission from Yavuzyigitoglu et al, 2016, via Copyright Clearance Center.
Most patients in our cohort with SF3B1-mutated UM eventually developed metastasis, but 
have a longer disease-free survival than BAP1-mutated UM, implying that SF3B1-mutated 
micro-metastases remain longer in their dormant state than BAP1-mutated micro-metas-
tases. In our own patient cohort, the effect of SF3B1 is probably masked by the bulk of UM 
patients with BAP1 mutations, as we did not observe a significant difference in prognosis 
for patients with or without a SF3B1-mutated UM (Figure 7A). However, in the disomy 
3 group, SF3B1 mutations do show an association with a worse prognosis. The overall 
survival curve of all UM, stratified by mutation subtype, confirms that SF3B1-mutated 
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overall survival can vary greatly between SF3B1-mutated cases, as some develop metasta-
ses within 5 years whereas others after a decade (Figure 7B)12. What causes this difference 
in metastatic potential is not clear and we did not find a specific segregation with the other 
well-known clinical-pathological or genetic prognostic markers using principle compo-
nent analysis. However the number of patients in the early metastasizing subgroups was 
small which could have prohibited a proper analysis. We are in the process of collecting 
data of more patients with SF3B1-mutated tumors to survey RNA expression and epigen-
etic differences between these early and late metastasizing tumors, which might help us 
understand these different effects of aberrant splicing on metastatic risk.
2.4 EIF1AX plays an important role in the initiation of translation
The EIF1AX gene is mutated in approximately 20% of UM and is involved in the initia-
tion of gene translation in eukaryotic cells13. Ribosomes bind the 5’ end of the mRNA in a 
relatively unstable state, which allows scanning of the mRNA for the start codon. Several 
eukaryotic initiation factors (EIFs) support the ribosome in this process and subsequently 
stabilize the ribosome once it reaches a start codon. EIF1A consists of a globular domain 
and two unstructured tails, the N- and C-terminal tail, which are involved in the scanning 
of the mRNA and the accurate recognition of the start codon. 
 
UM patients harboring only an EIF1AX mutation (in addition to a GNAQ or GNA11 mu-
tation) hardly metastasize; in our cohort, none of the patients with a pure EIF1AX muta-
tion developed metastases: the only EIF1AX-mutated patient who developed metastases 
had a concurrent BAP1 mutation (Figure 7B). Remarkably, UM-associated mutations in 
EIF1AX-indicated in figure 8 by the red dots- occur exclusively in the N-terminal tail of 
the protein, a highly conserved region in eukaryotes. Mutations in the N-terminal tail 
inhibit the scanning process by stabilizing the ribosome. This promotes the utilization 
of less optimal start codons and thereby alters gene expression in UM70. Experiments in 
yeast show that EIF1A mutations alter the relative use of start codons in mRNA encoded 
by tumor suppressor genes or oncogenes. Immunohistochemical staining of EIF1AX in 
samples harboring a mutation showed a positive staining throughout the cytoplasm of the 
cell, showing that mutations in the EIF1AX gene do not cause loss of the protein13. EIF1AX 
mutations have also been observed in other cancer types, such as breast cancer, prostate 
cancer, adenocarcinoma and glioma (indicated in figure 8 by the grey dots)71. Surprisingly, 
these mutations are found throughout the entire protein-coding DNA, as opposed to UM, 
where mutations are only observed in the N-terminal tail. This raises the question if the 
N-terminal region of EIF1AX executes specific functions or engages with specific binding 
partners in UM. Change of function mutations in the EIF1AX gene might make melano-
cytes more malignant and stimulate their division, but not enough to initiate metastasis. 
Whether UM cells do not spread at all or whether micro-metastases are present in distant 
organs but remain dormant, is unknown.
Figure 8. EIF1AX mutations. Malignant mutations in the EIF1AX protein observed in UM (red) and other cancer 
types (grey). All observed mutations are in-frame mutations71
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3. Chromosomal abnormalities and RNA expression in UM
UM progression involves several chromosomal gains and losses. Chromosome 8q gain 
and complete loss of chromosome 3 frequently occur in high-risk UM, whereas low meta-
static risk UM carry two copies of chromosome 3 and often show gains of chromosome 
6q (UM type A) and distal 8q (UM category B)18, 72-74. Thirty percent of UM patients also 
have a deletion of chromosome 1p, which is associated with a higher metastatic risk 75. 
Aberrations on other chromosomes have been observed, but are less frequent and show 
no correlation to metastatic risk. Cytogenetic analyses are useful but very time and la-
bor consuming. Culturing UM tumor cells is hampered by overgrowth of fibroblasts and 
only short time cultures can be used to obtain an accurate karyotype. Nowadays, a Single 
Nucleotide Polymorphism (SNP) array technology is used to determine copy number 
variations (CNV) in tumor specimens. Apart from the observation that CNV analysis as 
such is an independent prognostic test and does contribute to prognostication models76, 
77, we have observed earlier intriguing differences between these CNVs in metastasizing 
UM which did urge us to go back to the results obtained with karyotype analysis. We no-
ticed that whereas BAP1-mutated tumors did harbor in general a few whole chromosome 
anomalies resulting in isochromosome formation (e.g. (i)8q or (i)6p), in SF3B1-mutated 
tumors smaller gain or losses of the terminal parts of chromosome 6p and 8q are more 
prevalent14. Whether this is a consequence of the underlying BAP1 or SF3B1 mutation 
causing a different route to generate these chromosomal aberrations or that the resulting 
genetic changes sort out the most optimal effect in combination with the specific mutated 
gene, is not clear. Most, if not all UM, present with both the mutation and the match-
ing set of CNVs, but we occasionally observe these mutations without the corresponding 
CNV patterns or vice versa. A scrutinized genetic survey of these rare cases, preferably 
with –when available- also the subsequent metastatic tissues may shed more light on this 
causality dilemma. Alternatively, site-directed mutagenesis of these genes using CRISPR/
Cas9 in melanocytic cells could help us to answer the chicken and egg story and analyze 
other intriguing differences regarding the altered pathways and route towards metastasis 
between BAP1 or SF3B1-mutated tumors.
 
Figure 9. Differential gene expression between class 1 and class 2 UM. Several chromosomal re-
gions contain differentially expressed genes identified by a locally adaptive statistical procedure (LAP)-
analysis. White bars indicate locations of the microarray-probes, whereas red (upregulation) or 
green (downregulation) indicate a differentially expressed gene. Adapted from van Gils et al, 2008.
Nevertheless, these chromosomal abnormalities contribute to the development of UM by 
altering gene expression. Specific gene expression profiles (GEP) are associated with low 







Potential biomarkers and therapeutics
(class 2)16, 78-80. Interestingly, we described in a previous publication that differential ex-
pression only partially correlated with chromosomal abnormalities (Figure 9). For exam-
ple, a large part of the genes located on chromosome 3p were significantly downregulated 
in class 2 UM, whereas genes located on chromosome 3q were not81. In addition, parts of 
chromosome 8q and 6q showed upregulation. This indicates that other mechanisms, such 
as methylation, might compensate for chromosomal abnormalities.
The oncogene MYC is located in the frequently amplified chromosome 8q24 region. 
Several analyses show that the presence of extra copies of chromosome 8 is associated 
with a worse prognosis74, 82-84. Although MYC signaling has been shown to be involved 
in UM development, no direct association has been observed between MYC expression 
and metastatic death17. Expression of the adjacently-located long non-coding RNA PVT1 
(plasmacytoma variant translocation gene) does show a direct association with metastasis. 
This indicates that gene expression regulation is complex and that other processes, in ad-
dition to copy number status, are involved in regulating expression levels. PVT1 is often 
amplified in several cancer types and acts as an oncogene by regulating transcriptional 
activity and acting as a miRNA sponge by binding to complementary miRNAs, thereby 
preventing the miRNAs from exerting their role in gene expression. Another oncogene 
located on the amplified 8q region is development and differentiation enhancing factor 1 
(DDEF). High-risk UM show higher DDEF expression than low-risk UM. DDEF regulates 
the remodeling of the cytoskeleton, which is necessary for cell motility. Overexpression of 
DDEF in low-risk UM cells increases their motility, suggesting that upregulation of DDEF 
contributes to the invasive phenotype of high-risk UM. However, most of these studies do 
not discriminate between SF3B1 and BAP1-mutated tumors, so these observations might 
not be valid for the often small 8q amplified regions of SF3B1-mutated tumors. Hence, 
repeating these analyses in well-defined UM subgroups based on genetic changes in the 
secondary driver genes might result in a different set of classifier genes. Furthermore, 
amplification of an isochromosome 8q (8q gain in combination with 8p loss), as seen fre-
quently in BAP1-mutated tumors is also present in other tumor types. In a recent study 
on hepatocellular carcinoma performed by The Cancer Genome Atlas (TCGA) network, 14 
of 23 BAP1-mutated samples did show signs of isochromosome 8q, suggesting a similar 
common and perhaps more universal underlying genetic mechanism85. It would be in-
teresting to determine whether other SF3B1-mutated tumors harbor similar SF3B1-CNV 
patterns in addition to the observed overlap in altered expressed RNAs.
Gene expression can also be used to predict disease-free survival of UM patients. Unsu-
pervised clustering of primary UM based on mRNA expression shows two distinct classes 
as shown by Onken et al16. Class 1 consists of EIF1AX and SF3B1-mutated UM that show 
the transcriptome of a differentiated melanocyte, whereas class 2 contains monosomy 3/
BAP1-mutated tumors characterized by a stem cell-like expression profile. Functional an-
notation of these differentially-expressed genes revealed involvement in development, 
cell communication, cell growth, cell motility and apoptosis. Interestingly, most of the 
identified developmental genes are known to be implicated in neural crest development16. 
TCGA contains the expression data of 80 primary UM. Monosomy 3 TCGA samples 
showed increased transcription of MAPK, AKT and the transcription factors FOXA1 and 
FOXM1, indicating increased proliferation in this group17. Several long non-coding RNAs 
were found to be higher expressed in monosomy 3 samples, such as the aforementioned 
PVT1 gene, as well as the oncogenes CYTOR and BANCR. The expression of multiple 
immunological genes was also significantly elevated in the poor prognosis clusters. This 
indicates an activation of the immune system, which is in contrast to what has been ob-
served in other cancer types, where an activated immune system is typically seen in tu-
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mors with low metastatic risk. An association between monosomy 3 and an inflammatory 
phenotype has been described previously86. An important difference may be that UM me-
tastasizes hematogeneously, and that the presence of infiltrating macrophages contributes 
to intratumoral vessel growth87-90.
Within the monosomy 3 TCGA samples, two separate clusters were observed, categories 
C and D17, 18. Surprisingly, one cluster showed an activation of the DNA damage response 
(DDR) pathway, which, however is not reflected in the mutational load of UM. MYC sig-
naling and HIF1a were also upregulated in this cluster, which is consistent with aberrant 
BAP1 expression. The other cluster is characterized by elevated levels of MAPK and AKT, 
two effectors of the Gα11/Q pathway. This implies that BAP1 loss may enhance the effect 
of oncogenic GNAQ and GNA11. 
4. UM metastases
Most UM research focuses on primary UM, although the metastases cause death in UM 
patients and not the primary tumor. Metastatic outgrowth of a tumor is a complicated, 
multi-step process that is often difficult to unravel. Only a few UM patients with metas-
tases undergo liver resection, and diagnostic biopsies usually do not provide sufficient 
material for additional research. Moreover, metastases samples can contain a mixture of 
UM cells, admixed reactive cells as well as hepatocytes, making a proper description of the 
genomic profile of UM metastases challenging. 
4.1 Metastatic spread of UM. 
The metastatic capacity of cancer cells is mainly determined by the interaction with the 
microenvironment. In order to allow UM cells to grow in distant organs, several steps 
have to be taken; they must lose contact with neighboring cells, home and survive in the 
host organ, become established and finally also be able to grow into macro-metastases91. 
Therefore, it could be hypothesized that UM cells need to acquire several additional ge-
netic aberrancies in order to successfully grow in distant organs. 
In 1882, the ophthalmologist Ernst Fuchs described the predisposition of uveal melanoma 
to metastasize to the liver and postulated an organ-specific predisposition for metasta-
ses92. Seven years later, Paget formulated the famous Seed and Soil hypothesis93 which 
suggests that metastasis is not random and cancer cells (the seeds) show a preference 
when metastasizing to distant organs (the soil). Since the large majority of UM metastasize 
to the liver, it could be implied that there is a favorable microenvironment in the liver for 
UM cells. Whether the primary tumor stimulates this microenvironment by promoting 
the development of pre-metastatic niches remains unclear. Unraveling which factors in 
the liver contribute to this favorable microenvironment might provide us with possible 
therapeutic targets. One factor that is thought to play an important role in creating a pre-
metastatic niche in specific organs are exosomes. These small (~100 nm) lipid bilayer-de-
limited vesicles are released from cells and carry several functional biomolecules that can 
be transferred to recipient cells. A specific repertoire of integrines on the exosome-surface 
dictates the adhesion of exosomes to specific cell types; Hoshino et al. have shown that 
tumor-derived exosomes preferentially interact with cells at the future metastatic site94. 
After these exosomes are taken up by the target cells, several signaling pathways and 
inflammatory responses are initiated which are necessary to complete the development 
of the pre-metastatic niche95. Since a study by Angi et al. has shown that primary cultured 
UM cells secrete almost half of their secreted proteins via exosomes, one may speculate 
that exosomes play a role in metastasis formation in UM96.
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metastases. This implies that UM cells have already spread into the circulation before the 
primary tumor was diagnosed and treated. A study by Eskelin et al calculated tumor dou-
bling times for UM and showed that primary UM metastasize already several years before 
treatment3. With this in mind, one would expect that circulating tumor cells (CTCs) could 
be detected at time of diagnosis. However, CTCs are mainly detected in blood of patients 
with metastatic UM, whereas patients with primary UM often show no CTCs97. Whether 
this is due to the low number of CTCs in blood at the time of diagnosis or the seeding of 
CTCs by metastatic lesions is unknown. Isolating these rare CTCs both at diagnosis and 
during the metastatic phase could aid our understanding of the metastatic process in UM. 
Another promising biomarker that could identify dissemination of UM is cell-free DNA 
(cfDNA). CfDNA are small fragments of DNA that are released in the circulation by (tu-
mor) cells and are present in increased amount in cancer patients. Several studies have 
showed that GNAQ and GNA11-mutations could be detected in cfDNA from metastatic 
UM patients and that their presence showed an association with metastases-volume and 
overall survival97-99. 
4.2 Chromosomal alterations in UM metastases.
A wide spectrum of chromosomal alterations can be identified in UM metastases, such 
as gain of 8q, 6q, 1q and alterations in chromosome 3. These chromosomal alterations are 
also commonly found in primary UM, however, the frequencies are different100. UM me-
tastases showed more copies of 8q than the corresponding primary UM101. Given this high 
prevalence of 8q amplifications in UM metastases, it could be hypothesized that the 8q re-
gion contains gene(s) that potentially promote metastasis. However, further investigation 
is necessary in order to determine whether upregulation of oncogenes such as MYC and 
PTP4A3 have a direct effect on metastasis, or that this is just a consequence of extra copies 
of chromosomal region 8q. As expected, the majority of UM metastases contained altera-
tions in chromosome 3. Whereas primary UM mainly show monosomy 3, UM metastases 
frequently showed isodisomy 3 and large regions of homozygosity100, 102. Monosomy 3 
at first stimulates tumor progression through BAP1 inactivation; however, haploinsuf-
ficiency of some chromosome 3 genes could result in a reduced expression of genes such 
as MITF, MBD4 and CTNNB1 and thereby limit UM progression16, 81. In response to this 
limitation, duplication of chromosome 3 could be a compensating mechanism in metas-
tasizing UM cells.
4.3 Mutational analysis in UM metastases
As described in the introduction, UM shows a remarkable low mutational burden com-
pared to other malignancies. Rodrigues et al sequenced 15 UM trio’s (germline, primary 
UM and UM metastases) and did not observe a significant increase in SNVs between pri-
mary UM and its metastases (median 13 SNVs vs 16 SNVs)102. All UM metastases con-
tained a mutually exclusive GNAQ or GNA11 mutation that matched with the primary 
UM, confirming that these mutations arise early in the development of the disease. Inter-
estingly, Shain et al also observed LOH of mutant GNAQ in multiple metastases samples, 
suggesting that GNAQ-mutated UM require a second hit later in UM progression. LOH of 
mutant GNAQ shifts the allelic balance towards mutant GNAQ, which activates the GαQ 
signaling even further, thus allowing cells to become fully malignant101. This corresponds 
with previous studies suggesting that GNA11-mutations are more potent oncogenes, 
since an over-representation of mutations in GNA11 was observed in UM metastases103. 
Secondary driver mutations in BAP1 and SF3B1 were observed in high frequencies in 
UM metastases as well, indicating early occurrence. Surprisingly, additional mutations in 
new oncogenes were also observed in UM metastases, which however, occurred in much 
lower frequencies than the secondary driver mutations. This indicates that these tertiary 
driver mutations occur later in UM progression, after mutational activation of BAP1 and 
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SF3B1. Tertiary driver mutations were found in oncogenes, such as PTEN, EZH2, CD-
KN2A, TP53101, 102. These newly-identified mutations might offer new opportunities in UM 
therapeutics. However, it is still early for the field to develop therapies targeting these 
genes. Firstly, it remains unclear to what extent each of these mutations contributes to the 
malignant phenotype. Secondly, novel targeted treatment may possibly only have an ef-
fect on metastatic UM subclones harboring particular actionable mutations.
5. Therapeutic options
We have gained considerable insight into the genetic background of UM, but this has not 
yet resulted in successful treatments of metastatic UM. Treatment of metastatic UM with 
classic chemotherapy has been disappointing, with low response rates104, 105. Over the past 
35 years, survival of patients with metastatic UM has not improved106. However, now that 
we know the genes and the pathways they might be involved in, we can start developing 
new therapeutic modalities for UM.
5.1 Targeting the Gα11/Q pathway 
Since the majority of UM contain mutations that deregulate the Gα11/q pathway, drugs 
targeting this pathway might be effective in the majority of UM, regardless of their fur-
ther mutational background. Inhibiting GNAQ and GNA11 themselves might be difficult, 
because of high GTP levels in the cytoplasm. Several studies have therefore focused on 
interfering with the critical downstream effectors, such as MAPK, PKC, PI3K and AKT 
signaling. Clinical trials with the MEK1/2 inhibitor selumetinib resulted in promising pre-
liminary results107. UM patients treated with selumetinib had an improved progression-
free survival of up to 15 weeks, compared to patients treated with chemotherapy. Unfor-
tunately, selumetinib did not improve overall survival in UM patients. This indicates that 
selumetinib can inhibit metastatic growth only for a limited time: once the tumor acquires 
resistance to MEK inhibition, it grows even more aggressively than non-treated metastatic 
tumors. A combination of the chemotherapeutic drug dacarbazine and selumetinib did 
not give improvement in survival108. Similar results were obtained with the MEK inhibitor 
trametinib and the Akt inhibitor GSK795: no improved survival rate was observed in 40 
metastatic UM patients109. 
These disappointing results could be explained by acquired resistance, which also causes 
CM patients to become resistant to the BRAF inhibitor vemurafenib110. Another reason 
for this limited response could be that these inhibitors act far downstream of oncogen-
ic GNAQ and GNA11. As shown by Mouti et al, progression of UM in zebrafish is de-
pendent on YAP activation, rather than activated extracellular signal-regulated kinases 
(ERK). Only a subset of the malignant uveal melanocytes showed activation of ERK, while 
knockdown of GNAQ or PLCB4 did not affect the levels of activated ERK, suggesting that 
MAPK signaling only partially contributes to the development and maintenance of UM111. 
Inhibiting only one arm of an oncogenic network is likely less efficient than interfering 
with nodes that act closer to GNAQ and GNA11, such as ARF6. 
ARF6 regulates multiple downstream signaling pathways and might therefore be a more 
suitable target for treatment of UM. Knockdown of ARF6 induces the re-localization of 
GNAQ and GNA11 from the cytoplasm to the plasma membrane, resulting in a decrease 
of all Gα11/q -mediated pathways. Yoo et al showed that inhibition of ARF6 in the GNAQ- 
and SF3B1-mutated UM cell line, Mel202, resulted in a lower tumor incidence and size 
when injected into immune-compromised mice31. A significant reduction in the levels of 
downstream activated ERK, RAC/RHO, p38, JNK and C-JUN was observed as well. Treat-
ing cells and xenograft mouse models with NAV-2729, a direct inhibitor of ARF6, resulted 
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ing and no toxicity was observed; however, this treatment is not yet FDA-approved and 
additional studies have to be performed to investigate whether pharmacological inhibi-
tion of ARF6 is an effective treatment for UM.
Other targets for UM treatment could be PLCB4 and YAP. YAP can be successfully inhib-
ited by the well-tolerated compound verteporfin. Treatment of xenograft mouse models 
with this drug showed a reduction in UM growth112. However, these compounds too only 
target one arm of the oncogenic Gα11/q network and it is therefore likely that they will 
only show a limited effect unless they are used in combination with another drug. 
5.2 HDAC inhibitors to reverse the effect of BAP1 loss
Several studies have described histone deacetylase inhibitors (HDACI) as promising 
anti-cancer drugs. HDACIs interfere with HDACs, which are frequently upregulated in 
cancer113-115. These HDACs remove acetyl groups from histones, which changes the struc-
ture and accessibility of chromatin and thereby affects gene expression116. UM cell lines 
or xenograft models treated with HDACI show a reduced proliferation and an induced 
cell cycle arrest. A study by Landreville117 et al described that BAP1-deficient cells have 
an increased sensitivity for HDACI. HDACIs initiated morphologic and transcriptomic 
changes consistent with melanocyte differentiation and reduced proliferation through G1 
cell cycle arrest. BAP1-deficient cells might be more sensitive to HDAC inhibition because 
of their increased H2A ubiquitination. It has been shown that distinct histone modifica-
tions act together to regulate chromatin structure and gene expression: for example, the 
deubiqituitinase enzyme H2A-DUB not only regulates deubiquitination of histones, but 
also acetylation118. Interfering with the acetylation of histones in BAP1-deficient UM might 
reverse the biochemical deficit caused by BAP1 loss by shifting the cell to a less aggressive, 
more differentiated state. HDACIs could therefore prolong survival of UM patients by 
keeping micro-metastases in a quiescent, differentiated state. 
5.3 Spliceosome inhibitors
SF3B1-mutated UM require a different approach. As mentioned before, tumors with an 
SF3B1 mutation show aberrant splicing of pre-mRNA resulting in an increased rate of 
transcripts containing premature termination codons. Mutations in splicing factors al-
ways occur in a heterozygous state and have never been observed to coincide with another 
splicing-factor mutation. The spliceosome is essential for survival and cancer cells require 
wildtype splicing to survive. Inhibiting the spliceosome in cancer cells with spliceosome 
inhibitors has shown exciting results in several different malignancies and might therefore 
also be a promising treatment for UM. 
Several components have been identified that are able to successfully inhibit the spliceo-
some assembly at an early stage, such as sudemycin119, E7107120 and spliceostatin A121. 
E7107 and spliceostatin A bind non-covalently to SF3B1 and thereby prevent exposure 
of the branchpoint-binding region of U2 snRNP. This results in defective formation of 
the spliceosome early in the splicing process. Mutations in the SF3B1 gene result in re-
sistance to E7107, as shown by long term treatment of human colorectal cancer cell lines 
with E7107122, indicating that only wildtype (WT) SF3B1 is affected. Since SF3B1-mutated 
UM require wildtype splicing in order to survive, interference of WT SF3B1 by E7107 will 
result in cell death.
In vivo treatment of isogenic murine myeloid leukemias that harbor an SRSF2 mutation 
with E7107, reduced the leukemic burden by inducing preferential cell death of cells 
bearing an SRSF2 mutation123. Inhibition with this compound showed the same effects as 
RNAi-mediated silencing of SF3B1, such as an accumulation of unspliced mRNA in the 
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nucleus. A subset of this unspliced mRNA leaked into the cytoplasm, which resulted in 
the production of aberrant proteins, including an unusually stable form of the cell cycle 
inhibitor p27120. Unfortunately, clinical trials with E7107 in patients with metastatic solid 
cancer had to be suspended due to an unexpected side effect in bilateral optic neuritis, 
resulting in loss of vision. However, in most patients the drug was well tolerated and 
inhibition of splicing was observed124, 125. Additional compound screens will be necessary 
to identify spliceosome inhibitors that act on the spliceosome assembly at a later stage. 
Recently, a phase 1 trial was started with the new spliceosome inhibitor H3B-8800126. 
While targeting the spliceosome will probably have most potential in SF3B1-mutated UM, 
it might also be beneficial to treat BAP1-mutated UM with these compounds, as it has been 
shown that cancer cells with an increased MYC activity might also be more vulnerable to 
spliceosome inhibition127. Since a subset of the BAP1-mutated tumors show an upregula-
tion of MYC, treatment of these tumors with spliceosome inhibitors might be a promising 
option. A possible problem with spliceosome-inhibitors might be their lack of specificity. 
Another method to alter splicing in cells is through oligonucleotides. Oligonucleotides 
bind to RNA in a sequence-specific manner and prevent interaction between the spliceo-
some and pre-mRNA by steric hindrance. Aberrantly-spliced genes, that contribute sig-
nificantly to the malignant phenotype of UM, can thereby be specifically targeted and 
inhibited. Oligonucleotides have been shown to regulate the presence of aberrant splice 
variants and restore the production of essential proteins128. Unfortunately, no oligonucle-
otide-based treatment has yet been approved for the treatment of cancer patients. 
5.4 Immunotherapy in UM
Metastasis can arise several years after successful removal of the primary tumor. This long 
latency period can be explained by the presence of dormant UM cells, and dormancy may 
be due to immunological inhibition. Once a cancer cell is able to overcome the immune 
response, micro-metastases can start to proliferate, which will result in a fatal outcome.
A new, exciting area of cancer drug development is immunotherapy. One example of 
immunotherapy is the use of monoclonal antibodies against CTLA-4, PD-1 and PD-L1. 
CTLA-4 and PD-L1 act as natural immune checkpoints in T cells, to tune down and there-
by avoid exaggerated immune responses. It has been shown that cancer cells suppress 
immune responses by upregulating the ligand PD-L1. The monoclonal antibodies used 
in immunotherapy block the checkpoints and subsequently unblock and thus activate T 
cells, which results in the removal of cancer cells. Many of these monoclonal antibodies 
have already been approved for clinical use, such as nivolumab targeting PD-1. Immuno-
therapy treatment of advanced melanoma, lung cancer and renal cancer patients showed 
remission and in some cases even eradicated metastatic disease. Unfortunately, these anti-
bodies show only limited activity in UM patients129-131. Dual immune-checkpoint blocking 
resulted in a response rate of 38% in CM, but no response was observed in UM patients132. 
These disappointing results cannot solely be explained by the fact that UM do not express 
PD-L1, since two studies show heterogeneous expression of PD-L1 (>5% positivity) in ap-
proximately 50% of the UM (Figure 10)131, 133. 
However, a potentially more promising strategy would be to inhibit checkpoints that have 
been shown to be consistently highly upregulated in metastatic UM, such as indoleamine-
pyrrole 2,3-dioxygenase (IDO) and T cell immunoreceptor with Ig and ITIM domains 
(TIGIT)17, 134. Interestingly, Rodrigues et al describe an unexpected high sensitivity to the 
PD-1 inhibitor pembrolizumab in one UM patient135. DNA sequencing identified a germ-
line mutation in MBD4, a gene located on chromosome 3 and involved in base excision re-
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the tumor to PD-1 inhibition. A similar UM patient was recently described 136, while within 
the TCGA-dataset, two other UM patients with MBD4 mutations were identified, indicat-
ing that a small fraction of the UM patients could directly profit from PD1-inhibition.
Figure 10. Heterogenous PD-L1 expression in primary UM. The lowest magnification (0.3x) shows 
the flat choroidal tumor, whereas the medium magnification (1.4x) shows diffuse membranous expres-
sion of PD-L1. This is confirmed at higher magnifications; the top right and lower right picture (20x and 
40x respectively) show positive membranous PD-L1 expression in UM cells (small arrowheads), posi-
tively-stained retinal pigmented epithelium cells (large arrowheads) and tumor-infiltrating macrophages 
(small arrows). Reproduced with permission from Zoroquiain et al, 2018 via Copyright Clearance Center.
A more classic approach to immunotherapy is inducing an immune response by making 
use of activated dendritic cells (DCs). A collaborative study in The Netherlands by Bol et 
al treated UM patients with autologous DCs loaded with antigens derived from gp100 or 
tyrosinase, two melanocyte-specific proteins137. No severe toxicities were observed after 
the vaccinations and 74% (n=17) of the patients showed the presence of tumor-specific T 
cells after DC vaccination, indicating an activation of the immune system. These patients 
showed a significantly longer disease-free and overall survival than patients that did not 
show an immune response (58 months vs 45 months respectively) (Figure 11). However, 
no significant difference in the overall survival rate was observed compared to the con-
trol group137. A new approach uses a novel molecule, tebentafusp, to initiate an immune 
response in UM patients. Tebentafusp acts as a bridge between UM and cytotoxic T cells 
and thereby ultimately results in T-cell activation and subsequent killing of UM cells 138, 139. 
Preliminary results indicate that biopsies, which were taken after the injection, confirmed 
the influx of lymphocytes and an increase in PD-L1 expression.
 
 
Figure 11. Survival of high risk UM patients after dendritic cell treatment. Kaplan-Meier curve showing the dis-
ease-free survival (A) and overall survival (B) in correlation with the presence of tumor antigen-specific T cells after 
receiving dendritic cell vaccination. Reproduced with permission from Bol et al, 2016, via Copyright Clearance Center.
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Still, the results obtained from widely used immunotherapy unfortunately present 
less promising results in UM patients than in CM patients. As the eye is an immune-
privileged site, immune responses may not develop as easily as in other locations, and 
may even be inhibited actively140. In most cancer types, immune infiltration is associ-
ated with good prognosis and sensitivity to immunotherapy. However, especially the 
prognostically infaust monosomy 3 UM show a dense immune infiltrate and increased 
HLA Class I expression89, 141, 142. This different response rates could be explained by the 
presence of immunosuppressive cells, such as regulatory T cells and macrophages, 
which dampen the immune response. A study of low risk and high risk tumors indi-
cated that extra copies of chromosome 8q were associated with influx of macrophages, 
while loss of BAP1 was linked to higher numbers of T cells142, 143. These data show that 
genetic changes are related to the development of the inflammatory phenotype in UM, 
but they do not explain why the immune system is so unresponsive in most patients. 
However, all these results imply that future immunotherapy agents should mainly fo-
cus on overcoming the immune suppression in UM. By determining the precise immune 
landscape in every tumor, we might be able to predict which UM would be sensitive 
to immunotherapy. Another factor that could explain the disappointing response rate to 
immunotherapy is the low mutational load of UM cells. As previously described, CM 
show a high mutational burden which correlates with a plethora of neo-antigens and 
thus renders them particularly suitable for immunotherapy. However, SF3B1-mutated 
UM could very well be more sensitive to immunotherapy if this is directed against the 
proteins produced by aberrant splicing. Mass spectrometry analysis of the proteome se-
creted by SF3B1-mutated UM could identify and characterize these aberrant proteins. 
These aforementioned treatments can be given systemically in order to remove any me-
tastases in distant organs; however they can also be given locally to UM patients with 
liver metastases by isolated hepatic perfusion (IHP). In case metastatic disease is confined 
to the liver, the liver can be isolated from the systemic circulation, which allows a much 
higher concentration of therapeutics to be used. Fifty to seventy-five percent of metastatic 
UM patients responded to IHP with the chemotherapeutic agent melphalan. The most 
common adverse effects were hematological events – such as thrombocytopenia, anemia, 
and neutropenia – which were clinically manageable, indicating that IHP with melphalan 
could be a promising treatment for UM patients with liver metastasis 144-146. Currently IHP 
is performed for established metastatic disease, but future drugs with less side-effects 
might allow targeted adjuvant treatment in high-risk UM patients147.
6. Future directions and conclusions
Even though our understanding of UM has advanced in the last decade, UM remains one 
of the very few malignancies for which there is no treatment available for metastatic dis-
ease. In recent years, there has been a tendency to transpose treatments shown to be effec-
tive in CM to UM, such as immunotherapy and MEK-inhibitors. However, as described in 
multiple studies, the biological behavior of these two malignancies is completely different 
and therefore they require a different approach. A better understanding of the complex 
genetic and immunologic background of UM will allow a more personalized approach 
which is necessary for effective treatment. Treatments targeting oncogenic GNAQ and 
GNA11 signaling could be applied to all UM patients, although it remains unclear if this 
will be sufficient for effective UM treatment. GNAQ and GNA11 are relatively weak on-
coproteins and can only become truly malignant when combined with co-mutations in 
secondary driver genes. Therefore, additional research into agents targeting these deregu-
lated processes, such as spliceosome inhibitors and HDAC inhibitors, is necessary. 
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mors could benefit from different therapeutic agents than BAP1-mutated tumors. This might 
require a more personalized approach, where the genetic background of each UM patient is 



















Figure 12. Schematic overview of the different UM subtypes. Each UM subtype is characterized by a TCGA subset, 
a specific mutation in one of the secondary driver-genes, several copy number variations and a different expression 
profile. Both intermediate and high risk UM could profit from immunotherapy or therapies that interfere with on-
cogenic GαQ signaling. Additionally, high risk, BAP1mut UM could profit from treatment with HDAC inhibitors, 
whereas intermediate risk, SF3B1mut UM could be more sensitive to spliceosome inhibitors. These treatments can 
be administered systemically, but also locally by isolated hepatic perfusion.
In the case of an EIF1AX-mutated UM, local treatment of the primary tumor could already 
be sufficient. However, SF3B1 and BAP1-mutated UM will require a more rigorous treat-
ment protocol. For these patients it is known that in many cases micro-metastases are 
already present at the time of diagnosis, meaning that besides treatment of the primary 
tumor, the dormant micro-metastases have to be targeted as well to improve overall pa-
tient survival. We therefore hypothesize that a combinatorial treatment approach in which 
local treatment of the primary tumor is combined with systemic treatment targeting the 
micro-metastases in high-risk cases would have the most potential in UM therapeutics. 
However, it remains controversial which specific characteristics are necessary to define 
high-risk UM patients, since different research groups use different prognostic param-
eters. In order to synchronize UM prognostication and treatment, an universal prognosti-
cation model using a combination of clinical, histological and genetic parameters should 
be considered to reliably identify high-risk UM patients76, 77, 148.  A number of important 
questions still remain open and research into these questions will dramatically aid the de-
velopment of treatments for metastatic UM: does the entire GNAQ and GNA11-signaling 
network contribute to the development and progression of UM or is it only one arm of 
the network? Which gene on chromosome 8q plays a role in the development of metasta-
ses? Which functions of the BAP1 protein contribute mostly to the aggressive phenotype 
observed in UM? What is the role of macrophages versus infiltrating T lymphocytes in 
high risk tumors, or are both only bystanders? And what stimulates dormant UM micro-
metastases in the liver to suddenly proliferate and give rise to fatal metastatic foci? The 
complexity and rarity of this type of cancer has made research into this malignancy diffi-
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The first observations about uveal melanoma metastasis were made over a century ago by 
the Austrian ophthalmologist Ernst Fuchs. In 1882 he described the concept of metastatic 
tropism of the ‘sarcom des uveal tractus’ to the liver and stated that enucleation was the 
best treatment1. In 1970 Zimmerman, McLean and Foster casted their doubts on the benefit 
of enucleation and described that other treatment modalities, such as radiotherapy, were 
also effective2. The first metastatic risk predictors were histological features, such as the 
presence of epithelioid cells and high mitotic count3. In 1996 the first genetic predictor of 
metastasis, loss of chromosome 3, was described by Prescher et al 4. With the rise of next-
generation sequencing techniques, loss of function of the tumor suppressor gene BAP1 
was identified5 and later on mutations in SF3B1 were detected in late metastasizing UM6.
Improving risk stratification in UM patients
Determining metastatic risk by performing BAP1 immunohistochemistry (IHC) is nowa-
days part of routine UM diagnostics7, 8. However, we recently implemented targeted next-
generation sequencing in UM diagnostics as well. With this technique, we can stratify pa-
tients that have underwent enucleation, endoresection or a prognostic biopsy, in either a 
low, intermediate or high metastatic risk group by combining mutation and copy number 
data9. Routine UM diagnostics allows us to investigate BAP1 expression, mutation status 
and copy number status, thereby providing us with the complete genetic make-up of the 
tumor. Diagnostic techniques, such as FISH, MLPA and IHC, only look at one feature. 
These techniques are still useful in UM diagnostics, however the percentage of sensitiv-
ity will likely be lower. Since it remains controversial which specific features should be 
present in UM in order to stratify a patient in the high risk group, it is important that we 
strive for an universal risk stratification method. The methods used for UM prognostica-
tion differ largely between different countries10, 11. If future treatment strategies are par-
tially dependent on the risk stratification, a united prognostication model using clinical, 
histological and genetic parameters should be considered to reliably identify UM patients 
with high metastatic risk. 
A drawback of all of these aforementioned methods is that patients that underwent eye-
conserving therapies cannot be prognostically categorized since in general there is no tu-
mor tissue available to perform genetic testing on. Moreover, treatment of the primary 
tumor by eye-preserving therapies has become increasingly common for small and medi-
um-sized UM. In some cases, patients undergo a biopsy, such as a fine-needle aspiration 
biopsy or a small incisional biopsy of the tumor. It has been shown that biopsies do not 
increase the risk of metastasis, however the procedure can have other complications such 
as retinal detachment, endophalmitis and vitreous bleeding12-14. Hence, there is a need for 
a non-invasive biomarker in blood that allows risk stratification of patients. 
Many advances have been made in the field of liquid biomarkers. The employment of 
circulating fetal DNA in maternal  blood to detect chromosomal aberrations of the fetus, 
set the example for cancer diagnostics15. For some cancer types, circulating tumor DNA 
(ctDNA) harboring a specific mutation is being detected to allow monitoring of the tu-
mor growth and treatment16-18. Several groups have investigated ctDNA presence in the 
blood of UM patients19-21. So far, results have been disappointing since ctDNA could not 
be detected in all metastatic UM patients. Additionally, all of these studies focused on 
mutations in GNAQ and GNA11, which hold little prognostic value. It has been shown 
that tumors need to be a certain size in order to allow ctDNA detection in blood22. The 
amount of ctDNA in blood depends on the tumor size and when the amount of ctDNA is 
low compared to the total amount of cell-free DNA, it will be hard to distinguish between 
true mutations and false positives. When there is only one copy of ctDNA mixed with 
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10.000 copies of normal DNA (0.01%), detection of ctDNA with current technologies is 
impossible. Most studies that describe detection of ctDNA, show a ctDNA percentage of 
0.1% or higher, which corresponds to a tumor with a diameter larger than 27 mm23. Since 
only 2% of the enucleated patients from our cohort had a UM with a basal diameter larger 
than 20 mm, we hypothesize that with current methods, ctDNA cannot be used to reliably 
predict prognosis for UM patients.
A more promising approach might be to enrich for tumor DNA or RNA by capturing me-
lanocyte-specific exosomes or circulating tumor cells from blood. If tumor DNA or RNA is 
specifically extracted from either melanocyte-specific exosomes or circulating tumor cells 
(CTCs), the percentage of tumor-derived material will be higher and once subjected to 
ultra-deep sequencing the sensitivity will be much higher. Subsequent detection of an ab-
errant, BAP1-specific  microRNA expression pattern in exosomes or identification of aber-
rantly methylated DNA in CTCs, will allow risk stratification. Since CTCs originate from 
the tumor, hypermethylation of the tumor suppressor genes KLF10, GSTP1 and MEGF10 
can be detected in BAP1-negative CTCs. As it has been shown that ctDNA still bears the 
methylation patterns of its originating cell, aberrant methylation might also be detectable 
in ctDNA24. In the future it may be possible to combine several molecular markers to 
increase sensitivity. A combination of proteins, aberrant miRNA patterns, aberrant DNA 
methylation or DNA mutations can be analyzed in order to stratify every UM patient into 
a certain metastatic-risk group. 
Unravelling UM tumorigenesis
Although chromosome 3 loss was shown to be strongly associated with high metastatic 
risk, it took almost 15 years to identify the responsible tumor-suppressor gene. Identify-
ing particular key genes in the development and progression towards metastasis of UM is 
an important step, however, this does not mean that the mechanisms that drive UM have 
been unraveled. Many other processes in the cell contribute to this malignant phenotype, 
such as epigenetic alterations. The discovery of hundreds of miRNAs which aberrant ex-
pression is implicated in tumor phenotypes, has already led to profound changes in our 
understanding. Yet, these only scratch the surface of the real complexity as microRNAs 
possess the capacity to target between tens and hundreds of genes simultaneously. We 
identified a set of microRNAs that show aberrant expression in BAP1-mutated UM. Sev-
eral of these microRNAs have already been identified previously as oncomiRs, however 
other microRNAs might be more instrumental for UM development. To translate these 
results into a clinical application, we need to validate our results in larger cohorts before 
we continue with determining the prognostic and therapeutic value of miRNAs. At this 
moment, there are no FDA-approved miRNA-based therapeutics being used in the clinic, 
but several miRNA therapeutics are currently being tested in phase 1/phase 2 clinical tri-
als25 . These therapies involve small RNA molecules that act as miRNA mimics or inhibi-
tors of miRNAs (antimiRs). One challenge for miRNA-based therapeutics is the delivery 
of the small RNA molecules. However, with the discovery of several miRNA-delivery 
vehicles, small RNA molecules can be delivered to specific tissues, which avoids poten-
tial toxicities26. Once we elucidated which aberrantly expressed miRNAs are essential for 
the development of metastatic properties in UM, we could either block or stimulate their 
function by making using of antimiRs or mimics, respectively. Since we identified several 
known oncomiRs, such as miRNA-17-5p, miRNA-151a-3p, miRNA-21-5p, we can benefit 
from studies that already investigated the therapeutic potential of these miRNAs27-29.
Additionally, we identified several functionally significant epigenetic alterations in UM. 
There are several well-established DNA methylation biomarkers in oncology, such as 








cancer. We identified several aberrantly methylated tumor-suppressor genes specific for 
high-risk UM; GSTP1, MEGF10 and KLF10. This knowledge will not only be useful in the 
clinic, as it might provide us with a biomarker for high-metastatic risk, but it also leads 
to new insights into the mechanisms that drive UM carcinogenesis. Our current challenge 
is to move from demonstrating an association with metastatic disease, to elucidating the 
etiological role of aberrant DNA methylation in UM. It is currently unclear whether these 
epigenetic alterations directly provide the tumor cell with oncogenic capabilities or that 
they simply add to the regulatory circuitry that are already known to be deregulated by 
gene mutations. The interesting aspect of methylation in cancer is the reversibility of the 
process. Whereas DNA mutations are set in stone, epigenetic processes have the immense 
advantage that they can be reversed. Treatment protocols using the two DNA-methyla-
tion inhibitors, 5-azacytidine and 5-aza-2’deoxycytidine force cells to return to their nor-
mal cell phenotype and have been approved by the FDA for myelodysplastic syndromes 
and chronic myelomonocytic leukemia treatment31-33. 
Towards reducing UM-metastasis related deaths 
Research into the mechanisms that drive carcinogenesis has resulted into a large number 
of mechanism-based targeted therapies that have shown to be successful in specific cancer 
types. The efficiency of these targeted therapy depends on the importance of the capability 
it is targeting34. Hanahan and Weinberg described the hallmarks of cancer; six biological 
capabilities acquired by cells during the development to human tumors. These capabili-
ties enable tumor growth and metastatic outgrowth and include sustained proliferation, 
induce replicative immortality, avoid growth suppression, resisting cell death, induce an-
giogenesis, activate invasion and metastasis35. If a capability is truly important in a tumor 
cell, inhibition of this feature should impair tumor growth and progression. Developing a 
mechanism-based targeted therapy for UM is vital, as metastatic UM is in general incur-
able. An additional advantage is that most of the targeted therapeutics have in principle, 
less off-target effects and thus less nonspecific toxicity. In order to develop these therapies, 
significant advances in our understanding of invasion and metastases need to be made. 
Several studies have focused on characterizing the genome of metastatic UM cells. Just 
like primary UM, metastatic UM show a remarkable low mutational load36. Initiating mu-
tations in GNAQ or GNA11 are present throughout the entire tumor, as well as secondary 
driver mutations in SF3B1 or BAP1. The chromosomal aberrations are similar as well, 
however the frequencies do change in some cases. One paper described a low percent-
age of tertiary mutations in oncogenes, such as, PTEN, EZH2 and TP5337. Since the driver 
mutations are conserved in metastases and there is no significant increase in genetic in-
stability, it is likely that the metastatic potential of UM is already determined early in the 
development. It has been shown by Eskelin et al that the tumor metastasizes several years 
before diagnosis, treatment of the primary tumor will therefore not be enough to prevent 
metastatic spreading. Thus, future therapies have to focus on removing or delaying the 
growth of micrometastases while treating the primary tumor simultaneously38. 
It is not entirely known which exact events initiate the malignant potential in UM and 
this hampers the development of an efficient therapy for metastatic UM. Since primary 
UM without secondary driver mutations are rare, GNAQ and GNA11 mutations alone 
are probably insufficient for malignant transformation. Additionally, a study by Shain et 
al showed that mutations in GNAQ and GNA11 were found in all samples from a given 
patient, which further confirms that these mutations are an early event37. Inhibiting this 
pathway might therefore reduce the proliferative potential of UM cells, whether they are 
needed for the malignant properties caused by the secondary driver mutations is unclear. 
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Since a large majority of the metastatic UM show loss of the tumor suppressor BAP1, 
the most direct therapy would be to reinitiate the expression of BAP1. Unfortunately, 
reactivating proteins remains a great challenge in cancer therapeutics. Instead, it might 
be more promising to use agents that modulate the downstream effect of BAP1. Interest-
ingly, our ROMS cohort contains several patients with a UM that show loss of BAP1, but 
that remained metastasis-free for over 10 years. Remarkably, patients with a germline 
BAP1-mutation have a longer DFS than patients with somatic mutations in BAP139. This 
confirms that the metastasis-promoting effect of BAP1 can be modulated by mechanism(s) 
that temporarily counteract this effect. Whether this is the presence of mutation in GNAQ 
or GNA11, upregulation of other pathways, change in methylation or something com-
pletely else, is unknown. We have shown for example that BAP1-mutated UM displayed 
a distinct epigenetic profile. Reverting this malignant phenotype by making use of HDAC 
inhibitors, could be applied to prevent metastatic UM cells from proliferating40, 41. Eluci-
dating the mechanisms that contribute to the malignant potential in UM could aid signifi-
cantly to the development of a therapy for BAP1-mutated UM. 
Metastatic UM that still show BAP1 expression generally harbor a mutation in a spliceo-
some gene, such as SF3B1, SRSF2 or U2AF16, 42 Mutations in these genes do not result in 
loss of function, but rather a change of function and might therefore require a different 
approach. Shifting the splicing balance with splicing modulators, such as E7107, has been 
shown to selectively kill tumor cells with mutations in their splicing machinery. However, 
this small molecule inhibits both aberrant as canonical splicing and therefore caused con-
siderate side-effects such as loss of vision, due to optic-nerve dysfunction43. Interestingly, 
the new spliceosome modulator H3B-8800 shows increased selectivity for spliceosome-
mutant tumor cells, compared to E710744 and might therefore be a promising drug for 
future clinical tests. Another method would be to investigate which genes are mainly af-
fected by aberrant splicing. SF3B1 is the most commonly mutated spliceosome-gene in 
cancer and it has been shown that mutant SF3B1 induces aberrant splicing of the tumor-
suppressor gene BRD9, thereby triggering subsequent degradation of BRD9 mRNA by 
nonsense-mediated decay45. BRD9 is a core component of the BAF nucleosome-remodel-
ing complex, which regulates chromatin remodeling and transcription. Disruption of this 
tumor-suppressor promotes tumor maintenance and metastatic progression. As prelimi-
nary data show different splicing patterns between early and late metastasizing SF3B1-
mutated UM, we hypothesize that certain mechanisms can reduce the oncogenic effect of 
mutant SF3B1. If we determine which other affected genes contribute to the development 
and metastatic spreading of UM and shift the balance towards the canonical mRNA, we 
potentially could dampen the oncogenic effect of aberrant splicing in tumor cells. 
Another approach to target metastatic UM would be to prolong UM latency. Research 
into the mechanisms that stimulate or prevent metastatic UM cells from expanding might 
provide us with new targets for future therapies. Borthwick et al performed autopsies on 
liver specimens of UM patients46. Even though these patients had no symptoms of meta-
static disease, single cells or small cell clumps were observed in the liver of all patients. 
Furthermore, it was shown that bone marrow samples contained melanoma cells in some 
cases, while bone marrow is not a frequent metastatic site for UM. This further supports 
the concept of early metastatic spreading to several organs, however these metastatic 
cells are unable to immediately develop metastatic lesions because several mechanisms in 
these distant organs prevent them from growing. A recent study by Babchia et al showed 
bidirectional crosstalk between UM cells and hepatic stellate cells influences homing of 
UM cells to the liver47. Co-culturing UM cells with liver cells allows us to study the signals 
exchanged by different cell types that exist symbiotically within the tumor mass. Describ-








which mechanism can suppress or facilitate colonization and growth of metastatic UM 
cells.
An important mediator of communication between cells are extracellular vesicles, such as 
exosomes. Exosomes perform intercellular transfer of bioactive molecules, such as RNA, 
proteins and lipid, both locally as systemically. Recent research has shown that exosomes 
are considered to be major drivers in the development of a pre-metastatic niche. Tumor 
cells release vesicles that can help prepare specific recipient organs for metastatic spread-
ing48, 49. Exosomes can upregulate pro-inflammatory S100 molecules in distant tissues, 
thereby creating a local inflammatory microenvironment, one of the basic requirements 
for the formation of a pre-metastatic niche50. In order for circulating tumor cells to colo-
nize, the extracellular matrix needs to be remodeled in pre-metastatic niches. It has been 
shown that exosomes co-localize with laminin and fibronectin, two factors that increase 
the adhesion of the extracellular matrix51. Another important prerequisite in the pre-met-
astatic niche is the formation of new blood vessels and increase in vascular permeability, 
which is also promoted by exosomes52-54. Thus, exosomes can contribute to several aspects 
of the pre-metastatic niche development. Further exploration of the exact function of UM 
exosomes might allow us to identify mechanisms that  could inhibit, prevent or maybe 
even alter the formation of a pre-metastatic niche and thereby avoid metastatic outgrowth. 
Future prospects
In general, most published studies are describing features associated with metastatic UM. 
Fundamental research is relatively rare in the field of ocular oncology. However, in or-
der to design an effective treatment, a more fundamental understanding of the multiple 
molecular aberrations in UM is a prerequisite. Elucidating the processes that drive UM 
development and metastasis will depend increasingly on refined culturing models, such 
as organoids, and eventually on animal models55. Such models will help us to develop 
comprehensive maps of aberrant signaling networks in UM. Since the UM field is small 
compared to other cancer types, it is essential that research groups all around the world 
join forces. An example of such an initiative is the ocular oncology group (OOG), which 
consists of international research groups that meet and initiate multicenter collaborations. 
Ideally, there should be collaborations with groups that work on malignancies with a 
similar genetic background as well, such as SF3B1-mutated leukemia and BAP1-mutated 
mesothelioma, since they could provide us with useful knowledge. 
In order to develop a more effective and durable therapy for UM, it is important to selec-
tively co-target multiple capabilities because therapeutic treatments can shift the depen-
dence of UM cells to other capabilities. We envision a combination of drugs that target 
the primary tumor and adjuvant drugs that will prevent distant micrometastases from 
developing further and thereby improve the survival of patients. This has already proofed 
its efficacy in breast cancer, where adjuvant therapy is commonly given to every patient, 
and colon cancer56-58. A study by Bol et al, applied dendritic-cell therapy as an adjuvant 
treatment in patients with BAP1-mutated UM59. Immunotherapy has been shown to be 
extremely efficient in cutaneous melanoma, however the results were less exciting in UM, 
which could be explained by the low mutational load. Therefore, we emphasize that adju-
vant treatments should be targeting UM-specific deregulated processed, such as the aber-










Figure 1. Deregulated processes that contribute to the development and metastasis of UM are found in every level 
of the central dogma
At present, description of the tumor cell genome of a recently dissected UM is routine pro-
cedure and allows UM patients to be prognostically categorized. Nonetheless, the treat-
ment strategies do not differ based on this data. When we look 10 or 20 years ahead of 
time, the (epi)genetic features present in the UM cells will determine the treatment strat-
egy. We foresee a far deeper insight into the roles played by the mutated genes. By then, 
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Uveal melanoma (UM) is an aggressive malignancy arising from the melanocytes present 
in the uveal tract of the eye. Although it is a relatively rare disease, UM is the most com-
mon primary intra-ocular tumor in adults. It is characterized by the frequent development 
of metastases, which in most cases results in a poor outcome. The metastatic risk varies 
greatly and depends on primary tumor characteristics. Several cytogenetic and genetic 
features have been demonstrated to have a strong association with metastatic risk, such as 
monosomy 3 and mutations in the BAP1 gene. The majority of the UM show a mutation 
in GNAQ or GNA11 and these are considered to arise early in the development of UM. 
In addition, UM often harbor a mutation in EIF1AX, SF3B1 or BAP1. Mutations in these 
so-called secondary driver genes determine the metastatic potential of the tumor. In this 
thesis we describe new advances in the research into prognostic markers. Furthermore, we 
investigate the role of epigenetic players, miRNAs and DNA methylation, in UM metasta-
sis. Finally, we discuss future treatments and biomarkers for metastatic UM.
In chapter 1 the clinical, histological and genetic features of UM is introduced and we 
highlight the current challenges in the field. In chapter 2 we focus on predicting the meta-
static risk in UM. In chapter 2.1 a novel, custom-designed sequencing method is described 
that can simultaneously detect mutations and copy number variations, thereby allowing 
rapid stratification of UM patients. It shows a good overlap with BAP1 immunohisto-
chemistry, a commonly used technique in UM diagnostics, and has the additional ad-
vantage that it can identify late-metastasizing UM patients harboring a SF3B1-mutation. 
Since only a small amount of DNA (~10ng) is necessary, it can also be used for patients 
that underwent a tumor biopsy. With the development of this new, inexpensive method, 
we can rapidly identify patients with high metastatic risk and subsequently predict the 
patients’ outcome and in the future potentially asses and stratify eligibility for new treat-
ments. In chapter 2.2 we describe an association between secondary driver mutations and 
chromosomal patterns. Copy number analysis by Single Nucleotide Polymorphism-array 
showed four distinct groups, which corresponded to specific gene mutations. The first 
group contained the BAP1-negative UM and showed frequent loss of chromosome 3, gain 
of the chromosome-arms 8q, 6q and loss of the chromosome-arms 1p, 8p and 16q. The 
second group contained the SF3B1-mutated UM and harbored frequent loss of parts of 
the chromosome-arms 1p, 6q, 8p and 11q and gain of chromosome-arm 8q. The third 
group consisted of the EIF1AX-mutated UM and in this group we observed very little 
chromosomal abnormalities, apart from gain of chromosome-arm 6p. The fourth group 
consisted of UM that showed no recurrent mutations (NRM) in EIF1AX, SF3B1 or BAP1. 
These results show that UM with different secondary driver mutations have a distinct 
biological mechanism contributing to UM pathogenesis. Whether the secondary driver 
genes mutations cause the chromosomal aberrations or whether it is the other way around 
is unknown. 
The genetic features associated with the development and metastatic spreading of UM 
are well described and both genetic and epigenetic mechanisms play a role in the devel-
opment, progression and metastatic spreading of a tumor. In chapter 3 we aim to elu-
cidate how epigenetic mechanisms, such as altered miRNA expression or methylation 
changes, contribute to metastatic spreading of UM. Chapter 3.1 focuses on the potential 
role of microRNAs in the metastatic spreading of UM. Next-generation RNA sequenc-
ing in 26 primary UM revealed differential expression of 13 microRNAs, including the 
known oncomiR’s miRNA-17-5p, miRNA-21-5p and miRNA-151a-3p. The differen-
tially expressed microRNAs corresponded to 106 differentially expressed target genes. 
These genes were shown to be involved in several cancer-related pathways, such as cell 
cycle regulation, EGF signaling and EIF2 signaling. By deregulating these pathways 
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aberrant microRNA expression might thereby promote metastatic spreading to distant 
organs. The identification of these aberrantly expressed microRNAs might offer an in-
teresting biomarker for UM diagnostics and putative, interesting therapeutic target. 
In chapter 3.2 we look at another important epigenetic feature that is often deregulated 
in cancer; DNA methylation. The genome-wide methylome of 26 primary UM was ana-
lyzed making use of the recently developed method MeD-seq. Regions with differential 
methylation were observed in all chromosomes, however a large number of differentially 
methylated regions was found on chromosomes 1, 8, 12 and 16. We found 757 genes to 
be differentially methylated in UM, of which the majority was found in BAP1-mutated 
UM. SF3B1-mutated UM were characterized by a large percentage of hypomethylation, 
whereas the EIF1AX and BAP1-mutated UM showed mostly hypermethylation. Interest-
ingly, we observed increased promoter methylation in BAP1-mutated primary UM and 
UM metastases specimens in the tumor-suppressor genes MEGF10, KLF11 and GSTP1. 
The results obtained in this study could be exploited for therapeutic purposes. Unlike 
DNA mutations, methylation can be easily reversed by demethylating agents. Remov-
ing excessive methylation in UM cells can reactivate tumor-suppressor genes and might 
thereby reduce proliferation and migration in UM. Whether aberrant methylation arises 
as a result of mutations in EIF1AX, SF3B1 and BAP1 or as an independent event early in 
the oncogenic transformation of melanocytes is unknown. In case of the latter, demethyl-
ating agents might strike the Achilles heel of UM.
Although significant advances have been made in UM research, the disease-free survival 
has remained unchanged the last 35 years. The development of a successful treatment for 
metastatic UM is vital, as metastatic UM is currently incurable. In addition, it is crucial 
to develop a biomarker that can predict the metastatic risk in all UM patients, including 
the ones treated with an eye-preserving therapy. In chapter 4.1 we describe a potential 
new non-invasive technique that could improve UM diagnostics. Extracellular vesicles 
from cultured UM cells are characterized by electron microscopy, western blot and flow 
cytometry. Our preliminary results indicate that the exosomes secreted by BAP1-mutated, 
high metastatic risk cells showed a higher amount of several miRNAs, including the on-
comiRs miRNA-21, miRNA-10B and miRNA-365.  To characterize the proteins present on 
UM exosomes, we performed mass spectrometry on exosomal, membrane proteins. Here 
we identified several proteins to be present in all exosome samples, such as the classical 
exosome markers CD81, CD63 and flotillin-1, as well as proteins that are only present in 
melanocytes. The presence of melanocyte-specific proteins on UM exosomes might allow 
us to develop a method that can selectively enrich for melanocyte exosomes in plasma. 
Detecting exosomes with a unique, metastatic uveal melanoma signature could poten-
tially offer us a non-invasive biomarker for metastatic UM.
In order to develop an effective, targeted treatment against metastatic UM, we need to 
have a more comprehensive understanding of the multiple molecular mechanism that 
contribute to UM carcinogenesis. In chapter 4.2 we review the molecular mechanisms 
behind the known DNA mutations and the therapeutic possibilities that arise from target-
ing these different aberrant pathways. Several treatments that have shown to be effective 
in other cancer types, such as immunotherapy and MEK-inhibitors, have been applied on 
UM as well. So far, the results have been disappointing. We hypothesize that this lack of 
success can be explained by differences in biological behavior between different cancer 
types. UM treatment might profit from a more personalized approach in which the ge-
netic background of each UM is investigated and determines the best treatment option. 








possible, conclusions are drawn. Finally, challenges for the field and future perspectives 
are discussed. In conclusion, this thesis provides new insights into the multifaceted epi-
genetic regulation of uveal melanoma cells. The gained knowledge provides us with a bet-
ter understanding of the biological processes behind UM which will bring us step-by-step 






















Oogmelanomen zijn tumoren, die ontstaan uit melanocyten die zich in het oog bevinden. 
Ondanks dat het een zeldzame ziekte is (~7 op 1.000.000), is het de meest voorkomende 
intra-oculaire maligniteit bij volwassenen. Bij ongeveer de helft van de patiënten metas-
taseert het oogmelanoom naar andere organen in het lichaam. Aangezien er tot op heden 
geen succesvolle therapie beschikbaar is voor gemetastaseerde oogmelanomen, leiden 
metastases vaak binnen een jaar tot de dood. Het risico op metastases wordt bepaald 
door de afwijkingen, die aanwezig zijn in de primaire tumor. De afgelopen jaren zijn er 
een aantal (cyto)genetische afwijkingen geïdentificeerd, die sterk geassocieerd zijn met 
metastasering, zoals verlies van chromosoom 3 en mutaties in het BAP1 gen. Het mer-
endeel van de oogmelanomen bevat een mutatie in GNAQ of GNA11, waarvan gedacht 
wordt, dat deze vroeg in de ontwikkeling van de tumor ontstaat. Daarnaast bevatten 
oogmelanomen vaak een mutatie in BAP1, SF3B1 of EIF1AX. Mutaties in deze zogeno-
emde secundaire driver genen bepalen of een tumor kan metastaseren. In het eerste deel 
van dit proefschrift bespreken we de nieuwe ontwikkelingen die bijdragen aan het voor-
spellen van het risico op metastasen. Vervolgens onderzoeken wij, welke epigenetische 
afwijkingen aanwezig zijn in metastaserende oogmelanomen. Daarnaast beschrijven 
we de ontwikkeling van toekomstige niet-invasieve biomarkers en bespreken we welke 
behandelingsstrategieën het beste zijn voor gemetastaseerde oogmelanomen.
In hoofdstuk 1 wordt een korte introductie gegeven over de klinische, histologische en 
genetische eigenschappen van oogmelanomen. Daarnaast benoemen wij de grootste uit-
dagingen in het veld. Vervolgens gaan wij in hoofdstuk 2 door met het beschrijven van 
verschillende ontwikkelingen, die ons kunnen helpen bij het identificeren van patiënten 
met een hoog risico op metastasen. In hoofdstuk 2.1 wordt een nieuwe methode be-
schreven, die gelijktijdig mutaties en chromosoomafwijkingen kan oppikken, waardoor 
het risico op metastasering bepaald kan worden. Aangezien er maar een kleine hoeveel-
heid DNA nodig is (~10 ng), kan deze methode ook gebruikt worden voor biopten. Deze 
techniek is inmiddels al in de routine oogmelanoom-diagnostiek geïmplementeerd en 
maakt het mogelijk om bij een groot deel van de oogmelanoompatiënten snel en betrou-
wbaar de prognose te bepalen. In hoofdstuk 2.2 focussen wij ons op de verschillende 
chromosoomafwijkingen die voorkomen in oogmelanomen met verschillende mutaties. 
Eventuele chromosoomafwijkingen worden opgepikt door DNA te analyseren met behu-
lp van een Single Nucleotide Polymorphism (SNP)-array. Op basis van chromosoomaf-
wijkingen kunnen er vier verschillende groepen gemaakt worden, die elk geassocieerd 
zijn met een specifieke mutatie. De eerste groep omvat oogmelanomen zonder BAP1 
expressie met frequent verlies van heel chromosoom 3 en de chromosoom-regio’s 1p, 
8p 16q en winst van de chromosoom-regio’s 8q en 6q. De SF3B1-gemuteerde oogmela-
nomen bevinden zich in groep 2 en laten frequent verlies van de chromosoom-regio’s 1p, 
6q, 8q en 11q zien. De derde groep bevat de EIF1AX-gemuteerde oogmelanomen en deze 
tumoren laten weinig tot geen chromosoomafwijkingen zien. In de vierde groep zitten 
oogmelanomen, die geen mutaties hebben in SF3B1, BAP1 of EIF1AX. Deze resultaten 
bevestigen, dat oogmelanomen met verschillende secundaire driver mutaties ook daad-
werkelijk een andere biologische achtergrond hebben. Of de secundaire driver mutaties 
leiden tot deze specifieke chromosoomafwijkingen of dat de chromosoomafwijkingen 
onafhankelijke gebeurtenissen zijn, die plaatsvinden vroeg in de ontwikkeling van de 
tumor, is nog niet bekend. 
In hoofdstuk 3 onderzoeken wij epigenetische veranderingen, die plaatsvinden in 
metastaserende oogmelanomen. Een groot deel van het oogmelanoom-onderzoek focust 
zich op veranderingen in het DNA zelf, terwijl epigenetische aspecten (d.w.z. veran-
deringen op of om het DNA, waarbij de DNA-sequentie niet verandert) ook een grote 
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rol spelen in de ontwikkeling en metastasering van tumoren. Hoofdstuk 3.1 beschrijft 
afwijkende expressie van microRNAs in metastaserende oogmelanomen. Met behulp 
van next-generation RNA sequencing hebben wij 13 microRNAs geïdentificeerd, die 
afwijkend tot expressie komen in metastaserende oogmelanomen, waaronder een 
aantal microRNAs waarvan al bewezen is dat ze een rol spelen bij de tumorgenese (bijv. 
microRNA-17, microRNA-21 en microRNA-151a). Aangezien microRNAs de expressie 
van bepaalde genen kunnen veranderen door specifieke, complementaire binding aan 
mRNA, hebben wij de microRNA data gecombineerd met mRNA data. Hierdoor heb-
ben wij 106 genen geïdentificeerd, die afwijkende expressie vertonen. Deze genen zijn 
betrokken bij verschillende processen, zoals regulatie van de celcyclus, EGF-signalering 
en EIF2-signalering, waarvan bekend is dat ze vaak gedereguleerd zijn in tumoren. Af-
wijkende expressie van bepaalde microRNAs kan metastasering van een tumor stimul-
eren door dit soort essentiële processen te verstoren. In de toekomst kunnen wij wellicht 
deze afwijkende microRNA-niveaus gebruiken als biomarker. Daarnaast kunnen wij 
met toekomstige therapieën proberen, deze afwijkende microRNAs weer naar normale 
niveaus te brengen door ze te remmen of te stimuleren, waardoor gedereguleerde pro-
cessen in een tumorcel afnemen. 
Hoofdstuk 3.2 focust zich op een ander epigenetisch aspect, namelijk DNA methylatie. 
DNA methylatie kan de transcriptie van genen beïnvloeden doordat de aan het DNA 
gekoppelde methylgroepen (CH3) de structuur van het DNA veranderen. Om de DNA 
methylatie binnen oogmelanomen te analyseren hebben wij gebruik gemaakt van een 
nieuwe techniek; MeD-seq. Vergeleken met andere technieken, bekijkt MeD-seq een 
veel groter deel van het genoom. In deze studie hebben wij afwijkende DNA-methylatie 
gevonden in alle chromosomen, maar vooral in de chromosomen 1, 8, 12 en 16. De BAP1-
gemuteerde oogmelanomen lieten het hoogste aantal afwijkingen in DNA-methylatie 
zien. Waar in de SF3B1-gemuteerde oogmelanomen vooral hypomethylatie (afname van 
methylatie in DNA) te zien was, vertoonden de BAP1- en EIF1AX-gemuteerde oogmela-
nomen vooral hypermethylatie (toename van methylatie in DNA). Een interessante bev-
inding was de hypermethylatie in promoteren van de tumor-suppressie genen MEGF10, 
KLF11 en GSTP1 in de BAP1-gemuteerde oogmelanomen. Aangezien oogmelanomen 
relatief weinig DNA-mutaties bevatten, kan afwijkende DNA methylatie van genen die 
de deling, groei en ontwikkeling van een cel beïnvloeden, sterk bijdragen aan de maligne 
eigenschappen van een tumor. Waar mutaties in het DNA bijna onmogelijk zijn om te 
corrigeren met therapieën, kan afwijkende DNA methylatie worden teruggedraaid door 
middel van bepaalde chemische stoffen. Hierdoor kunnen gemethyleerde tumor-sup-
pressie genen weer gereactiveerd worden om zo de celdeling en migratie van tumorcel-
len te beperken. Het is nog onduidelijk of afwijkende DNA methylatie geïnitieerd wordt 
door de DNA-mutaties, of dat het een onafhankelijke gebeurtenis is vroeg in de ontwik-
keling van de tumor. In het laatste geval zal het corrigeren van DNA methylatie wellicht 
een effectieve behandelingsstrategie zijn.
 
De laatste jaren is er veel onderzoek gedaan naar oogmelanomen, wat ertoe geleid heeft, 
dat onze kennis in dit veld flink gegroeid is. Helaas is de overleving van oogmelanoom-
patiënten de laatste 35 jaar niet veranderd. Het ontwikkelen van een succesvolle thera-
pie voor gemetastaseerde oogmelanomen is essentieel, aangezien het op dit moment 
ongeneeslijk is. Daarnaast is het belangrijk om in de toekomst een biomarker in het 
bloed te identificeren, aangezien we hiermee voor alle patiënten – dus ook de patiënten 
die behandeld zijn met oog-sparende behandelingen- het risico op metastasen kunnen 
voorspellen. In hoofdstuk 4.1 beschrijven wij een potentiële niet-invasieve biomarkers, 
namelijk exosomen. Oogmelanoom-exosomen werden geanalyseerd met electronen 








quencing en mass spectometry uitgevoerd, om de RNA-inhoud en membraan-eiwitten 
respectievelijk te analyseren. In onze eerste resultaten zien we, dat de exosomen van 
de BAP1-gemuteerde oogmelanoomcellen een specifiek microRNA patroon laten zien. 
In deze exosomen zien we een verhoogde expressie van bepaalde microRNAs, zoals 
microRNA-21, microRNA-10B en microRNA-365. Daarnaast hebben wij ontdekt, dat 
er eiwitten in het membraan van de oogmelanoom-exosomen zitten, die specifiek zijn 
voor melanocytaire-cellen. Daarom gaan wij uit van de hypothese dat oogmelanoom-
exosomen uit het bloed kunnen worden geïsoleerd met behulp van magnetische kralen, 
die specifiek binden aan de melanoom-eiwitten, waardoor er verrijkt kan worden voor 
genetisch materiaal, dat afkomstig is van de tumor. Vervolgens kan het RNA-patroon 
geanalyseerd worden in deze exosomen en kunnen we bepalen of een patiënt een hoog 
risico BAP1-gemuteerde oogmelanoom heeft.
Zodra patiënten met een verhoogd risico geïdentificeerd worden, moet er een efficiënte 
behandeling kunnen worden aangeboden Voor de ontwikkeling van nieuwe succesvolle 
therapieën voor de behandeling van metastaserende oogmelanomen, is het belangrijk 
om een beter begrip te hebben van de verschillende moleculaire mechanismen, die 
bijdragen aan de metastasering van oogmelanomen. In hoofdstuk 4.2 beschrijven wij 
verschillende studies, die onderzoeken welke moleculaire processen er in een cel worden 
verstoord door mutaties in GNAQ, GNA11, SF3B1, EIF1AX of BAP1. We bespreken hoe 
de deregulatie van deze processen kan bijdragen aan de tumorgenese en we benoe-
men therapeutische strategieën, die eventueel kunnen ingrijpen in deze gedereguleerde 
processen. Behandelingen die goede resultaten laten zien in andere vormen van kanker 
hebben geen tot weinig resultaat bij de behandeling van oogmelanoom-patiënten. Deze 
teleurstellende resultaten kunnen verklaard worden door het feit, dat oogmelanomen 
een andere biologische achtergrond hebben en daarom dus niet of nauwelijks reageren 
op deze behandelingen. Daarom benadrukken wij in deze review, dat het essentieel is 
om een op maat gemaakte behandeling te ontwikkelen bij de behandeling van oogmela-
noom-patiënten. 
In hoofdstuk 5 worden de belangrijkste bevindingen van dit proefschrift samengevat en 
besproken. We benoemen de grootste uitdagingen in het veld en adviseren over de na te 
streven toekomstige doelen. Kortom, dit proefschrift beschrijft de epigenetische veran-
deringen, die optreden in metastaserende oogmelanomen en geeft nieuwe inzichten in 
potentiële niet-invasieve biomarkers en behandelingen voor gemetastaseerde oogmela-
nomen.
























AA   amino acid
ABs   apoptotic bodies 
ABCC5   multidrug resistance-associated protein 5
ARF6   ADP-ribosylation factor 6
BAP1   BRCA1-associated protein 1 
BARD1   BRCA1-associated RING domain protein 1
bp   base pair
BRAF   v-raf murine sarcoma viral oncogene homolog B1
BRCA1   breast cancer 1, early obset 
BRD9   bromodomain containing 9 
CD   cluster of differentiation
cDNA   copy deoxyribonucleic acid
cfDNA   cell-free DNA
CDK6   cyclin-dependent kinase 6 
CM   cutaneous melanoma
CN   copy number
CNV   copy number variation
CpG   cytosine-phosphate-guanine
CTC   circulating tumor cells
ctDNA   circulating tumor DNA
CYSTLR2  cysteinyl leukotriene receptor 2 
DC   dendritic cell 
DDR   DNA-damage response
DE   differentially expressed
DFS   disease-free survival
DNA   deoxyribonucleic acid
DUB   deubiquitinating enzyme
EIF1AX   eukaryotic translation initiation factor 1A,X-linked
EIF2   eukaryotic initiation factor 2
EGF   epidermal growth factor 
EMT   epithelial-mesenchymal transition 
ER   endoplasmic reticulum
EV   extracellular vesicle 
EZH2   enhancer of zeste homolog 2 
FC   fold change 
FCS   fetal calf serum 
FDA   food and drug administration
FDR   fold discovery rate
FFPE   formalin-fixed, paraffin-embedded
FGF   fibroblast growth factor 
FNAB   fine-needle aspiration biopsy 
FLOT1   flotillin-1
FISH   fluorescence in situ hybridization
GDP   guanosine diphosphate
GEF   guanine nucleotide exchange factor 
GEP   gene expression profile
GNAQ   guanine nucleotide-binding protein G subunit alpha Q
GNA11   guanine nucleotide-binding protein G subunit alpha 11 
GP-100   glycoprotein 100
GPCR   G-protein coupled receptor 
GPR143   G-protein coupled receptor 143
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GSTP1   glutathione S-transferase P 1
GTP   guanine triphosphate
HDAC   histone deacetylase
HLA   human leukocyte antigen
HE   haematoxylin-eosin
IDO   indoleamine-pyrrole 2,3-dioxygenase
IHC   immunohistochemistry
IHP   isolated hepatic perfusion 
IP3R3   inositol 1,4,5-triphosphate receptor type 3
IPA   ingenuity pathway analysis
KLF11   krueppel-like factor 11
LC-MS/MS  liquid chromatography-tandem mass-spectrometry
LOH   loss of heterozygosity
MAPK   mitogen-activated kinase 
MART-1   melanoma antigen recognized by T cells  
mb   megabase
MEGF10   multiple EGF-like domains
MEK   mitogen-activated protein kinase kinase 
METC   medical ethical testing committee
miRNA   micro ribonucleic acid 
MITF   melanocyte inducing transcription factor
MLPA   multiplex ligation-dependent probe amplification
mRNA   messenger ribonucleic acid
MVs   microvesicles 
NGS   next-generation sequencing 
NHEJ   non-homologous end joining 
NLS   nuclear localisation signal 
NMD   nonsense-mediated decay
NRM   no recurrent mutations
N/A   not available
OOG   Ocular Oncology group
PCA   principal component analysis
PCR   polymerase chain reaction
PCLB4   phospholipase C beta 4
PD-1   programmed cell death protein 1 
PRAME   preferentially expressed antigen in melanoma 
PR-DUB   polycomb respressive deubiquitinase 
PTEN   phosphatase and tensin homolog 
PVT1   plasmacytoma variant translocation 1
qPCR   quantitative polymerase chain reaction 
RIN   RNA integrity number
RISC   RNA-induced silencing complex
RNA   ribonucleic acid
rRNA   ribosomal ribonucleic acid
ROMS   rotterdam ocular melanoma studygroup
RPM   reads per million
RT   room temperature
RT-PCR   real-time polymerase chain reaction
SF3B1   splicing factor 3B subunit1
SNP   single nucleotide polymorphism
SNV   single nucleotide variations








TCGA   The Cancer Genome Atlas 
TP53   tumor protein P53
tRNA   transfer ribonucleic acid 
TYRP1   tyrosinase-related protein 1
U2AF1   U2 small nuclear RNA auxiliary factor 1 
UCH   ubiquitin carboxy-terminal hydrolase 
ULD   ubiqituin-like domain
UM   uveal melanoma 
WT   wildtype 
YAP1   yes-associated protein
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